{"66c84ea4f07e5527fd7da0fcb3734657fabf7470": [["IntroductionSince the first clinical use of a VEGF antagonist for cancer and vascular eye disease more than a decade ago(1), there has been rapid development of new drugs targeting the VEGF-VEGFR2 and Angpt-TIE2 pathways (2) .", [["cancer", "ANATOMY", 66, 72], ["vascular eye", "ANATOMY", 77, 89], ["cancer", "DISEASE", 66, 72], ["vascular eye disease", "DISEASE", 77, 97], ["VEGF", "GENE_OR_GENE_PRODUCT", 46, 50], ["cancer", "CANCER", 66, 72], ["vascular eye", "MULTI-TISSUE_STRUCTURE", 77, 89], ["VEGF", "GENE_OR_GENE_PRODUCT", 185, 189], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 190, 196], ["Angpt-TIE2", "GENE_OR_GENE_PRODUCT", 201, 211], ["VEGF", "PROTEIN", 46, 50], ["VEGF", "PROTEIN", 185, 189], ["VEGFR2", "PROTEIN", 190, 196], ["Angpt", "PROTEIN", 201, 206], ["TIE2", "PROTEIN", 207, 211], ["a VEGF antagonist", "TREATMENT", 44, 61], ["cancer", "PROBLEM", 66, 72], ["vascular eye disease", "PROBLEM", 77, 97], ["new drugs", "TREATMENT", 161, 170], ["the VEGF", "TEST", 181, 189], ["vascular", "ANATOMY", 77, 85], ["eye", "ANATOMY", 86, 89], ["disease", "OBSERVATION", 90, 97], ["rapid", "OBSERVATION_MODIFIER", 140, 145], ["new", "OBSERVATION_MODIFIER", 161, 164], ["drugs", "OBSERVATION", 165, 170]]], ["In the Angpt-Tie2 pathway the major ligands are ANGPT1, which is a strong Tie2 agonist, and ANGPT2, which acts as a context-dependent antagonist of Tie2 (3, 4) .", [["Angpt-Tie2", "GENE_OR_GENE_PRODUCT", 7, 17], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 48, 54], ["Tie2", "GENE_OR_GENE_PRODUCT", 74, 78], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 92, 98], ["Tie2", "GENE_OR_GENE_PRODUCT", 148, 152], ["Angpt", "PROTEIN", 7, 12], ["Tie2", "PROTEIN", 13, 17], ["ANGPT1", "PROTEIN", 48, 54], ["Tie2", "PROTEIN", 74, 78], ["ANGPT2", "PROTEIN", 92, 98], ["Tie2", "PROTEIN", 148, 152]]], ["One of the key distinctions between these two ligands is that ANGPT1 self-clusters into higher order oligomers, and this is critical to induce Tie2 activation (5, 6) .", [["ANGPT1", "GENE_OR_GENE_PRODUCT", 62, 68], ["Tie2", "GENE_OR_GENE_PRODUCT", 143, 147], ["ANGPT1", "PROTEIN", 62, 68], ["Tie2", "PROTEIN", 143, 147], ["higher order oligomers", "OBSERVATION_MODIFIER", 88, 110], ["Tie2", "OBSERVATION", 143, 147]]], ["ANGPT1 is secreted by a variety of perivascular cell types to act on its cognate receptor Tie2 on the cell surface of endothelium, where it regulates junction stability to protect against vascular leakage.", [["perivascular cell", "ANATOMY", 35, 52], ["cell surface", "ANATOMY", 102, 114], ["endothelium", "ANATOMY", 118, 129], ["junction", "ANATOMY", 150, 158], ["vascular", "ANATOMY", 188, 196], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 0, 6], ["perivascular cell", "CELL", 35, 52], ["Tie2", "GENE_OR_GENE_PRODUCT", 90, 94], ["cell surface", "CELLULAR_COMPONENT", 102, 114], ["endothelium", "TISSUE", 118, 129], ["vascular", "MULTI-TISSUE_STRUCTURE", 188, 196], ["ANGPT1", "PROTEIN", 0, 6], ["perivascular cell types", "CELL_TYPE", 35, 58], ["Tie2", "PROTEIN", 90, 94], ["perivascular cell types", "TREATMENT", 35, 58], ["vascular leakage", "PROBLEM", 188, 204], ["perivascular cell types", "OBSERVATION", 35, 58], ["endothelium", "ANATOMY", 118, 129], ["vascular", "ANATOMY", 188, 196], ["leakage", "OBSERVATION", 197, 204]]], ["Localized or transient increases in blood vessel permeability occur during inflammation, ischemia, and tumor-related neoangiogenesis (7) (8) (9) .", [["blood vessel", "ANATOMY", 36, 48], ["tumor", "ANATOMY", 103, 108], ["inflammation", "DISEASE", 75, 87], ["ischemia", "DISEASE", 89, 97], ["tumor", "DISEASE", 103, 108], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 36, 48], ["tumor", "CANCER", 103, 108], ["transient increases in blood vessel permeability", "PROBLEM", 13, 61], ["inflammation", "PROBLEM", 75, 87], ["ischemia", "PROBLEM", 89, 97], ["tumor-related neoangiogenesis", "PROBLEM", 103, 132], ["transient", "OBSERVATION_MODIFIER", 13, 22], ["increases", "OBSERVATION_MODIFIER", 23, 32], ["blood vessel permeability", "OBSERVATION", 36, 61], ["inflammation", "OBSERVATION", 75, 87], ["ischemia", "OBSERVATION", 89, 97], ["tumor", "OBSERVATION", 103, 108], ["neoangiogenesis", "OBSERVATION", 117, 132]]], ["Because the reduction of vascular leak has been linked to better patient outcomes in sepsis, ARDS and other conditions, therapeutic targeting of the Angpt-Tie2 pathway has been attempted by many groups (2, (10) (11) (12) (13) (14) (15) .IntroductionCurrently a number of investigational drugs are being tested that are aimed at activating Tie2 activity (2) .", [["vascular", "ANATOMY", 25, 33], ["sepsis", "DISEASE", 85, 91], ["ARDS", "DISEASE", 93, 97], ["vascular", "MULTI-TISSUE_STRUCTURE", 25, 33], ["patient", "ORGANISM", 65, 72], ["Angpt-Tie2", "GENE_OR_GENE_PRODUCT", 149, 159], ["2, (10) (11) (12) (13) (14)", "SIMPLE_CHEMICAL", 203, 230], ["Tie2", "GENE_OR_GENE_PRODUCT", 339, 343], ["Angpt", "PROTEIN", 149, 154], ["Tie2", "PROTEIN", 155, 159], ["Tie2", "PROTEIN", 339, 343], ["patient", "SPECIES", 65, 72], ["vascular leak", "PROBLEM", 25, 38], ["sepsis", "PROBLEM", 85, 91], ["ARDS", "PROBLEM", 93, 97], ["other conditions", "PROBLEM", 102, 118], ["the Angpt-Tie2 pathway", "TREATMENT", 145, 167], ["investigational drugs", "TREATMENT", 271, 292], ["reduction", "OBSERVATION_MODIFIER", 12, 21], ["vascular", "ANATOMY", 25, 33], ["leak", "OBSERVATION", 34, 38], ["sepsis", "OBSERVATION", 85, 91], ["ARDS", "OBSERVATION", 93, 97]]], ["These include the recombinant proteins BowAng1 (16) and COMP-ANG1 (17) , where the Tie2-binding fibrinogen-like domain (FLD) of ANGPT1 is fused to either the Fc of IgG1 (BowAng1) or the coiled-coil domain (CCD) of rat cartilage oligomeric matrix protein (COMP), respectively.", [["BowAng1 (16)", "GENE_OR_GENE_PRODUCT", 39, 51], ["COMP-ANG1 (17)", "GENE_OR_GENE_PRODUCT", 56, 70], ["Tie2", "GENE_OR_GENE_PRODUCT", 83, 87], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 96, 106], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 128, 134], ["IgG1", "GENE_OR_GENE_PRODUCT", 164, 168], ["BowAng1", "GENE_OR_GENE_PRODUCT", 170, 177], ["rat", "ORGANISM", 214, 217], ["cartilage oligomeric matrix protein", "GENE_OR_GENE_PRODUCT", 218, 253], ["COMP", "GENE_OR_GENE_PRODUCT", 255, 259], ["recombinant proteins", "PROTEIN", 18, 38], ["BowAng1", "PROTEIN", 39, 46], ["16", "PROTEIN", 48, 50], ["COMP", "PROTEIN", 56, 60], ["ANG1", "PROTEIN", 61, 65], ["17", "PROTEIN", 67, 69], ["Tie2-binding fibrinogen-like domain", "PROTEIN", 83, 118], ["FLD", "PROTEIN", 120, 123], ["ANGPT1", "PROTEIN", 128, 134], ["Fc", "PROTEIN", 158, 160], ["IgG1", "PROTEIN", 164, 168], ["BowAng1", "PROTEIN", 170, 177], ["coiled-coil domain", "PROTEIN", 186, 204], ["CCD", "PROTEIN", 206, 209], ["rat cartilage oligomeric matrix protein", "PROTEIN", 214, 253], ["COMP", "PROTEIN", 255, 259], ["rat", "SPECIES", 214, 217], ["the recombinant proteins BowAng1", "TEST", 14, 46], ["COMP-ANG1", "TEST", 56, 65], ["the Tie2-binding fibrinogen", "TEST", 79, 106], ["ANGPT1", "TEST", 128, 134], ["the coiled-coil domain (CCD", "TREATMENT", 182, 209], ["Tie2", "ANATOMY", 83, 87], ["rat cartilage", "ANATOMY", 214, 227]]], ["Small molecules that inhibit the activity of TIE2 phosphatase VE-PTP are able to potently activate Tie2 in a ligand independent manner (18, 19) .", [["TIE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["VE-PTP", "GENE_OR_GENE_PRODUCT", 62, 68], ["Tie2", "GENE_OR_GENE_PRODUCT", 99, 103], ["TIE2 phosphatase", "PROTEIN", 45, 61], ["VE", "PROTEIN", 62, 64], ["PTP", "PROTEIN", 65, 68], ["Tie2", "PROTEIN", 99, 103], ["Small molecules", "PROBLEM", 0, 15], ["the activity of TIE2 phosphatase VE", "TEST", 29, 64], ["molecules", "OBSERVATION", 6, 15], ["Tie2", "OBSERVATION", 99, 103]]], ["In addition, therapeutic antibodies have been developed against ANGPT2 that antagonizes Tie2 in the inflamed vasculature.", [["vasculature", "ANATOMY", 109, 120], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 64, 70], ["Tie2", "GENE_OR_GENE_PRODUCT", 88, 92], ["vasculature", "MULTI-TISSUE_STRUCTURE", 109, 120], ["therapeutic antibodies", "PROTEIN", 13, 35], ["ANGPT2", "PROTEIN", 64, 70], ["Tie2", "PROTEIN", 88, 92], ["therapeutic antibodies", "TREATMENT", 13, 35], ["inflamed", "ANATOMY_MODIFIER", 100, 108], ["vasculature", "ANATOMY", 109, 120]]], ["These include ANGPT2 neutralization antibodies such as trebananib, MEDI3617, LY3127804, nesvacumab and REGN910-3, as well as bispecific ANGPT2-VEGF-targeted antibodies vanucizumab/RG7221 and RG7216 (2, (20) (21) (22) .", [["trebananib", "CHEMICAL", 55, 65], ["MEDI3617", "CHEMICAL", 67, 75], ["LY3127804", "CHEMICAL", 77, 86], ["nesvacumab", "CHEMICAL", 88, 98], ["vanucizumab", "CHEMICAL", 168, 179], ["RG7221", "CHEMICAL", 180, 186], ["RG7216", "CHEMICAL", 191, 197], ["trebananib", "CHEMICAL", 55, 65], ["MEDI3617", "CHEMICAL", 67, 75], ["LY3127804", "CHEMICAL", 77, 86], ["nesvacumab", "CHEMICAL", 88, 98], ["REGN910-3", "CHEMICAL", 103, 112], ["RG7216", "CHEMICAL", 191, 197], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 14, 20], ["trebananib", "SIMPLE_CHEMICAL", 55, 65], ["MEDI3617", "SIMPLE_CHEMICAL", 67, 75], ["LY3127804", "SIMPLE_CHEMICAL", 77, 86], ["nesvacumab", "SIMPLE_CHEMICAL", 88, 98], ["REGN910-3", "GENE_OR_GENE_PRODUCT", 103, 112], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 136, 142], ["VEGF", "GENE_OR_GENE_PRODUCT", 143, 147], ["vanucizumab", "SIMPLE_CHEMICAL", 168, 179], ["RG7221", "SIMPLE_CHEMICAL", 180, 186], ["RG7216", "SIMPLE_CHEMICAL", 191, 197], ["2, (20) (21) (22)", "SIMPLE_CHEMICAL", 199, 216], ["ANGPT2 neutralization antibodies", "PROTEIN", 14, 46], ["ANGPT2", "PROTEIN", 136, 142], ["VEGF", "PROTEIN", 143, 147], ["ANGPT2 neutralization antibodies", "TEST", 14, 46], ["trebananib", "TEST", 55, 65], ["nesvacumab", "TEST", 88, 98], ["REGN910", "TEST", 103, 110], ["bispecific ANGPT2", "TEST", 125, 142]]], ["More recently, ANGPT2-targeted antibody ABTAA has been shown to trigger ANGPT2 clustering, converting ANGPT2 into an 'ANGPT1-like' agonist of TIE2 (23) .", [["ABTAA", "CHEMICAL", 40, 45], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 15, 21], ["ABTAA", "GENE_OR_GENE_PRODUCT", 40, 45], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 72, 78], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 102, 108], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 118, 124], ["ANGPT2", "PROTEIN", 15, 21], ["ABTAA", "PROTEIN", 40, 45], ["ANGPT2", "PROTEIN", 72, 78], ["ANGPT2", "PROTEIN", 102, 108], ["ANGPT1", "PROTEIN", 118, 124], ["ANGPT2", "TEST", 15, 21], ["an 'ANGPT1", "TEST", 114, 124]]], ["To date, ANG-TIE-targeted drugs have been tested in patients with cancer as well as in patients with retinal vascular diseases such as wet age-related macular degeneration (wAMD) and diabetic macular oedema (DMO) (2) .", [["cancer", "ANATOMY", 66, 72], ["retinal vascular", "ANATOMY", 101, 117], ["macular", "ANATOMY", 151, 158], ["macular", "ANATOMY", 192, 199], ["ANG", "CHEMICAL", 9, 12], ["cancer", "DISEASE", 66, 72], ["retinal vascular diseases", "DISEASE", 101, 126], ["macular degeneration", "DISEASE", 151, 171], ["wAMD", "DISEASE", 173, 177], ["diabetic macular oedema", "DISEASE", 183, 206], ["DMO", "DISEASE", 208, 211], ["ANG-TIE", "SIMPLE_CHEMICAL", 9, 16], ["patients", "ORGANISM", 52, 60], ["cancer", "CANCER", 66, 72], ["patients", "ORGANISM", 87, 95], ["retinal vascular", "MULTI-TISSUE_STRUCTURE", 101, 117], ["macular", "TISSUE", 151, 158], ["macular", "TISSUE", 192, 199], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 87, 95], ["ANG", "TEST", 9, 12], ["drugs", "TREATMENT", 26, 31], ["cancer", "PROBLEM", 66, 72], ["retinal vascular diseases", "PROBLEM", 101, 126], ["macular degeneration", "PROBLEM", 151, 171], ["diabetic macular oedema", "PROBLEM", 183, 206], ["cancer", "OBSERVATION", 66, 72], ["retinal", "ANATOMY_MODIFIER", 101, 108], ["vascular", "ANATOMY", 109, 117], ["diseases", "OBSERVATION", 118, 126], ["macular degeneration", "OBSERVATION", 151, 171], ["diabetic", "OBSERVATION_MODIFIER", 183, 191], ["macular oedema", "OBSERVATION", 192, 206]]], ["In all of these clinical settings, vascular leak is believed to play a pathogenic role.IntroductionMode of delivery is an important consideration of Angpt-Tie-targeted therapies.", [["vascular", "ANATOMY", 35, 43], ["vascular leak", "DISEASE", 35, 48], ["vascular", "MULTI-TISSUE_STRUCTURE", 35, 43], ["Angpt", "SIMPLE_CHEMICAL", 149, 154], ["Tie", "GENE_OR_GENE_PRODUCT", 155, 158], ["Tie", "PROTEIN", 155, 158], ["vascular leak", "PROBLEM", 35, 48], ["delivery", "TREATMENT", 107, 115], ["Angpt", "TREATMENT", 149, 154], ["targeted therapies", "TREATMENT", 159, 177], ["vascular", "ANATOMY", 35, 43], ["leak", "OBSERVATION", 44, 48]]], ["In addition to binding Tie2 at the cell-cell contacts and stabilizing endothelial junctions, ANGPT1 has an affinity to bind to a variety of extracellular matrices (ECM) (24) , responsible for anchoring endothelial Tie2 to cell-ECM attachments.", [["cell-cell contacts", "ANATOMY", 35, 53], ["endothelial junctions", "ANATOMY", 70, 91], ["extracellular matrices", "ANATOMY", 140, 162], ["ECM", "ANATOMY", 164, 167], ["endothelial", "ANATOMY", 202, 213], ["cell", "ANATOMY", 222, 226], ["ECM", "ANATOMY", 227, 230], ["ANGPT1", "CHEMICAL", 93, 99], ["Tie2", "GENE_OR_GENE_PRODUCT", 23, 27], ["cell-cell contacts", "CELLULAR_COMPONENT", 35, 53], ["endothelial junctions", "CELLULAR_COMPONENT", 70, 91], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 93, 99], ["extracellular matrices", "CELLULAR_COMPONENT", 140, 162], ["ECM", "CELLULAR_COMPONENT", 164, 167], ["endothelial Tie2", "GENE_OR_GENE_PRODUCT", 202, 218], ["cell", "CELL", 222, 226], ["ECM attachments", "CELLULAR_COMPONENT", 227, 242], ["Tie2", "PROTEIN", 23, 27], ["ANGPT1", "PROTEIN", 93, 99], ["endothelial Tie2", "PROTEIN", 202, 218], ["an affinity", "PROBLEM", 104, 115], ["endothelial junctions", "ANATOMY", 70, 91]]], ["As the action(s) of endogenous ANGPT1 is largely restricted to mediating pericyte-endothelium communication, in order to create a systemic therapy to activate Tie2, we needed to consider how to overcome the 'stickiness' or affinity of ANGPT1 to rapidly bind ECM and become immobile.", [["pericyte", "ANATOMY", 73, 81], ["endothelium", "ANATOMY", 82, 93], ["ECM", "ANATOMY", 258, 261], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 31, 37], ["pericyte", "CELL", 73, 81], ["endothelium", "TISSUE", 82, 93], ["Tie2", "GENE_OR_GENE_PRODUCT", 159, 163], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 235, 241], ["ECM", "CELLULAR_COMPONENT", 258, 261], ["endogenous ANGPT1", "PROTEIN", 20, 37], ["Tie2", "PROTEIN", 159, 163], ["ANGPT1", "PROTEIN", 235, 241], ["ECM", "PROTEIN", 258, 261], ["endogenous ANGPT1", "PROBLEM", 20, 37], ["a systemic therapy", "TREATMENT", 128, 146], ["the 'stickiness'", "PROBLEM", 203, 219], ["ANGPT1", "TREATMENT", 235, 241], ["endothelium", "ANATOMY", 82, 93], ["immobile", "OBSERVATION", 273, 281]]], ["To overcome the issue of ECM binding, we replaced the coiled-coil domain and linker sequence of ANGPT1 with a 57 amino acid segment derived from serum complement C4BP that naturally folds into a heptavalent scaffold, which allows the recombinant protein to circulate freely while maintaining potent Tie2 activating ability.Construction of C4BP-ANG1, a recombinant ANG1 mimetic that activates TIE2In contrast to native ANGPT1 comprised of an N-terminus supercluster domain (SCD) and coiled-coil domain (CCOD) followed by a Tie2-binding fibrinogen-like domain (FLD) (Fig1A), two recombinant fusions between ANGPT1 FLD (amino acid 281-498) and the C-terminus domain of C4BP\u03b1 (amino acid 541-597) were constructed as C4BP-ANG1 and ANG1-C4BP in their N-to C-terminus orders and produced using HEK293 and CHO cell production systems (Methods).", [["ECM", "ANATOMY", 25, 28], ["serum", "ANATOMY", 145, 150], ["HEK293", "ANATOMY", 788, 794], ["CHO cell", "ANATOMY", 799, 807], ["amino acid", "CHEMICAL", 113, 123], ["amino acid 281-498", "CHEMICAL", 617, 635], ["amino acid 541-597", "CHEMICAL", 673, 691], ["amino acid", "CHEMICAL", 113, 123], ["N", "CHEMICAL", 441, 442], ["amino acid", "CHEMICAL", 617, 627], ["C", "CHEMICAL", 645, 646], ["amino acid 541-597", "CHEMICAL", 673, 691], ["C", "CHEMICAL", 751, 752], ["ECM", "CELLULAR_COMPONENT", 25, 28], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 96, 102], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["C4BP", "GENE_OR_GENE_PRODUCT", 162, 166], ["Tie2", "GENE_OR_GENE_PRODUCT", 299, 303], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 339, 348], ["ANG1", "GENE_OR_GENE_PRODUCT", 364, 368], ["TIE2In", "GENE_OR_GENE_PRODUCT", 392, 398], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 418, 424], ["Tie2", "GENE_OR_GENE_PRODUCT", 522, 526], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 535, 545], ["Fig1A", "GENE_OR_GENE_PRODUCT", 565, 570], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 605, 611], ["amino acid 281-498", "AMINO_ACID", 617, 635], ["C4BP\u03b1", "GENE_OR_GENE_PRODUCT", 666, 671], ["amino acid 541-597", "AMINO_ACID", 673, 691], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 713, 722], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 727, 736], ["HEK293", "CELL", 788, 794], ["CHO cell", "CELL", 799, 807], ["ECM", "PROTEIN", 25, 28], ["coiled-coil domain", "PROTEIN", 54, 72], ["linker sequence", "PROTEIN", 77, 92], ["ANGPT1", "PROTEIN", 96, 102], ["57 amino acid segment", "PROTEIN", 110, 131], ["serum complement C4BP", "PROTEIN", 145, 166], ["recombinant protein", "PROTEIN", 234, 253], ["Tie2", "PROTEIN", 299, 303], ["C4BP", "PROTEIN", 339, 343], ["ANG1", "PROTEIN", 344, 348], ["ANG1", "PROTEIN", 364, 368], ["TIE2In", "PROTEIN", 392, 398], ["ANGPT1", "PROTEIN", 418, 424], ["N-terminus supercluster domain", "PROTEIN", 441, 471], ["SCD", "PROTEIN", 473, 476], ["coiled-coil domain", "PROTEIN", 482, 500], ["CCOD", "PROTEIN", 502, 506], ["Tie2-binding fibrinogen-like domain", "PROTEIN", 522, 557], ["FLD", "PROTEIN", 559, 562], ["Fig1A", "PROTEIN", 565, 570], ["ANGPT1 FLD", "PROTEIN", 605, 615], ["amino acid 281-498", "PROTEIN", 617, 635], ["C-terminus domain", "PROTEIN", 645, 662], ["C4BP\u03b1", "PROTEIN", 666, 671], ["amino acid 541-597", "PROTEIN", 673, 691], ["C4BP", "PROTEIN", 713, 717], ["ANG1", "PROTEIN", 718, 722], ["ANG1", "PROTEIN", 727, 731], ["C4BP", "PROTEIN", 732, 736], ["N-to C-terminus orders", "PROTEIN", 746, 768], ["HEK293", "CELL_LINE", 788, 794], ["ECM binding", "PROBLEM", 25, 36], ["the coiled-coil domain", "TREATMENT", 50, 72], ["ANGPT1", "TREATMENT", 96, 102], ["a 57 amino acid segment", "TREATMENT", 108, 131], ["serum complement C4BP", "TEST", 145, 166], ["a heptavalent scaffold", "TREATMENT", 193, 215], ["the recombinant protein", "TREATMENT", 230, 253], ["C4BP", "TEST", 339, 343], ["ANG1", "PROBLEM", 344, 348], ["a recombinant ANG1 mimetic", "TREATMENT", 350, 376], ["an N-terminus supercluster domain (SCD)", "PROBLEM", 438, 477], ["coiled-coil domain (CCOD", "TREATMENT", 482, 506], ["a Tie2-binding fibrinogen", "TEST", 520, 545], ["two recombinant fusions", "TREATMENT", 573, 596], ["ANGPT1 FLD", "TEST", 605, 615], ["amino acid", "TEST", 617, 627], ["the C-terminus domain", "TEST", 641, 662], ["C4BP", "TEST", 666, 670], ["amino acid", "TEST", 673, 683], ["C4BP", "TEST", 713, 717], ["ANG1", "TEST", 718, 722], ["ANG1", "TEST", 727, 731], ["C4BP", "TEST", 732, 736], ["HEK293", "TEST", 788, 794], ["CHO cell production systems", "TREATMENT", 799, 826], ["heptavalent scaffold", "OBSERVATION", 195, 215]]], ["It is expected that the C4BP segment forms a sevenunit stalk further secured by intermolecular disulfide bridges (Fig1B, top), which cluster seven FLDs of ANGPT1 in a stable molecular complex (Fig1B, bottom).", [["disulfide", "CHEMICAL", 95, 104], ["C4BP", "GENE_OR_GENE_PRODUCT", 24, 28], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 155, 161], ["C4BP segment", "PROTEIN", 24, 36], ["intermolecular disulfide bridges", "PROTEIN", 80, 112], ["Fig1B", "PROTEIN", 114, 119], ["FLDs", "PROTEIN", 147, 151], ["ANGPT1", "PROTEIN", 155, 161], ["molecular complex", "PROTEIN", 174, 191], ["Fig1B", "PROTEIN", 193, 198], ["a sevenunit stalk", "TREATMENT", 43, 60], ["intermolecular disulfide bridges", "TREATMENT", 80, 112], ["ANGPT1", "TREATMENT", 155, 161], ["disulfide bridges", "OBSERVATION", 95, 112], ["stable", "OBSERVATION_MODIFIER", 167, 173], ["complex", "OBSERVATION_MODIFIER", 184, 191]]], ["In keeping, both C4BP-ANG1 and ANG1-C4BP appeared as high order oligomers of ~250 kDa in size on non-reducing SDS-PAGE, in contrast to their reduced monomeric counterparts of ~35 kDa (Fig1C).", [["SDS", "CHEMICAL", 110, 113], ["C4BP", "GENE_OR_GENE_PRODUCT", 17, 21], ["ANG1", "GENE_OR_GENE_PRODUCT", 22, 26], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 31, 40], ["Fig1C", "GENE_OR_GENE_PRODUCT", 184, 189], ["C4BP", "PROTEIN", 17, 21], ["ANG1", "PROTEIN", 22, 26], ["ANG1", "PROTEIN", 31, 35], ["C4BP", "PROTEIN", 36, 40], ["Fig1C", "PROTEIN", 184, 189], ["C4BP", "TEST", 17, 21], ["ANG1", "TEST", 22, 26], ["ANG1", "TEST", 31, 35], ["C4BP", "TEST", 36, 40], ["non-reducing SDS", "TEST", 97, 113], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["Electron microscopy further confirmed the formation of C4BP-ANG1 heptamers (Fig1D).", [["C4BP-ANG1 heptamers", "GENE_OR_GENE_PRODUCT", 55, 74], ["Fig1D", "GENE_OR_GENE_PRODUCT", 76, 81], ["C4BP", "PROTEIN", 55, 59], ["ANG1 heptamers", "PROTEIN", 60, 74], ["Fig1D", "PROTEIN", 76, 81], ["Electron microscopy", "TEST", 0, 19], ["C4BP", "TEST", 55, 59]]], ["Because storage stability of ANGPT1-based biologics tends to be problematic (25), we expressed and tested several variants of the fusion constructions.", [["ANGPT1", "CHEMICAL", 29, 35], ["ANGPT1", "SIMPLE_CHEMICAL", 29, 35], ["ANGPT1", "PROTEIN", 29, 35], ["fusion constructions", "DNA", 130, 150], ["ANGPT1", "TEST", 29, 35], ["the fusion constructions", "TREATMENT", 126, 150], ["stability", "OBSERVATION_MODIFIER", 16, 25]]], ["The results showed regardless of the N-to-C domain order and 6xHis tag location all C4BP-ANG1 variants formed stable complexes (supplementary Figure S1 ), and could be safely stored in physiological buffer conditions with no formation of protein aggregates.", [["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 84, 93], ["C4BP", "PROTEIN", 84, 88], ["ANG1", "PROTEIN", 89, 93], ["supplementary Figure S1", "PROTEIN", 128, 151], ["all C4BP", "TEST", 80, 88], ["protein aggregates", "PROBLEM", 238, 256], ["stable", "OBSERVATION_MODIFIER", 110, 116], ["protein aggregates", "OBSERVATION", 238, 256]]], ["In addition, we specifically tested ANG1-C4BP after freeze-thaw cycles.", [["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 36, 45], ["ANG1", "PROTEIN", 36, 40], ["C4BP", "PROTEIN", 41, 45], ["ANG1", "TEST", 36, 40], ["freeze-thaw cycles", "TREATMENT", 52, 70]]], ["There was no quantity or quality decline of the protein complex as determined by UPLC-SEC analysis (supplementary Figure S2 ).C4BP-ANG1 activates TIE2 in cultured cellsTo determine direct binding between C4BP-ANG1 and Tie2, in a series of co-immunoprecipitation assays we showed binding of C4BP-ANG1 and ANG1-C4BP to Tie2-Fc (Fig2A).", [["cells", "ANATOMY", 163, 168], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 126, 135], ["TIE2", "GENE_OR_GENE_PRODUCT", 146, 150], ["cells", "CELL", 163, 168], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 204, 213], ["Tie2", "GENE_OR_GENE_PRODUCT", 218, 222], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 290, 299], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 304, 313], ["Tie2-Fc", "GENE_OR_GENE_PRODUCT", 317, 324], ["Fig2A", "GENE_OR_GENE_PRODUCT", 326, 331], ["protein complex", "PROTEIN", 48, 63], ["C4BP", "PROTEIN", 126, 130], ["ANG1", "PROTEIN", 131, 135], ["TIE2", "PROTEIN", 146, 150], ["cultured cells", "CELL_LINE", 154, 168], ["C4BP", "PROTEIN", 204, 208], ["ANG1", "PROTEIN", 209, 213], ["Tie2", "PROTEIN", 218, 222], ["C4BP", "PROTEIN", 290, 294], ["ANG1", "PROTEIN", 295, 299], ["ANG1", "PROTEIN", 304, 308], ["C4BP", "PROTEIN", 309, 313], ["Tie2", "PROTEIN", 317, 321], ["Fc (Fig2A)", "PROTEIN", 322, 332], ["the protein complex", "PROBLEM", 44, 63], ["UPLC", "TEST", 81, 85], ["SEC analysis", "TEST", 86, 98], ["C4BP", "TEST", 126, 130], ["cultured cells", "TEST", 154, 168], ["C4BP", "TEST", 204, 208], ["co-immunoprecipitation assays", "TEST", 239, 268], ["C4BP", "TEST", 290, 294], ["ANG1", "TEST", 295, 299], ["ANG1", "TEST", 304, 308], ["C4BP", "TEST", 309, 313], ["Tie2", "TEST", 317, 321], ["no", "UNCERTAINTY", 10, 12], ["quantity", "OBSERVATION_MODIFIER", 13, 21], ["quality", "OBSERVATION_MODIFIER", 25, 32], ["decline", "OBSERVATION", 33, 40]]], ["As expected, by adding purified C4BP-ANG1 or ANG1-C4BP to culture medium of human umbilical vein cells (HUVECs) we observed activation of Tie2 as measured by phospho-Akt (Fig2B).", [["human umbilical vein cells", "ANATOMY", 76, 102], ["HUVECs", "ANATOMY", 104, 110], ["phospho", "CHEMICAL", 158, 165], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 32, 41], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 45, 54], ["human umbilical vein cells", "CELL", 76, 102], ["HUVECs", "CELL", 104, 110], ["Tie2", "GENE_OR_GENE_PRODUCT", 138, 142], ["phospho-Akt", "GENE_OR_GENE_PRODUCT", 158, 169], ["Fig2B", "GENE_OR_GENE_PRODUCT", 171, 176], ["C4BP", "PROTEIN", 32, 36], ["ANG1", "PROTEIN", 37, 41], ["ANG1", "PROTEIN", 45, 49], ["C4BP", "PROTEIN", 50, 54], ["human umbilical vein cells", "CELL_TYPE", 76, 102], ["HUVECs", "CELL_LINE", 104, 110], ["Tie2", "PROTEIN", 138, 142], ["phospho-Akt (Fig2B)", "PROTEIN", 158, 177], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["purified C4BP", "TEST", 23, 36], ["ANG1", "TEST", 37, 41], ["ANG1", "TEST", 45, 49], ["culture", "TEST", 58, 65], ["human umbilical vein cells", "TREATMENT", 76, 102], ["Tie2", "TEST", 138, 142], ["phospho", "TEST", 158, 165], ["umbilical vein", "ANATOMY", 82, 96]]], ["Using a human embryonic kidney (HEK293) cell system that stably expressed full-length Tie2, we showed both C4BP-ANG1 and ANG-C4BP induced Tie2 phosphorylation in a dose-dependent manner (Fig2C).", [["embryonic kidney (HEK293) cell system", "ANATOMY", 14, 51], ["human", "ORGANISM", 8, 13], ["embryonic kidney", "CELL", 14, 30], ["HEK293) cell", "CELL", 32, 44], ["Tie2", "GENE_OR_GENE_PRODUCT", 86, 90], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 107, 116], ["ANG-C4BP", "GENE_OR_GENE_PRODUCT", 121, 129], ["Tie2", "GENE_OR_GENE_PRODUCT", 138, 142], ["human embryonic kidney (HEK293) cell system", "CELL_LINE", 8, 51], ["Tie2", "PROTEIN", 86, 90], ["C4BP", "PROTEIN", 107, 111], ["ANG1", "PROTEIN", 112, 116], ["ANG", "PROTEIN", 121, 124], ["C4BP", "PROTEIN", 125, 129], ["Tie2", "PROTEIN", 138, 142], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["a human embryonic kidney", "TREATMENT", 6, 30], ["cell system", "TEST", 40, 51], ["Tie2", "TEST", 86, 90], ["C4BP", "TEST", 107, 111], ["ANG1", "TEST", 112, 116], ["ANG-C4BP induced Tie2 phosphorylation", "TREATMENT", 121, 158], ["kidney", "ANATOMY", 24, 30]]], ["Furthermore, immunofluorescence studies showed a dynamic redistribution pattern of Tie2 on the surface of HUVECs following C4BP-ANG1 stimulation, resembling the effects of natural ANGPT1 (26) .", [["surface", "ANATOMY", 95, 102], ["HUVECs", "ANATOMY", 106, 112], ["Tie2", "GENE_OR_GENE_PRODUCT", 83, 87], ["surface", "CELLULAR_COMPONENT", 95, 102], ["HUVECs", "CELL", 106, 112], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 123, 132], ["Tie2", "PROTEIN", 83, 87], ["HUVECs", "CELL_TYPE", 106, 112], ["C4BP", "PROTEIN", 123, 127], ["ANG1", "PROTEIN", 128, 132], ["immunofluorescence studies", "TEST", 13, 39], ["C4BP", "TEST", 123, 127], ["ANG1 stimulation", "TREATMENT", 128, 144], ["dynamic", "OBSERVATION", 49, 56], ["redistribution pattern", "OBSERVATION", 57, 79]]], ["C4BP-ANG1 caused Tie2 to coalesce into small puncta that also migrated towards the cell periphery (Fig2D), further suggesting adequate signaling through Tie2 is achieved.", [["puncta", "ANATOMY", 45, 51], ["cell periphery", "ANATOMY", 83, 97], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 0, 9], ["Tie2", "GENE_OR_GENE_PRODUCT", 17, 21], ["puncta", "CELLULAR_COMPONENT", 45, 51], ["cell periphery", "CELLULAR_COMPONENT", 83, 97], ["Fig2D", "GENE_OR_GENE_PRODUCT", 99, 104], ["Tie2", "GENE_OR_GENE_PRODUCT", 153, 157], ["C4BP", "PROTEIN", 0, 4], ["ANG1", "PROTEIN", 5, 9], ["Tie2", "PROTEIN", 17, 21], ["Tie2", "PROTEIN", 153, 157], ["C4BP", "TEST", 0, 4], ["ANG1", "PROBLEM", 5, 9], ["Tie2", "PROBLEM", 17, 21], ["small puncta", "PROBLEM", 39, 51], ["small", "OBSERVATION_MODIFIER", 39, 44], ["puncta", "OBSERVATION", 45, 51], ["migrated", "OBSERVATION_MODIFIER", 62, 70], ["cell", "ANATOMY_MODIFIER", 83, 87], ["periphery", "ANATOMY_MODIFIER", 88, 97], ["suggesting", "UNCERTAINTY", 115, 125], ["adequate signaling", "OBSERVATION", 126, 144]]], ["As expected, confluent HUVECs in culture formed continuous cell-cell junctions (Fig2E), whereas treatment of the cells with either LPS or VEGF caused disruption of the junctions in some areas.", [["HUVECs", "ANATOMY", 23, 29], ["cell-cell junctions", "ANATOMY", 59, 78], ["cells", "ANATOMY", 113, 118], ["LPS", "CHEMICAL", 131, 134], ["HUVECs", "CELL", 23, 29], ["cell", "CELL", 59, 63], ["cell junctions", "CELLULAR_COMPONENT", 64, 78], ["Fig2E", "GENE_OR_GENE_PRODUCT", 80, 85], ["cells", "CELL", 113, 118], ["LPS", "SIMPLE_CHEMICAL", 131, 134], ["VEGF", "GENE_OR_GENE_PRODUCT", 138, 142], ["confluent HUVECs", "CELL_LINE", 13, 29], ["VEGF", "PROTEIN", 138, 142], ["confluent HUVECs in culture", "TEST", 13, 40], ["the cells", "PROBLEM", 109, 118], ["LPS", "PROBLEM", 131, 134], ["VEGF", "PROBLEM", 138, 142], ["disruption of the junctions", "PROBLEM", 150, 177], ["confluent", "OBSERVATION_MODIFIER", 13, 22], ["HUVECs", "ANATOMY", 23, 29], ["continuous cell", "OBSERVATION", 48, 63], ["cell junctions", "OBSERVATION", 64, 78], ["VEGF", "OBSERVATION", 138, 142], ["junctions", "ANATOMY_MODIFIER", 168, 177]]], ["Meanwhile, when C4BP-ANG1 was present, junctional integrity was maintained in spite of LPS and VEGF treatments (Fig2E), and this is consistent with the function of ANGPT1 in maintaining endothelial quiescence and stability.In vivo pharmacoefficacy of C4BP-ANG1With as little as 0.2 \u03bcg/g (in body weight) of purified C4BP-ANG1 was injected intravenously in mice, elevated levels of phospho-Tie2 were detected in the lung (Fig3A).", [["junctional", "ANATOMY", 39, 49], ["endothelial", "ANATOMY", 186, 197], ["body", "ANATOMY", 291, 295], ["intravenously", "ANATOMY", 339, 352], ["lung", "ANATOMY", 415, 419], ["LPS", "CHEMICAL", 87, 90], ["phospho", "CHEMICAL", 381, 388], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 16, 25], ["junctional", "CELLULAR_COMPONENT", 39, 49], ["LPS", "SIMPLE_CHEMICAL", 87, 90], ["VEGF", "GENE_OR_GENE_PRODUCT", 95, 99], ["Fig2E", "GENE_OR_GENE_PRODUCT", 112, 117], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 164, 170], ["endothelial", "CELL", 186, 197], ["C4BP-ANG1With", "GENE_OR_GENE_PRODUCT", 251, 264], ["body", "ORGANISM_SUBDIVISION", 291, 295], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 316, 325], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 339, 352], ["mice", "ORGANISM", 356, 360], ["phospho-Tie2", "GENE_OR_GENE_PRODUCT", 381, 393], ["lung", "ORGAN", 415, 419], ["Fig3A", "GENE_OR_GENE_PRODUCT", 421, 426], ["C4BP", "PROTEIN", 16, 20], ["ANG1", "PROTEIN", 21, 25], ["VEGF", "PROTEIN", 95, 99], ["ANGPT1", "PROTEIN", 164, 170], ["C4BP", "PROTEIN", 251, 255], ["ANG1With", "PROTEIN", 256, 264], ["C4BP", "PROTEIN", 316, 320], ["ANG1", "PROTEIN", 321, 325], ["phospho", "PROTEIN", 381, 388], ["Tie2", "PROTEIN", 389, 393], ["mice", "SPECIES", 356, 360], ["mice", "SPECIES", 356, 360], ["C4BP", "TEST", 16, 20], ["junctional integrity", "PROBLEM", 39, 59], ["LPS", "TREATMENT", 87, 90], ["VEGF treatments", "TREATMENT", 95, 110], ["C4BP", "TEST", 251, 255], ["purified C4BP-ANG1", "TREATMENT", 307, 325], ["elevated levels of phospho-Tie2", "PROBLEM", 362, 393], ["junctional integrity", "OBSERVATION", 39, 59], ["consistent with", "UNCERTAINTY", 132, 147], ["endothelial quiescence", "OBSERVATION", 186, 208], ["stability", "OBSERVATION_MODIFIER", 213, 222], ["lung", "ANATOMY", 415, 419]]], ["A strong phospho-Tie2 signal persisted for at least 6 hours following a bolus injection of C4BP-ANG1, and residual Tie2 activities remained detectable 16 hours later (Fig3B and 3C) .", [["phospho-Tie2", "GENE_OR_GENE_PRODUCT", 9, 21], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 91, 100], ["Tie2", "GENE_OR_GENE_PRODUCT", 115, 119], ["phospho", "PROTEIN", 9, 16], ["Tie2", "PROTEIN", 17, 21], ["C4BP", "PROTEIN", 91, 95], ["ANG1", "PROTEIN", 96, 100], ["Tie2", "PROTEIN", 115, 119], ["A strong phospho", "TEST", 0, 16], ["a bolus injection of C4BP-ANG1", "TREATMENT", 70, 100], ["residual Tie2 activities", "PROBLEM", 106, 130]]], ["Intraperitoneal injection of young mice also resulted in Tie2 activation in the lung (Fig3D).", [["Intraperitoneal", "ANATOMY", 0, 15], ["lung", "ANATOMY", 80, 84], ["Intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 15], ["mice", "ORGANISM", 35, 39], ["Tie2", "GENE_OR_GENE_PRODUCT", 57, 61], ["lung", "ORGAN", 80, 84], ["Fig3D", "GENE_OR_GENE_PRODUCT", 86, 91], ["Tie2", "PROTEIN", 57, 61], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["Intraperitoneal injection", "TREATMENT", 0, 25], ["Tie2 activation", "OBSERVATION", 57, 72], ["lung", "ANATOMY", 80, 84]]], ["Since vascular therapies have broad indications for ocular diseases (27) , we also tested pharmacokinetics of the compound following intraocular injection in rabbits.", [["vascular", "ANATOMY", 6, 14], ["ocular", "ANATOMY", 52, 58], ["intraocular", "ANATOMY", 133, 144], ["ocular diseases", "DISEASE", 52, 67], ["vascular", "MULTI-TISSUE_STRUCTURE", 6, 14], ["ocular", "ORGAN", 52, 58], ["intraocular", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 144], ["rabbits", "ORGANISM", 158, 165], ["rabbits", "SPECIES", 158, 165], ["rabbits", "SPECIES", 158, 165], ["vascular therapies", "TREATMENT", 6, 24], ["ocular diseases", "PROBLEM", 52, 67], ["intraocular injection in rabbits", "TREATMENT", 133, 165], ["vascular", "ANATOMY", 6, 14]]], ["Following a single intravitreal injection of C4BP-ANG1, the presence of the drug was detected to last for at least 5 days in the aqueous (Fig3E), and 7 days in the vitreous (Fig3F), demonstrating excellent in vivo stability of the biologic.C4BP-ANG1 ameliorates pathological vascular leakageNext, we performed a series of pharmacologic tests using mouse models, in which we evaluated the effects of the drugs in protecting mice from pathologic vascular leakage (Fig4).", [["vitreous", "ANATOMY", 164, 172], ["vascular", "ANATOMY", 275, 283], ["vascular", "ANATOMY", 444, 452], ["vascular leakage", "DISEASE", 275, 291], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 45, 54], ["aqueous", "ORGANISM_SUBSTANCE", 129, 136], ["vitreous", "ORGANISM_SUBSTANCE", 164, 172], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 240, 249], ["vascular", "MULTI-TISSUE_STRUCTURE", 275, 283], ["mouse", "ORGANISM", 348, 353], ["mice", "ORGANISM", 423, 427], ["vascular", "MULTI-TISSUE_STRUCTURE", 444, 452], ["C4BP", "PROTEIN", 45, 49], ["ANG1", "PROTEIN", 50, 54], ["C4BP", "PROTEIN", 240, 244], ["ANG1", "PROTEIN", 245, 249], ["mouse", "SPECIES", 348, 353], ["mice", "SPECIES", 423, 427], ["mouse", "SPECIES", 348, 353], ["mice", "SPECIES", 423, 427], ["a single intravitreal injection of C4BP", "TREATMENT", 10, 49], ["C4BP", "TEST", 240, 244], ["pathological vascular leakage", "PROBLEM", 262, 291], ["pharmacologic tests", "TEST", 322, 341], ["mouse models", "TREATMENT", 348, 360], ["the drugs", "TREATMENT", 399, 408], ["pathologic vascular leakage", "PROBLEM", 433, 460], ["excellent", "OBSERVATION_MODIFIER", 196, 205], ["vascular", "ANATOMY", 275, 283], ["leakage", "OBSERVATION", 284, 291], ["vascular", "ANATOMY", 444, 452], ["leakage", "OBSERVATION", 453, 460]]], ["By using Evan's Blue tracer, we examined the in vivo efficacy of C4BP-ANG1 in preventing VEGF-induced microvascular leakage in the skin.", [["microvascular", "ANATOMY", 102, 115], ["skin", "ANATOMY", 131, 135], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 65, 74], ["VEGF", "GENE_OR_GENE_PRODUCT", 89, 93], ["microvascular", "TISSUE", 102, 115], ["skin", "ORGAN", 131, 135], ["C4BP", "PROTEIN", 65, 69], ["ANG1", "PROTEIN", 70, 74], ["VEGF", "PROTEIN", 89, 93], ["C4BP", "TEST", 65, 69], ["ANG1", "PROBLEM", 70, 74], ["VEGF", "PROBLEM", 89, 93], ["microvascular leakage in the skin", "PROBLEM", 102, 135], ["microvascular", "ANATOMY", 102, 115], ["leakage", "OBSERVATION", 116, 123], ["skin", "ANATOMY", 131, 135]]], ["The experiments demonstrated C4BP, either administrated locally through intradermal injection (Fig4A), or systemically through i.v. injection (Fig4B), markedly reduced leakage at the locations of intradermal VEGF injection.", [["intradermal", "ANATOMY", 72, 83], ["intradermal", "ANATOMY", 196, 207], ["C4BP", "GENE_OR_GENE_PRODUCT", 29, 33], ["VEGF", "GENE_OR_GENE_PRODUCT", 208, 212], ["C4BP", "PROTEIN", 29, 33], ["VEGF", "PROTEIN", 208, 212], ["C4BP", "PROBLEM", 29, 33], ["intradermal injection (Fig4A)", "TREATMENT", 72, 101], ["markedly reduced leakage", "PROBLEM", 151, 175], ["intradermal VEGF injection", "TREATMENT", 196, 222], ["C4BP", "OBSERVATION", 29, 33], ["reduced", "OBSERVATION_MODIFIER", 160, 167], ["leakage", "OBSERVATION", 168, 175], ["intradermal VEGF", "OBSERVATION", 196, 212]]], ["Furthermore, in a chemical-induced vascular leakage model using mustard oil, the levels of Evan's Blue leakage were also significantly lower in the C4BP-ANG1 treatment group (Fig4C).", [["vascular", "ANATOMY", 35, 43], ["oil", "ANATOMY", 72, 75], ["ANG1", "CHEMICAL", 153, 157], ["vascular", "MULTI-TISSUE_STRUCTURE", 35, 43], ["oil", "ORGANISM_SUBSTANCE", 72, 75], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 148, 157], ["C4BP", "PROTEIN", 148, 152], ["ANG1", "PROTEIN", 153, 157], ["a chemical-induced vascular leakage model", "TREATMENT", 16, 57], ["mustard oil", "TREATMENT", 64, 75], ["the levels", "TEST", 77, 87], ["Evan", "TEST", 91, 95], ["Blue leakage", "PROBLEM", 98, 110], ["the C4BP", "TEST", 144, 152], ["ANG1 treatment group (Fig4C)", "TREATMENT", 153, 181], ["vascular", "ANATOMY", 35, 43], ["leakage", "OBSERVATION", 44, 51], ["Blue leakage", "OBSERVATION", 98, 110], ["lower", "OBSERVATION_MODIFIER", 135, 140], ["C4BP", "ANATOMY", 148, 152]]], ["To model lung injury leading to ARDS in sepsis, we adapted a lipopolysaccharide-inhalation protocol to induce lung edema.", [["lung", "ANATOMY", 9, 13], ["lung edema", "ANATOMY", 110, 120], ["lung injury", "DISEASE", 9, 20], ["ARDS", "DISEASE", 32, 36], ["sepsis", "DISEASE", 40, 46], ["lipopolysaccharide", "CHEMICAL", 61, 79], ["lung edema", "DISEASE", 110, 120], ["lung", "ORGAN", 9, 13], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 61, 79], ["lung", "ORGAN", 110, 114], ["edema", "PATHOLOGICAL_FORMATION", 115, 120], ["model lung injury", "PROBLEM", 3, 20], ["ARDS", "PROBLEM", 32, 36], ["sepsis", "PROBLEM", 40, 46], ["a lipopolysaccharide-inhalation protocol", "TREATMENT", 59, 99], ["lung edema", "PROBLEM", 110, 120], ["lung", "ANATOMY", 9, 13], ["injury", "OBSERVATION", 14, 20], ["ARDS", "OBSERVATION", 32, 36], ["sepsis", "OBSERVATION", 40, 46], ["lung", "ANATOMY", 110, 114], ["edema", "OBSERVATION", 115, 120]]], ["The mice were divided into groups with or without being treated with C4BP-ANG1 from i.v. injection.", [["mice", "ORGANISM", 4, 8], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 69, 78], ["i.v.", "SIMPLE_CHEMICAL", 84, 88], ["C4BP", "PROTEIN", 69, 73], ["ANG1", "PROTEIN", 74, 78], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["The mice", "TREATMENT", 0, 8], ["C4BP-ANG1", "TREATMENT", 69, 78]]], ["As expected, mice that received two doses of C4BP-ANG1 treatments were partially protected from lipopolysaccharide-induced lung injury as measured by vascular leakage (Fig4D) .", [["lung", "ANATOMY", 123, 127], ["vascular", "ANATOMY", 150, 158], ["lipopolysaccharide", "CHEMICAL", 96, 114], ["lung injury", "DISEASE", 123, 134], ["mice", "ORGANISM", 13, 17], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 45, 54], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 96, 114], ["lung", "ORGAN", 123, 127], ["vascular", "MULTI-TISSUE_STRUCTURE", 150, 158], ["C4BP", "PROTEIN", 45, 49], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["C4BP", "TREATMENT", 45, 49], ["ANG1 treatments", "TREATMENT", 50, 65], ["lipopolysaccharide", "PROBLEM", 96, 114], ["lung injury", "PROBLEM", 123, 134], ["lung", "ANATOMY", 123, 127], ["injury", "OBSERVATION", 128, 134], ["vascular", "ANATOMY", 150, 158], ["leakage", "OBSERVATION", 159, 166]]], ["Meanwhile, in a tolerance test with repeated doses, we injected mice daily for 14 days.", [["mice", "ORGANISM", 64, 68], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["a tolerance test", "TEST", 14, 30], ["repeated doses", "TREATMENT", 36, 50]]], ["There were no overt adverse effects (not shown).DiscussionHere we sought to develop a \"bio-better\" analog of ANGPT1 as pharmaceutical candidate using a rational recombinant engineering design.", [["ANGPT1", "CHEMICAL", 109, 115], ["ANGPT1", "SIMPLE_CHEMICAL", 109, 115], ["overt adverse effects", "PROBLEM", 14, 35], ["a rational recombinant engineering design", "TREATMENT", 150, 191], ["no", "UNCERTAINTY", 11, 13]]], ["Our overall strategy was to overcome a key therapeutic limitation of native ANGPT1, which is nonspecific sequestration by the ECM and easy to aggregate, while still to preserve a high degree of oligomerization.", [["ECM", "ANATOMY", 126, 129], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 76, 82], ["ECM", "CELLULAR_COMPONENT", 126, 129], ["ANGPT1", "PROTEIN", 76, 82], ["ECM", "PROTEIN", 126, 129], ["nonspecific sequestration", "PROBLEM", 93, 118], ["a high degree of oligomerization", "PROBLEM", 177, 209], ["nonspecific", "OBSERVATION_MODIFIER", 93, 104], ["sequestration", "OBSERVATION", 105, 118], ["high degree", "OBSERVATION_MODIFIER", 179, 190], ["oligomerization", "OBSERVATION", 194, 209]]], ["We chose a protein scaffold segment from C4BP, an abundant serum complement protein complex, which is characterized by seven functional polypeptide chains extending from an intertwined scaffold (28) .", [["serum", "ANATOMY", 59, 64], ["C4BP", "GENE_OR_GENE_PRODUCT", 41, 45], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["protein scaffold segment", "PROTEIN", 11, 35], ["C4BP", "PROTEIN", 41, 45], ["serum complement protein complex", "PROTEIN", 59, 91], ["polypeptide chains", "PROTEIN", 136, 154], ["a protein scaffold segment from C4BP", "TEST", 9, 45], ["an abundant serum complement protein complex", "PROBLEM", 47, 91], ["seven functional polypeptide chains", "PROBLEM", 119, 154], ["polypeptide chains", "OBSERVATION", 136, 154], ["scaffold", "OBSERVATION_MODIFIER", 185, 193]]], ["We constructed several variants of C4BP-ANG1 fusion proteins and showed all formed stable heptamers when expressed in HEK293 and CHO cells.", [["HEK293", "ANATOMY", 118, 124], ["CHO cells", "ANATOMY", 129, 138], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 35, 44], ["HEK293", "CELL", 118, 124], ["CHO cells", "CELL", 129, 138], ["C4BP", "PROTEIN", 35, 39], ["ANG1 fusion proteins", "PROTEIN", 40, 60], ["heptamers", "PROTEIN", 90, 99], ["HEK293", "CELL_LINE", 118, 124], ["CHO cells", "CELL_LINE", 129, 138], ["C4BP", "TEST", 35, 39], ["ANG1 fusion proteins", "TEST", 40, 60], ["all formed stable heptamers", "PROBLEM", 72, 99], ["stable", "OBSERVATION", 83, 89], ["CHO cells", "OBSERVATION", 129, 138]]], ["Intradermal, intravenous, intraperitoneal and intravitreal injections of mice and rabbits all showed longlasting activity and protection from a variety types of inflammatory vascular leak.DiscussionIn recent years, there have been major advances in drug development that specifically target the Angpt-Tie pathway.", [["intravenous", "ANATOMY", 13, 24], ["intraperitoneal", "ANATOMY", 26, 41], ["vascular", "ANATOMY", 174, 182], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 24], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 41], ["mice", "ORGANISM", 73, 77], ["rabbits", "ORGANISM", 82, 89], ["vascular", "MULTI-TISSUE_STRUCTURE", 174, 182], ["Angpt", "GENE_OR_GENE_PRODUCT", 295, 300], ["Tie", "GENE_OR_GENE_PRODUCT", 301, 304], ["Angpt", "PROTEIN", 295, 300], ["Tie", "PROTEIN", 301, 304], ["mice", "SPECIES", 73, 77], ["rabbits", "SPECIES", 82, 89], ["mice", "SPECIES", 73, 77], ["rabbits", "SPECIES", 82, 89], ["Intradermal", "TREATMENT", 0, 11], ["intravenous", "TREATMENT", 13, 24], ["intraperitoneal and intravitreal injections of mice and rabbits", "TREATMENT", 26, 89], ["longlasting activity", "PROBLEM", 101, 121], ["inflammatory vascular leak", "PROBLEM", 161, 187], ["intraperitoneal", "ANATOMY", 26, 41], ["longlasting activity", "OBSERVATION", 101, 121], ["variety", "OBSERVATION_MODIFIER", 144, 151], ["types", "OBSERVATION_MODIFIER", 152, 157], ["inflammatory", "OBSERVATION_MODIFIER", 161, 173], ["vascular", "ANATOMY", 174, 182], ["leak", "OBSERVATION", 183, 187]]], ["Strategies include ANGPT1 mimetics, ANGPT2 neutralizing antibodies, bi-specific, doubletargeting antiangiogenic antibodies or affinity traps linking ANGPT2 with VEGF, or similarly, ANGPT2 with Tie2, and small molecule inhibitors of VEPTP or Tie2 catalytic activities, among others (2) .", [["ANGPT1", "GENE_OR_GENE_PRODUCT", 19, 25], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 36, 42], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 149, 155], ["VEGF", "GENE_OR_GENE_PRODUCT", 161, 165], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 181, 187], ["Tie2", "GENE_OR_GENE_PRODUCT", 193, 197], ["VEPTP", "GENE_OR_GENE_PRODUCT", 232, 237], ["Tie2", "GENE_OR_GENE_PRODUCT", 241, 245], ["ANGPT1", "PROTEIN", 19, 25], ["ANGPT2 neutralizing antibodies", "PROTEIN", 36, 66], ["bi-specific, doubletargeting antiangiogenic antibodies", "PROTEIN", 68, 122], ["ANGPT2", "PROTEIN", 149, 155], ["VEGF", "PROTEIN", 161, 165], ["ANGPT2", "PROTEIN", 181, 187], ["Tie2", "PROTEIN", 193, 197], ["VEPTP", "PROTEIN", 232, 237], ["Tie2", "PROTEIN", 241, 245], ["ANGPT1 mimetics", "TREATMENT", 19, 34], ["ANGPT2 neutralizing antibodies", "TEST", 36, 66], ["doubletargeting antiangiogenic antibodies", "TREATMENT", 81, 122], ["affinity traps", "TEST", 126, 140], ["VEGF", "PROBLEM", 161, 165], ["Tie2", "TEST", 193, 197], ["small molecule inhibitors", "TREATMENT", 203, 228], ["VEPTP", "TREATMENT", 232, 237]]], ["With the exception of Tie2 kinase inhibitors, all these therapies are designed to elevate the activity and function of Tie2 to promote vascular stabilization and reduce vascular response to inflammatory signals.", [["vascular", "ANATOMY", 135, 143], ["vascular", "ANATOMY", 169, 177], ["Tie2", "GENE_OR_GENE_PRODUCT", 22, 26], ["Tie2", "GENE_OR_GENE_PRODUCT", 119, 123], ["vascular", "MULTI-TISSUE_STRUCTURE", 135, 143], ["vascular", "MULTI-TISSUE_STRUCTURE", 169, 177], ["Tie2 kinase", "PROTEIN", 22, 33], ["Tie2", "PROTEIN", 119, 123], ["Tie2 kinase inhibitors", "TREATMENT", 22, 44], ["all these therapies", "TREATMENT", 46, 65], ["vascular stabilization", "TREATMENT", 135, 157], ["inflammatory signals", "PROBLEM", 190, 210], ["vascular", "ANATOMY", 135, 143], ["stabilization", "OBSERVATION", 144, 157], ["vascular", "ANATOMY", 169, 177], ["inflammatory", "OBSERVATION", 190, 202]]], ["Theoretically, these activities should counteract VEGF-induced neovascularization and inflammatory leakage that is characteristic of many human diseases.", [["neovascularization", "DISEASE", 63, 81], ["VEGF", "GENE_OR_GENE_PRODUCT", 50, 54], ["human", "ORGANISM", 138, 143], ["VEGF", "PROTEIN", 50, 54], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["VEGF", "PROBLEM", 50, 54], ["neovascularization", "PROBLEM", 63, 81], ["inflammatory leakage", "PROBLEM", 86, 106], ["many human diseases", "PROBLEM", 133, 152], ["neovascularization", "OBSERVATION", 63, 81], ["inflammatory leakage", "OBSERVATION", 86, 106], ["many", "OBSERVATION_MODIFIER", 133, 137], ["human diseases", "OBSERVATION", 138, 152]]], ["Many clinical studies have demonstrated an association between elevated expression of circulating ANGPT2 and poor clinical outcome in diseases characterized by vascular leakage and tissue damage (2, 29) .", [["vascular", "ANATOMY", 160, 168], ["tissue", "ANATOMY", 181, 187], ["vascular leakage", "DISEASE", 160, 176], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 98, 104], ["vascular", "MULTI-TISSUE_STRUCTURE", 160, 168], ["tissue", "TISSUE", 181, 187], ["ANGPT2", "PROTEIN", 98, 104], ["Many clinical studies", "TEST", 0, 21], ["circulating ANGPT2", "PROBLEM", 86, 104], ["poor clinical outcome in diseases", "PROBLEM", 109, 142], ["vascular leakage and tissue damage", "PROBLEM", 160, 194], ["diseases", "OBSERVATION", 134, 142], ["vascular", "ANATOMY", 160, 168], ["leakage", "OBSERVATION", 169, 176], ["tissue", "OBSERVATION_MODIFIER", 181, 187], ["damage", "OBSERVATION", 188, 194]]], ["While it remains unclear if these elevated levels of ANGPT2 antagonizing Tie2 activity during inflammation are causal, agonistic ANGPT1 mimetic treatment with C4BP-ANG1 is predicted to ameliorate vascular destabilization that occurs in severe infectious conditions such as pneumonia from flu or coronavirus.", [["vascular", "ANATOMY", 196, 204], ["inflammation", "DISEASE", 94, 106], ["vascular destabilization", "DISEASE", 196, 220], ["pneumonia", "DISEASE", 273, 282], ["flu", "DISEASE", 288, 291], ["coronavirus", "DISEASE", 295, 306], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 53, 59], ["Tie2", "GENE_OR_GENE_PRODUCT", 73, 77], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 129, 135], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 159, 168], ["vascular", "MULTI-TISSUE_STRUCTURE", 196, 204], ["ANGPT2", "PROTEIN", 53, 59], ["Tie2", "PROTEIN", 73, 77], ["ANGPT1", "PROTEIN", 129, 135], ["C4BP", "PROTEIN", 159, 163], ["ANG1", "PROTEIN", 164, 168], ["these elevated levels", "PROBLEM", 28, 49], ["ANGPT2 antagonizing", "TREATMENT", 53, 72], ["inflammation", "PROBLEM", 94, 106], ["agonistic ANGPT1 mimetic treatment", "TREATMENT", 119, 153], ["C4BP-ANG1", "TREATMENT", 159, 168], ["vascular destabilization", "PROBLEM", 196, 220], ["severe infectious conditions", "PROBLEM", 236, 264], ["pneumonia", "PROBLEM", 273, 282], ["flu", "PROBLEM", 288, 291], ["coronavirus", "PROBLEM", 295, 306], ["vascular", "ANATOMY", 196, 204], ["destabilization", "OBSERVATION", 205, 220], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["infectious", "OBSERVATION", 243, 253], ["pneumonia", "OBSERVATION", 273, 282]]], ["Indeed, several clinical studies confirm that the ratio of circulating ANGPT1/ANGPT2 is predictive of patient outcome (30, 31) .DiscussionPrior to this study, ANGPT1-mimetic therapies have been designed and tried where the N-terminus domains of the ANGPT1 analogs have been removed and replaced with less \"sticky\" structures.", [["N", "CHEMICAL", 223, 224], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 71, 77], ["ANGPT2", "GENE_OR_GENE_PRODUCT", 78, 84], ["patient", "ORGANISM", 102, 109], ["ANGPT1", "SIMPLE_CHEMICAL", 159, 165], ["ANGPT1", "GENE_OR_GENE_PRODUCT", 249, 255], ["ANGPT1", "PROTEIN", 71, 77], ["ANGPT2", "PROTEIN", 78, 84], ["ANGPT1", "PROTEIN", 159, 165], ["N-terminus domains", "PROTEIN", 223, 241], ["ANGPT1", "PROTEIN", 249, 255], ["patient", "SPECIES", 102, 109], ["several clinical studies", "TEST", 8, 32], ["the ratio", "TEST", 46, 55], ["circulating ANGPT1", "TEST", 59, 77], ["this study", "TEST", 147, 157], ["ANGPT1-mimetic therapies", "TREATMENT", 159, 183], ["the N-terminus domains", "TREATMENT", 219, 241], ["the ANGPT1 analogs", "TREATMENT", 245, 263]]], ["These strategies include BowAng1, which contains a dimerization Fc domain and a tandem arrangement of the FLD, achieving a multimericity of 2x2=4.", [["BowAng1", "CHEMICAL", 25, 32], ["BowAng1", "SIMPLE_CHEMICAL", 25, 32], ["BowAng1", "PROTEIN", 25, 32], ["dimerization Fc domain", "PROTEIN", 51, 73], ["FLD", "PROTEIN", 106, 109], ["2x2=4", "PROTEIN", 140, 145], ["BowAng1", "PROBLEM", 25, 32], ["a dimerization Fc domain", "PROBLEM", 49, 73], ["the FLD", "TEST", 102, 109], ["FLD", "OBSERVATION", 106, 109]]], ["A second strategy fused the FLD of ANGPT1 to the short coiled-coil domain of cartilage oligomeric matrix protein (COMP), which generated a pentameric complex with \"super ligand\" activity.", [["ANGPT1", "GENE_OR_GENE_PRODUCT", 35, 41], ["cartilage oligomeric matrix protein", "GENE_OR_GENE_PRODUCT", 77, 112], ["COMP", "GENE_OR_GENE_PRODUCT", 114, 118], ["FLD", "PROTEIN", 28, 31], ["ANGPT1", "PROTEIN", 35, 41], ["coiled-coil domain", "PROTEIN", 55, 73], ["cartilage oligomeric matrix protein", "PROTEIN", 77, 112], ["COMP", "PROTEIN", 114, 118], ["pentameric complex", "PROTEIN", 139, 157], ["ANGPT1", "TREATMENT", 35, 41], ["the short coiled-coil domain of", "TREATMENT", 45, 76], ["cartilage oligomeric matrix protein (COMP)", "PROBLEM", 77, 119], ["FLD", "OBSERVATION", 28, 31], ["short", "OBSERVATION_MODIFIER", 49, 54], ["cartilage", "ANATOMY", 77, 86], ["oligomeric matrix protein", "OBSERVATION", 87, 112]]], ["However, while COMP-ANG1 has improved solubility over native ANG1, the coiledcoil-to-coiled-coil interactions, which tend to have broad interaction preference among different coiled-coil domains (32, 33) , have the propensity to trigger protein aggregation during production (15, 25) .", [["ANG1", "CHEMICAL", 20, 24], ["COMP", "GENE_OR_GENE_PRODUCT", 15, 19], ["ANG1", "GENE_OR_GENE_PRODUCT", 61, 65], ["COMP", "PROTEIN", 15, 19], ["ANG1", "PROTEIN", 20, 24], ["native ANG1", "PROTEIN", 54, 65], ["coiled-coil domains", "PROTEIN", 175, 194], ["native ANG1", "TREATMENT", 54, 65], ["the coiledcoil-to-coiled-coil interactions", "TREATMENT", 67, 109], ["broad interaction preference", "PROBLEM", 130, 158], ["different coiled-coil domains", "TREATMENT", 165, 194], ["trigger protein aggregation", "PROBLEM", 229, 256], ["improved", "OBSERVATION_MODIFIER", 29, 37], ["solubility", "OBSERVATION_MODIFIER", 38, 48], ["protein aggregation", "OBSERVATION", 237, 256]]], ["It may also retain at the ECM after injection due to a general affinity of the coiled-coil domain towards tissue coiled-coil proteins that are abundantly found in the ECM (24, 34) .", [["ECM", "ANATOMY", 26, 29], ["tissue", "ANATOMY", 106, 112], ["ECM", "ANATOMY", 167, 170], ["ECM", "CELLULAR_COMPONENT", 26, 29], ["tissue", "TISSUE", 106, 112], ["ECM", "CELLULAR_COMPONENT", 167, 170], ["coiled-coil domain", "PROTEIN", 79, 97], ["tissue coiled-coil proteins", "PROTEIN", 106, 133], ["ECM", "PROTEIN", 167, 170], ["a general affinity", "PROBLEM", 53, 71], ["the coiled-coil domain", "TREATMENT", 75, 97], ["tissue coiled-coil proteins", "TREATMENT", 106, 133], ["coiled", "OBSERVATION", 79, 85], ["coil proteins", "OBSERVATION", 120, 133], ["ECM", "OBSERVATION_MODIFIER", 167, 170]]], ["We hypothesized that the selection of a scaffold with better serum-compatibility may solve multiple problems: 1) ECM-sequestration 2) degradation from systemic circulation 3) protein aggregation during production and storage and 4) possible antigenicity.", [["serum", "ANATOMY", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["multiple problems", "PROBLEM", 91, 108], ["ECM-sequestration", "PROBLEM", 113, 130], ["systemic circulation", "PROBLEM", 151, 171], ["protein aggregation", "PROBLEM", 175, 194], ["antigenicity", "PROBLEM", 241, 253]]], ["Besides forming a heptameric scaffold, the selected C4BP complex used to construct C4BP-ANG1 does not carry immunogenicity of the parent protein.", [["C4BP", "GENE_OR_GENE_PRODUCT", 52, 56], ["C4BP", "GENE_OR_GENE_PRODUCT", 83, 87], ["C4BP complex", "PROTEIN", 52, 64], ["C4BP", "PROTEIN", 83, 87], ["ANG1", "PROTEIN", 88, 92], ["parent protein", "PROTEIN", 130, 144], ["a heptameric scaffold", "TREATMENT", 16, 37], ["the selected C4BP complex", "TREATMENT", 39, 64], ["C4BP", "TEST", 83, 87], ["heptameric scaffold", "OBSERVATION", 18, 37]]], ["Hence, while C4BP-ANG1 structurally resembles native C4BP heptameric complex, it is able to function as a potent Tie2 ligand via its highly clustered FLDs.", [["C4BP", "GENE_OR_GENE_PRODUCT", 13, 17], ["ANG1", "GENE_OR_GENE_PRODUCT", 18, 22], ["C4BP", "GENE_OR_GENE_PRODUCT", 53, 57], ["Tie2", "GENE_OR_GENE_PRODUCT", 113, 117], ["FLDs", "PATHOLOGICAL_FORMATION", 150, 154], ["C4BP", "PROTEIN", 13, 17], ["ANG1", "PROTEIN", 18, 22], ["C4BP heptameric complex", "PROTEIN", 53, 76], ["Tie2 ligand", "PROTEIN", 113, 124], ["C4BP", "TEST", 13, 17], ["native C4BP heptameric complex", "PROBLEM", 46, 76], ["a potent Tie2 ligand", "TREATMENT", 104, 124], ["heptameric complex", "OBSERVATION", 58, 76]]], ["Furthermore, C4BP-ANG1 is well tolerated in mice with daily injections for two weeks.", [["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 13, 22], ["mice", "ORGANISM", 44, 48], ["C4BP", "PROTEIN", 13, 17], ["ANG1", "PROTEIN", 18, 22], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["C4BP", "TEST", 13, 17]]], ["Since the fusion was constructed using all human protein sequences of C4BP and ANG1, we have not performed long-term injection studies beyond 14 days due to the concern of development of cross-species neutralizing antibodies.DiscussionIn summary, we designed and constructed a new C4BP-ANG1 fusion as a new candidate ANGPT1 mimetic therapy.", [["human", "ORGANISM", 43, 48], ["C4BP", "GENE_OR_GENE_PRODUCT", 70, 74], ["ANG1", "GENE_OR_GENE_PRODUCT", 79, 83], ["C4BP", "GENE_OR_GENE_PRODUCT", 281, 285], ["ANG1", "GENE_OR_GENE_PRODUCT", 286, 290], ["ANGPT1", "SIMPLE_CHEMICAL", 317, 323], ["human protein sequences", "DNA", 43, 66], ["C4BP", "PROTEIN", 70, 74], ["ANG1", "PROTEIN", 79, 83], ["cross-species neutralizing antibodies", "PROTEIN", 187, 224], ["C4BP", "PROTEIN", 281, 285], ["ANG1", "PROTEIN", 286, 290], ["ANGPT1", "PROTEIN", 317, 323], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["the fusion", "TREATMENT", 6, 16], ["all human protein sequences", "TEST", 39, 66], ["long-term injection studies", "TREATMENT", 107, 134], ["cross-species neutralizing antibodies", "PROBLEM", 187, 224], ["a new C4BP-ANG1 fusion", "TREATMENT", 275, 297], ["a new candidate ANGPT1 mimetic therapy", "TREATMENT", 301, 339]]], ["The fusion displays remarkable stability with high multimericity that can potently activate Tie2 and is suitable for systemic administration.", [["Tie2", "GENE_OR_GENE_PRODUCT", 92, 96], ["Tie2", "PROTEIN", 92, 96], ["high multimericity", "PROBLEM", 46, 64], ["systemic administration", "TREATMENT", 117, 140], ["fusion", "OBSERVATION", 4, 10], ["remarkable", "OBSERVATION_MODIFIER", 20, 30], ["stability", "OBSERVATION_MODIFIER", 31, 40], ["high multimericity", "OBSERVATION", 46, 64]]], ["Furthermore, the study validated a general strategy to use a C4BP scaffold in drug design when high degree of oligomeric states is desired.Materials and MethodsConstruction of C4BP-ANG1 cDNA ANG1-C4BP and C4BP-ANG1 refer to chimeric fusions between ANGPT1 C-terminus FLD and C4BP Cterminus segments in an N-to-C-terminus order, respectively, in either direction.", [["C4BP", "GENE_OR_GENE_PRODUCT", 61, 65], ["C4BP", "GENE_OR_GENE_PRODUCT", 176, 180], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 191, 200], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 205, 214], ["C4BP Cterminus", "GENE_OR_GENE_PRODUCT", 275, 289], ["C4BP", "PROTEIN", 61, 65], ["C4BP", "PROTEIN", 176, 180], ["ANG1 cDNA", "DNA", 181, 190], ["ANG1", "DNA", 191, 195], ["C4BP", "PROTEIN", 196, 200], ["C4BP", "PROTEIN", 205, 209], ["ANG1", "DNA", 210, 214], ["ANGPT1 C-terminus", "PROTEIN", 249, 266], ["FLD", "PROTEIN", 267, 270], ["C4BP Cterminus segments", "PROTEIN", 275, 298], ["N-to-C-terminus", "DNA", 305, 320], ["the study", "TEST", 13, 22], ["a C4BP scaffold in drug design", "TREATMENT", 59, 89], ["high degree of oligomeric states", "PROBLEM", 95, 127], ["Materials", "TEST", 139, 148], ["MethodsConstruction of C4BP", "TEST", 153, 180], ["ANG1", "TEST", 191, 195], ["C4BP", "TEST", 196, 200], ["C4BP", "TEST", 205, 209], ["chimeric fusions", "TEST", 224, 240], ["ANGPT1", "TEST", 249, 255], ["oligomeric states", "OBSERVATION", 110, 127]]], ["The C4BP C-terminus segment is derived from human C4BP\u03b1 protein (Accession No.", [["C4BP", "GENE_OR_GENE_PRODUCT", 4, 8], ["human", "ORGANISM", 44, 49], ["C4BP\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["C4BP C-terminus segment", "PROTEIN", 4, 27], ["human C4BP\u03b1 protein", "PROTEIN", 44, 63], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["The C4BP C", "TEST", 0, 10], ["human C4BP", "TEST", 44, 54], ["terminus segment", "ANATOMY_MODIFIER", 11, 27]]], ["NP_000706.1).", [["NP_000706.1", "CHEMICAL", 0, 11]]], ["The C-terminus FLD segment of ANGPT1 is derived from the human sequence (Accession No.", [["ANGPT1", "GENE_OR_GENE_PRODUCT", 30, 36], ["human", "ORGANISM", 57, 62], ["C-terminus FLD segment", "PROTEIN", 4, 26], ["ANGPT1", "PROTEIN", 30, 36], ["human sequence", "DNA", 57, 71], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["The C-terminus FLD segment of ANGPT1", "TEST", 0, 36], ["FLD", "OBSERVATION", 15, 18], ["segment", "ANATOMY_MODIFIER", 19, 26]]], ["NP_001137.2; amino acid 281-498).", [["NP_001137.2", "CHEMICAL", 0, 11], ["amino acid 281-498", "CHEMICAL", 13, 31], ["amino acid 281-498", "CHEMICAL", 13, 31], ["amino acid", "AMINO_ACID", 13, 23], ["amino acid", "TEST", 13, 23]]], ["DNA sequences encoding ANG1-C4BP and C4BP-ANG1 were synthesized by Integrated DNA Technologies and cloned into pcDNA3 vector, a poly-histidine tag was included on the C-termini of the sequences.Recombinant protein production and purificationProduction of recombinant C4BP-ANG1 and ANG1-C4BP was performed in HEK293 clonal expression system that was described previously (35) .", [["HEK293 clonal", "ANATOMY", 308, 321], ["poly-histidine", "CHEMICAL", 128, 142], ["poly-histidine", "CHEMICAL", 128, 142], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 23, 32], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 37, 46], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 111, 117], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 267, 276], ["ANG1-C4BP", "GENE_OR_GENE_PRODUCT", 281, 290], ["HEK293 clonal", "CELL", 308, 321], ["DNA sequences", "DNA", 0, 13], ["ANG1", "PROTEIN", 23, 27], ["C4BP", "PROTEIN", 28, 32], ["C4BP", "PROTEIN", 37, 41], ["ANG1", "PROTEIN", 42, 46], ["pcDNA3 vector", "DNA", 111, 124], ["poly-histidine tag", "DNA", 128, 146], ["C-termini", "PROTEIN", 167, 176], ["C4BP", "PROTEIN", 267, 271], ["ANG1", "PROTEIN", 272, 276], ["ANG1", "PROTEIN", 281, 285], ["C4BP", "PROTEIN", 286, 290], ["DNA sequences", "TEST", 0, 13], ["ANG1", "TEST", 23, 27], ["C4BP", "TEST", 28, 32], ["C4BP", "TEST", 37, 41], ["a poly-histidine tag", "TREATMENT", 126, 146], ["Recombinant protein production", "TEST", 194, 224], ["purification", "TEST", 229, 241], ["recombinant C4BP", "TEST", 255, 271], ["ANG1", "TEST", 272, 276], ["ANG1-C4BP", "TEST", 281, 290], ["protein production", "OBSERVATION", 206, 224]]], ["Briefly, the constructs in expression vector pcDNA3 were transfected to HEK293 cells, and selected in DMEM medium supplemented with 800 \u00b5g/ml of G418 until individual colonies were visible under microscope.", [["HEK293 cells", "ANATOMY", 72, 84], ["colonies", "ANATOMY", 167, 175], ["G418", "CHEMICAL", 145, 149], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 45, 51], ["HEK293 cells", "CELL", 72, 84], ["expression vector pcDNA3", "DNA", 27, 51], ["HEK293 cells", "CELL_LINE", 72, 84], ["the constructs in expression vector pcDNA3", "TREATMENT", 9, 51], ["G418", "TREATMENT", 145, 149], ["individual colonies", "PROBLEM", 156, 175]]], ["Individual colonies were then selected and expanded in separate wells.", [["colonies", "ANATOMY", 11, 19], ["Individual colonies", "PROBLEM", 0, 19], ["colonies", "OBSERVATION", 11, 19]]], ["The expression of the recombinant protein was measured by ELISA using anti-His tag monoclonal antibody (Invitrogen) to capture and biotinylated anti-ANG1 antibody for detection (R&D System).", [["His", "CHEMICAL", 75, 78], ["anti-ANG1", "GENE_OR_GENE_PRODUCT", 144, 153], ["recombinant protein", "PROTEIN", 22, 41], ["anti-His tag monoclonal antibody", "PROTEIN", 70, 102], ["Invitrogen", "PROTEIN", 104, 114], ["anti-ANG1 antibody", "PROTEIN", 144, 162], ["the recombinant protein", "PROBLEM", 18, 41], ["ELISA", "TEST", 58, 63], ["anti", "TEST", 70, 74], ["His tag monoclonal antibody", "TREATMENT", 75, 102], ["biotinylated anti-ANG1 antibody", "TEST", 131, 162]]], ["The clones showing the highest titers of the recombinant protein were selected.", [["clones", "ANATOMY", 4, 10], ["clones", "CELL", 4, 10], ["recombinant protein", "PROTEIN", 45, 64], ["The clones", "TEST", 0, 10]]], ["Protein production was in a Nunc CellFactory system (ThermoFisher) using serum-free culture.", [["serum", "ANATOMY", 73, 78], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["Protein production", "PROBLEM", 0, 18], ["serum-free culture", "TEST", 73, 91]]], ["The medium was centrifuged to clear the cell debris, followed by concentrating and buffer exchange into IMAC binding buffer using Vivaflow 100 system (Sartorius).", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["the cell debris", "PROBLEM", 36, 51], ["buffer exchange into IMAC binding buffer", "TREATMENT", 83, 123], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["cell debris", "OBSERVATION", 40, 51], ["Sartorius", "ANATOMY", 151, 160]]], ["The resulting protein solution was purified by Histrap column (GE Healthcare) and then buffer exchanged into DPBS by using desalting column (Thermo).", [["The resulting protein solution", "TREATMENT", 0, 30]]], ["For further scale-up production of the C4BP-ANG1 variants, an alternative CHO expression system was used, as described previously (36, 37) .Biochemical characterization of C4BP-ANG1The molecular size of the protein complex was determined by gel electrophoresis, western blot and sizeexclusion chromatography.", [["CHO", "ANATOMY", 74, 77], ["C4BP-ANG1", "CHEMICAL", 172, 181], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 39, 48], ["CHO", "CELL", 74, 77], ["C4BP", "PROTEIN", 39, 43], ["ANG1", "PROTEIN", 44, 48], ["ANG1", "PROTEIN", 177, 181], ["protein complex", "PROTEIN", 207, 222], ["further scale", "TEST", 4, 17], ["the C4BP", "TEST", 35, 43], ["Biochemical characterization", "TEST", 140, 168], ["gel electrophoresis", "TEST", 241, 260], ["sizeexclusion chromatography", "TEST", 279, 307], ["molecular", "OBSERVATION_MODIFIER", 185, 194], ["size", "OBSERVATION_MODIFIER", 195, 199], ["protein complex", "OBSERVATION", 207, 222]]], ["Under either reduced or non-reduced conditions, the molecular size of the monomeric or the heptameric form was determined by SDS-PAGE and western blot, respectively.", [["heptameric form", "PROTEIN", 91, 106], ["reduced or non-reduced conditions", "PROBLEM", 13, 46], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["Anti-His tag monoclonal antibody (Invitrogen) was used in western blot analysis.Biochemical characterization of C4BP-ANG1TEM analysis of the protein complexes was conducted following a standard negative staining protocol (38) .", [["His", "CHEMICAL", 5, 8], ["Anti-His tag monoclonal antibody", "PROTEIN", 0, 32], ["Invitrogen", "PROTEIN", 34, 44], ["C4BP-ANG1TEM", "PROTEIN", 112, 124], ["protein complexes", "PROTEIN", 141, 158], ["Anti", "TREATMENT", 0, 4], ["His tag monoclonal antibody (Invitrogen)", "TREATMENT", 5, 45], ["blot analysis", "TEST", 66, 79], ["Biochemical characterization", "TEST", 80, 108], ["C4BP-ANG1TEM analysis", "TEST", 112, 133]]], ["In brief, purified C4BP-A1 was diluted in DPBS to a concentration of 100 ug/mL.", [["C4BP-A1", "GENE_OR_GENE_PRODUCT", 19, 26], ["DPBS", "SIMPLE_CHEMICAL", 42, 46], ["C4BP", "PROTEIN", 19, 23], ["A1", "PROTEIN", 24, 26]]], ["A 10 uL droplet was applied to a glow-discharged carbon-coated copper grids and allowed to sit for 1 minutes.", [["carbon", "CHEMICAL", 49, 55], ["copper", "CHEMICAL", 63, 69], ["carbon", "CHEMICAL", 49, 55], ["copper", "CHEMICAL", 63, 69], ["copper grids", "SIMPLE_CHEMICAL", 63, 75], ["A 10 uL droplet", "TREATMENT", 0, 15], ["a glow-discharged carbon-coated copper grids", "TREATMENT", 31, 75]]], ["The grids were washed by dipping in two separate drops of water followed by two drops of 2% uranyl acetate (Electron Microscopy Sciences).", [["uranyl acetate", "CHEMICAL", 92, 106], ["uranyl acetate", "CHEMICAL", 92, 106], ["uranyl acetate", "SIMPLE_CHEMICAL", 92, 106], ["2% uranyl acetate", "TREATMENT", 89, 106]]], ["Grids were examined at the Northwestern Electron Probe Instrumentation Center (EPIC) using Hitachi HT-7700 Biological S/TEM Microscope.Biochemical characterization of C4BP-ANG1C4BP-ANG1 and Tie2 ectodomain (amino acid 1-745 of Tie2 in Tie2-Fc fusion) binding was measured by coimmunoprecipitation assay.", [["amino acid 1-745", "CHEMICAL", 207, 223], ["amino acid", "CHEMICAL", 207, 217], ["C4BP-ANG1C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 167, 185], ["Tie2", "GENE_OR_GENE_PRODUCT", 190, 194], ["amino acid", "AMINO_ACID", 207, 217], ["Tie2", "GENE_OR_GENE_PRODUCT", 227, 231], ["Tie2-Fc", "GENE_OR_GENE_PRODUCT", 235, 242], ["C4BP-ANG1C4BP", "PROTEIN", 167, 180], ["ANG1", "PROTEIN", 181, 185], ["Tie2 ectodomain", "PROTEIN", 190, 205], ["Tie2", "PROTEIN", 227, 231], ["Tie2", "PROTEIN", 235, 239], ["Biochemical characterization", "TEST", 135, 163], ["C4BP-", "TEST", 167, 172], ["ANG1C4BP", "TEST", 172, 180], ["ANG1", "TEST", 181, 185], ["Tie2 ectodomain", "TEST", 190, 205], ["amino acid", "TEST", 207, 217], ["Tie2 in Tie2-Fc fusion", "TREATMENT", 227, 249]]], ["100 ng recombinant Ang1-C4BP, C4BP-Ang1 or native Angpt1 protein (R&D systems) was mixed with 100 ng Tie2-Fc (with His tag, R&D systems) in TBST buffer at 4\u2103 for 4 hours.", [["His", "CHEMICAL", 115, 118], ["Ang1-C4BP", "GENE_OR_GENE_PRODUCT", 19, 28], ["C4BP-Ang1", "GENE_OR_GENE_PRODUCT", 30, 39], ["Angpt1", "GENE_OR_GENE_PRODUCT", 50, 56], ["Tie2-Fc", "GENE_OR_GENE_PRODUCT", 101, 108], ["Ang1", "PROTEIN", 19, 23], ["C4BP", "PROTEIN", 24, 28], ["C4BP", "PROTEIN", 30, 34], ["Ang1", "PROTEIN", 35, 39], ["native Angpt1 protein", "PROTEIN", 43, 64], ["R&D systems", "PROTEIN", 66, 77], ["Tie2", "PROTEIN", 101, 105], ["Fc", "PROTEIN", 106, 108], ["His tag", "PROTEIN", 115, 122], ["ng recombinant Ang1", "TEST", 4, 23], ["C4BP", "TEST", 24, 28], ["C4BP", "TEST", 30, 34], ["Ang1", "TEST", 35, 39], ["His tag, R&D systems", "TREATMENT", 115, 135], ["TBST buffer", "TREATMENT", 140, 151]]], ["Then 10 ul protein G agarose beads (Sigma) were added and incubated for another 1 hour.", [["ul protein G agarose beads", "TREATMENT", 8, 34]]], ["The beads were collected by centrifugation and washed five times by TBST.", [["beads", "ANATOMY", 4, 9], ["The beads", "TREATMENT", 0, 9], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["The immunoprecipitated proteins were eluted by reducing SDS-PAGE sample buffer and analyzed by western blot using anti-His tag antibody.Biochemical characterization of C4BP-ANG1Cell-based experimental studies of C4BP-ANG1 Two experimental systems were used to evaluate cell signaling response to C4BP-ANG1 treatment: human umbilical vein cells (HUVECs, ATCC) and HEK293 with stable expression of full length Tie2 with a Cterminus FLAG tag.", [["cell", "ANATOMY", 269, 273], ["human umbilical vein cells", "ANATOMY", 317, 343], ["HUVECs", "ANATOMY", 345, 351], ["ATCC", "ANATOMY", 353, 357], ["HEK293", "ANATOMY", 363, 369], ["His", "CHEMICAL", 119, 122], ["C4BP", "GENE_OR_GENE_PRODUCT", 168, 172], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 212, 221], ["cell", "CELL", 269, 273], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 296, 305], ["human umbilical vein cells", "CELL", 317, 343], ["HUVECs", "CELL", 345, 351], ["ATCC", "CELL", 353, 357], ["HEK293", "CELL", 363, 369], ["Tie2", "GENE_OR_GENE_PRODUCT", 408, 412], ["immunoprecipitated proteins", "PROTEIN", 4, 31], ["anti-His tag antibody", "PROTEIN", 114, 135], ["C4BP", "PROTEIN", 168, 172], ["ANG1Cell", "PROTEIN", 173, 181], ["C4BP", "PROTEIN", 212, 216], ["ANG1", "PROTEIN", 217, 221], ["C4BP", "PROTEIN", 296, 300], ["ANG1", "PROTEIN", 301, 305], ["human umbilical vein cells", "CELL_TYPE", 317, 343], ["HUVECs", "CELL_LINE", 345, 351], ["ATCC", "CELL_LINE", 353, 357], ["HEK293", "CELL_LINE", 363, 369], ["Tie2", "PROTEIN", 408, 412], ["Cterminus FLAG tag", "PROTEIN", 420, 438], ["human", "SPECIES", 317, 322], ["human", "SPECIES", 317, 322], ["The immunoprecipitated proteins", "TREATMENT", 0, 31], ["His tag antibody", "TEST", 119, 135], ["Biochemical characterization", "TEST", 136, 164], ["C4BP", "TEST", 168, 172], ["ANG1Cell", "TEST", 173, 181], ["experimental studies", "TEST", 188, 208], ["C4BP", "TEST", 212, 216], ["Two experimental systems", "TREATMENT", 222, 246], ["C4BP", "TEST", 296, 300], ["ANG1 treatment", "TREATMENT", 301, 315], ["human umbilical vein cells", "TREATMENT", 317, 343], ["ATCC", "TEST", 353, 357], ["HEK293", "TEST", 363, 369], ["umbilical vein", "ANATOMY", 323, 337], ["stable", "OBSERVATION_MODIFIER", 375, 381], ["full length", "OBSERVATION_MODIFIER", 396, 407], ["FLAG tag", "OBSERVATION", 430, 438]]], ["Dose and time response of HUVEC cells were conducted by adding purified C4BP-ANG1 proteins directly to the culture medium for indicated period of time, followed by cell lysis for immunoblotting of phospho-Akt.", [["HUVEC cells", "ANATOMY", 26, 37], ["cell", "ANATOMY", 164, 168], ["phospho", "CHEMICAL", 197, 204], ["HUVEC cells", "CELL", 26, 37], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 72, 81], ["cell", "CELL", 164, 168], ["phospho-Akt", "GENE_OR_GENE_PRODUCT", 197, 208], ["HUVEC cells", "CELL_LINE", 26, 37], ["C4BP", "PROTEIN", 72, 76], ["ANG1 proteins", "PROTEIN", 77, 90], ["phospho", "PROTEIN", 197, 204], ["Akt", "PROTEIN", 205, 208], ["HUVEC cells", "PROBLEM", 26, 37], ["purified C4BP", "TEST", 63, 76], ["ANG1 proteins", "PROBLEM", 77, 90], ["the culture medium", "TEST", 103, 121], ["cell lysis", "TEST", 164, 174], ["phospho", "TEST", 197, 204], ["HUVEC cells", "OBSERVATION", 26, 37]]], ["The HEK293 cell study was conducted with the stimulation of the cells with C4BP-ANG1 followed by anti-FLAG immunoprecipitation (IP) of Tie2-FLAG that were stably expressed at the cell surface.", [["HEK293 cell", "ANATOMY", 4, 15], ["cells", "ANATOMY", 64, 69], ["cell surface", "ANATOMY", 179, 191], ["HEK293 cell", "CELL", 4, 15], ["cells", "CELL", 64, 69], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 75, 84], ["anti-FLAG", "ORGANISM_SUBSTANCE", 97, 106], ["Tie2", "GENE_OR_GENE_PRODUCT", 135, 139], ["FLAG", "GENE_OR_GENE_PRODUCT", 140, 144], ["cell surface", "CELLULAR_COMPONENT", 179, 191], ["HEK293 cell", "CELL_LINE", 4, 15], ["C4BP", "PROTEIN", 75, 79], ["ANG1", "PROTEIN", 80, 84], ["Tie2", "PROTEIN", 135, 139], ["FLAG", "PROTEIN", 140, 144], ["The HEK293 cell study", "TEST", 0, 21], ["C4BP-ANG1", "TREATMENT", 75, 84], ["anti-FLAG immunoprecipitation", "TREATMENT", 97, 126], ["Tie2-FLAG", "TREATMENT", 135, 144], ["HEK293 cell", "OBSERVATION", 4, 15], ["Tie2", "ANATOMY", 135, 139], ["cell", "OBSERVATION_MODIFIER", 179, 183], ["surface", "OBSERVATION_MODIFIER", 184, 191]]], ["Tie2-FLAG from IP was then subjected to immunoblotting analysis of phospho-Tie2 measured by anti-phosphotyrosine antibody blotting (4G10 Platinum, Millipore).Biochemical characterization of C4BP-ANG1Immunofluorescence staining of HUVEC in response to C4BP-ANG1 was conducted as described previously (39) .", [["HUVEC", "ANATOMY", 230, 235], ["phospho", "CHEMICAL", 67, 74], ["Tie2-FLAG", "GENE_OR_GENE_PRODUCT", 0, 9], ["phospho-Tie2", "GENE_OR_GENE_PRODUCT", 67, 79], ["C4BP", "GENE_OR_GENE_PRODUCT", 190, 194], ["HUVEC", "CELL", 230, 235], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 251, 260], ["Tie2", "PROTEIN", 0, 4], ["FLAG", "PROTEIN", 5, 9], ["phospho", "PROTEIN", 67, 74], ["Tie2", "PROTEIN", 75, 79], ["anti-phosphotyrosine antibody", "PROTEIN", 92, 121], ["4G10", "PROTEIN", 132, 136], ["C4BP", "PROTEIN", 190, 194], ["HUVEC", "CELL_LINE", 230, 235], ["C4BP", "PROTEIN", 251, 255], ["ANG1", "PROTEIN", 256, 260], ["immunoblotting analysis", "TEST", 40, 63], ["phospho", "TEST", 67, 74], ["anti-phosphotyrosine antibody blotting", "TEST", 92, 130], ["Biochemical characterization", "TEST", 158, 186], ["C4BP", "TEST", 190, 194], ["HUVEC", "PROBLEM", 230, 235], ["C4BP", "TEST", 251, 255], ["ANG1", "TEST", 256, 260], ["HUVEC", "ANATOMY", 230, 235]]], ["In brief, HUVECs were transfected by electroporation with full-length Tie2 fused with a C-terminus FLAG tag.", [["HUVECs", "ANATOMY", 10, 16], ["C", "CHEMICAL", 88, 89], ["HUVECs", "CELL", 10, 16], ["Tie2", "GENE_OR_GENE_PRODUCT", 70, 74], ["HUVECs", "CELL_LINE", 10, 16], ["Tie2", "PROTEIN", 70, 74], ["C-terminus FLAG tag", "PROTEIN", 88, 107], ["a C-terminus FLAG tag", "PROBLEM", 86, 107], ["HUVECs", "ANATOMY", 10, 16], ["FLAG tag", "OBSERVATION", 99, 107]]], ["Two days after transfection, purified C4BP-ANG1 protein or buffer control was added to the culture medium.", [["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 38, 47], ["C4BP", "PROTEIN", 38, 42], ["ANG1 protein", "PROTEIN", 43, 55], ["transfection", "TREATMENT", 15, 27], ["purified C4BP", "TEST", 29, 42], ["ANG1 protein", "TREATMENT", 43, 55], ["buffer control", "TREATMENT", 59, 73], ["the culture medium", "TEST", 87, 105]]], ["Following an incubation period of 15 min the cells were fix and then stained with anti-FLAG antibody (Sigma) to detect Tie2-FLAG.", [["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50], ["Tie2-FLAG", "GENE_OR_GENE_PRODUCT", 119, 128], ["anti-FLAG antibody", "PROTEIN", 82, 100], ["Sigma", "PROTEIN", 102, 107], ["Tie2", "PROTEIN", 119, 123], ["FLAG", "PROTEIN", 124, 128], ["an incubation period", "TREATMENT", 10, 30], ["anti-FLAG antibody", "TEST", 82, 100], ["Tie2", "TEST", 119, 123]]], ["To investigate the integrity of cell junctions, HUVECs were treated with LPS (100 ng/mL) or VEGF (100 ng/mL) for 30 min, in presence of vehicle or C4BP-A1 (500 ng/mL).", [["cell junctions", "ANATOMY", 32, 46], ["HUVECs", "ANATOMY", 48, 54], ["LPS", "CHEMICAL", 73, 76], ["cell junctions", "CELLULAR_COMPONENT", 32, 46], ["HUVECs", "CELL", 48, 54], ["LPS", "SIMPLE_CHEMICAL", 73, 76], ["VEGF", "GENE_OR_GENE_PRODUCT", 92, 96], ["C4BP-A1", "GENE_OR_GENE_PRODUCT", 147, 154], ["HUVECs", "CELL_TYPE", 48, 54], ["VEGF", "PROTEIN", 92, 96], ["C4BP", "PROTEIN", 147, 151], ["LPS", "TREATMENT", 73, 76], ["VEGF", "TREATMENT", 92, 96], ["C4BP", "TEST", 147, 151], ["cell junctions", "OBSERVATION", 32, 46], ["HUVECs", "ANATOMY", 48, 54]]], ["The cells were fixed and stained with anti-VE-Cadherin antibody (Millipore).In vivo Tie2 activation assayVehicle or C4BP-Ang1 were intravenously injected to 8 weeks old female Balb/c mice or intraperitoneally injected to P6 Balb/c neonates.", [["cells", "ANATOMY", 4, 9], ["intravenously", "ANATOMY", 131, 144], ["cells", "CELL", 4, 9], ["anti-VE-Cadherin antibody", "GENE_OR_GENE_PRODUCT", 38, 63], ["Tie2", "GENE_OR_GENE_PRODUCT", 84, 88], ["C4BP-Ang1", "GENE_OR_GENE_PRODUCT", 116, 125], ["Balb/c mice", "ORGANISM", 176, 187], ["Balb/c neonates", "ORGANISM", 224, 239], ["anti-VE", "PROTEIN", 38, 45], ["Cadherin antibody", "PROTEIN", 46, 63], ["Millipore", "PROTEIN", 65, 74], ["Tie2", "PROTEIN", 84, 88], ["assayVehicle", "PROTEIN", 100, 112], ["C4BP", "PROTEIN", 116, 120], ["Ang1", "PROTEIN", 121, 125], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["anti-VE", "TEST", 38, 45], ["C4BP-Ang1", "TREATMENT", 116, 125], ["Balb/c mice", "TREATMENT", 176, 187]]], ["After the specified time, the mice were sacrificed, and their lungs were collected and lysed by RIPA buffer supplemented with proteinase/phosphatase inhibitor cocktail (50 mg tissue per mL lysis buffer).", [["lungs", "ANATOMY", 62, 67], ["tissue", "ANATOMY", 175, 181], ["mice", "ORGANISM", 30, 34], ["lungs", "ORGAN", 62, 67], ["tissue", "TISSUE", 175, 181], ["proteinase", "PROTEIN", 126, 136], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["RIPA buffer", "TREATMENT", 96, 107], ["proteinase/phosphatase inhibitor cocktail", "TREATMENT", 126, 167], ["lungs", "ANATOMY", 62, 67]]], ["Tie2 protein was immunoprecipitated from the lysates by using anti-Tie2 antibody (Millipore) and protein A/G-sepharose.", [["lysates", "ANATOMY", 45, 52], ["Tie2", "GENE_OR_GENE_PRODUCT", 0, 4], ["lysates", "ORGANISM_SUBSTANCE", 45, 52], ["anti-Tie2 antibody", "GENE_OR_GENE_PRODUCT", 62, 80], ["G-sepharose", "GENE_OR_GENE_PRODUCT", 107, 118], ["Tie2 protein", "PROTEIN", 0, 12], ["anti-Tie2 antibody", "PROTEIN", 62, 80], ["Millipore", "PROTEIN", 82, 91], ["protein A", "PROTEIN", 97, 106], ["G-sepharose", "PROTEIN", 107, 118], ["Tie2 protein", "TEST", 0, 12], ["the lysates", "TEST", 41, 52], ["anti-Tie2 antibody", "TEST", 62, 80], ["Millipore", "TEST", 82, 91], ["protein", "TEST", 97, 104], ["sepharose", "PROBLEM", 109, 118]]], ["The phosphorylation level of precipitated Tie2 was assessed by anti-phosphotyrosine antibody as described above.In vivo Tie2 activation assayRabbit eye pharmacokinetic study New Zealand White (NZW) rabbits were used to assess the intraocular pharmacokinetics of C4BP-ANG1.", [["eye", "ANATOMY", 148, 151], ["intraocular", "ANATOMY", 230, 241], ["Tie2", "GENE_OR_GENE_PRODUCT", 42, 46], ["anti-phosphotyrosine", "GENE_OR_GENE_PRODUCT", 63, 83], ["Tie2", "GENE_OR_GENE_PRODUCT", 120, 124], ["rabbits", "ORGANISM", 198, 205], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 262, 271], ["precipitated Tie2", "PROTEIN", 29, 46], ["anti-phosphotyrosine antibody", "PROTEIN", 63, 92], ["Tie2", "PROTEIN", 120, 124], ["C4BP", "PROTEIN", 262, 266], ["ANG1", "PROTEIN", 267, 271], ["rabbits", "SPECIES", 198, 205], ["The phosphorylation level", "TEST", 0, 25], ["Tie2", "TEST", 42, 46], ["anti-phosphotyrosine antibody", "TEST", 63, 92], ["eye pharmacokinetic study", "TEST", 148, 173], ["New Zealand White (NZW) rabbits", "TREATMENT", 174, 205]]], ["Briefly, proparacaine hydrochloride (Alcain, Alcon) was administered into both eyes to minimize discomfort.", [["eyes", "ANATOMY", 79, 83], ["proparacaine hydrochloride", "CHEMICAL", 9, 35], ["Alcain", "CHEMICAL", 37, 43], ["proparacaine hydrochloride", "CHEMICAL", 9, 35], ["Alcain", "CHEMICAL", 37, 43], ["proparacaine hydrochloride", "SIMPLE_CHEMICAL", 9, 35], ["Alcain", "SIMPLE_CHEMICAL", 37, 43], ["Alcon", "SIMPLE_CHEMICAL", 45, 50], ["eyes", "ORGAN", 79, 83], ["proparacaine hydrochloride (Alcain, Alcon)", "TREATMENT", 9, 51], ["discomfort", "PROBLEM", 96, 106]]], ["Approximately 1\u03bcg of C4BP-ANG1 protein in 100\u03bcL DPBS solution was injected intravitreously to one of the eyes using a 700 series Hamilton syringe and a 30 gauge needle.", [["eyes", "ANATOMY", 105, 109], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 21, 30], ["eyes", "ORGAN", 105, 109], ["C4BP", "PROTEIN", 21, 25], ["ANG1 protein", "PROTEIN", 26, 38], ["C4BP-ANG1 protein in 100\u03bcL DPBS solution", "TREATMENT", 21, 61], ["a 700 series Hamilton syringe", "TREATMENT", 116, 145], ["a 30 gauge needle", "TREATMENT", 150, 167], ["eyes", "ANATOMY", 105, 109]]], ["The contralateral eye was injected with the buffer as a control.", [["eye", "ANATOMY", 18, 21], ["eye", "ORGAN", 18, 21], ["the buffer", "TREATMENT", 40, 50], ["contralateral", "ANATOMY_MODIFIER", 4, 17], ["eye", "ANATOMY", 18, 21]]], ["Aqueous humor was collected daily (preinjection sample: day 0) for seven consecutive days.", [["Aqueous humor", "ANATOMY", 0, 13], ["Aqueous humor", "ORGANISM_SUBSTANCE", 0, 13], ["Aqueous humor", "TEST", 0, 13]]], ["The levels of C4BP-ANG1 were measured by ELISA as described above.", [["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 14, 23], ["C4BP", "PROTEIN", 14, 18], ["ANG1", "PROTEIN", 19, 23], ["The levels of C4BP-ANG1", "TEST", 0, 23], ["ELISA", "TEST", 41, 46]]], ["On the seventh day the animals were sacrificed and vitreous humor samples from both eyes were collected for detection of C4BP-ANG1 levels by ELISA.In vivo Tie2 activation assayIn vivo assessment of C4BP-ANG1In vivo Tie2 activation assayMiles assay for VEGF induced skin vascular leakage was performed as described previously (41) .", [["vitreous humor samples", "ANATOMY", 51, 73], ["eyes", "ANATOMY", 84, 88], ["skin vascular", "ANATOMY", 265, 278], ["animals", "ORGANISM", 23, 30], ["vitreous humor samples", "ORGANISM_SUBSTANCE", 51, 73], ["eyes", "ORGAN", 84, 88], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 121, 130], ["Tie2", "GENE_OR_GENE_PRODUCT", 155, 159], ["C4BP-ANG1In", "GENE_OR_GENE_PRODUCT", 198, 209], ["Tie2", "GENE_OR_GENE_PRODUCT", 215, 219], ["VEGF", "GENE_OR_GENE_PRODUCT", 252, 256], ["skin vascular", "MULTI-TISSUE_STRUCTURE", 265, 278], ["C4BP", "PROTEIN", 121, 125], ["ANG1", "PROTEIN", 126, 130], ["Tie2", "PROTEIN", 155, 159], ["C4BP", "PROTEIN", 198, 202], ["ANG1In", "PROTEIN", 203, 209], ["Tie2", "PROTEIN", 215, 219], ["VEGF", "PROTEIN", 252, 256], ["vitreous humor samples", "TEST", 51, 73], ["C4BP-ANG1 levels", "TEST", 121, 137], ["ELISA", "TEST", 141, 146], ["vivo assessment", "TEST", 179, 194], ["C4BP", "TEST", 198, 202], ["vivo Tie2 activation assay", "TREATMENT", 210, 236], ["Miles assay", "TEST", 236, 247], ["VEGF induced skin vascular leakage", "PROBLEM", 252, 286], ["skin", "ANATOMY", 265, 269], ["vascular", "ANATOMY", 270, 278], ["leakage", "OBSERVATION", 279, 286]]], ["Briefly, 8 weeks old female Balb/c mice were i.p. injected with histamine inhibitor pyrilamine (40 ul/g body weight) followed by tail vein injection of 100 \u03bcL Evans blue dye (1% in PBS).", [["body", "ANATOMY", 104, 108], ["tail vein", "ANATOMY", 129, 138], ["histamine", "CHEMICAL", 64, 73], ["pyrilamine", "CHEMICAL", 84, 94], ["Evans blue", "CHEMICAL", 159, 169], ["histamine", "CHEMICAL", 64, 73], ["pyrilamine", "CHEMICAL", 84, 94], ["Balb/c mice", "ORGANISM", 28, 39], ["histamine", "SIMPLE_CHEMICAL", 64, 73], ["pyrilamine", "SIMPLE_CHEMICAL", 84, 94], ["body", "ORGANISM_SUBDIVISION", 104, 108], ["tail vein", "MULTI-TISSUE_STRUCTURE", 129, 138], ["Evans blue dye", "SIMPLE_CHEMICAL", 159, 173], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["Balb/c mice", "TREATMENT", 28, 39], ["histamine inhibitor pyrilamine", "TREATMENT", 64, 94], ["ul/g body weight", "TREATMENT", 99, 115], ["tail vein injection", "TREATMENT", 129, 148], ["tail vein", "ANATOMY", 129, 138]]], ["After 30 min, the mice were anesthetized by Ketamine/Xylazine cocktail.", [["Ketamine", "CHEMICAL", 44, 52], ["Xylazine", "CHEMICAL", 53, 61], ["Ketamine", "CHEMICAL", 44, 52], ["Xylazine", "CHEMICAL", 53, 61], ["mice", "ORGANISM", 18, 22], ["Ketamine", "SIMPLE_CHEMICAL", 44, 52], ["Xylazine", "SIMPLE_CHEMICAL", 53, 61], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["Ketamine", "TREATMENT", 44, 52], ["Xylazine cocktail", "TREATMENT", 53, 70]]], ["Then vehicle or VEGF (100ng, R&D Systems), either in the presence or the absence of C4BP-Ang1 (250 ng), was intradermally injected into different sites of the mouse flank.", [["intradermally", "ANATOMY", 108, 121], ["sites", "ANATOMY", 146, 151], ["flank", "ANATOMY", 165, 170], ["VEGF", "GENE_OR_GENE_PRODUCT", 16, 20], ["C4BP-Ang1", "GENE_OR_GENE_PRODUCT", 84, 93], ["mouse", "ORGANISM", 159, 164], ["flank", "ORGANISM_SUBDIVISION", 165, 170], ["VEGF", "PROTEIN", 16, 20], ["C4BP", "PROTEIN", 84, 88], ["Ang1", "PROTEIN", 89, 93], ["mouse flank", "DNA", 159, 170], ["mouse", "SPECIES", 159, 164], ["mouse", "SPECIES", 159, 164], ["C4BP-Ang1", "TREATMENT", 84, 93], ["mouse", "ANATOMY_MODIFIER", 159, 164], ["flank", "ANATOMY", 165, 170]]], ["The mice were sacrificed 20 min after the intradermal injections and the leakage of Evans blue was photographed and then quantified by deionized formamide extraction followed by spectrophotometer measurement on 620 nm.In vivo Tie2 activation assayTo investigate whether pretreatment with C4BP-Ang1 prevents VEGF induced skin vascular leakage, two groups of 10 weeks old female Balb/c mice received tail vein injection of either Evans blue or Evans blue solution with C4BP-Ang1 (0.5 ug/g body weight).", [["intradermal", "ANATOMY", 42, 53], ["skin vascular", "ANATOMY", 320, 333], ["tail vein", "ANATOMY", 398, 407], ["body", "ANATOMY", 487, 491], ["skin vascular leakage", "DISEASE", 320, 341], ["Evans blue", "CHEMICAL", 428, 438], ["Evans blue", "CHEMICAL", 442, 452], ["formamide", "CHEMICAL", 145, 154], ["Evans blue", "CHEMICAL", 442, 452], ["mice", "ORGANISM", 4, 8], ["Evans blue", "SIMPLE_CHEMICAL", 84, 94], ["Tie2", "GENE_OR_GENE_PRODUCT", 226, 230], ["C4BP-Ang1", "GENE_OR_GENE_PRODUCT", 288, 297], ["VEGF", "GENE_OR_GENE_PRODUCT", 307, 311], ["skin vascular", "MULTI-TISSUE_STRUCTURE", 320, 333], ["Balb/c mice", "ORGANISM", 377, 388], ["tail vein", "MULTI-TISSUE_STRUCTURE", 398, 407], ["Evans blue", "SIMPLE_CHEMICAL", 428, 438], ["Evans blue solution", "SIMPLE_CHEMICAL", 442, 461], ["C4BP-Ang1", "GENE_OR_GENE_PRODUCT", 467, 476], ["body", "ORGANISM_SUBDIVISION", 487, 491], ["Tie2", "PROTEIN", 226, 230], ["C4BP", "PROTEIN", 288, 292], ["Ang1", "PROTEIN", 293, 297], ["VEGF", "PROTEIN", 307, 311], ["C4BP", "PROTEIN", 467, 471], ["Ang1", "PROTEIN", 472, 476], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 384, 388], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 384, 388], ["the intradermal injections", "TREATMENT", 38, 64], ["the leakage of Evans blue", "PROBLEM", 69, 94], ["deionized formamide extraction", "TREATMENT", 135, 165], ["spectrophotometer measurement", "TEST", 178, 207], ["C4BP", "TEST", 288, 292], ["Ang1", "TREATMENT", 293, 297], ["VEGF induced skin vascular leakage", "PROBLEM", 307, 341], ["Balb/c mice", "TREATMENT", 377, 388], ["tail vein injection", "TREATMENT", 398, 417], ["Evans blue", "TREATMENT", 428, 438], ["C4BP-Ang1", "TREATMENT", 467, 476], ["skin", "ANATOMY", 320, 324], ["vascular", "ANATOMY", 325, 333], ["leakage", "OBSERVATION", 334, 341], ["tail vein", "ANATOMY", 398, 407]]], ["After 30 min, VEGF at different doses were intradermally injected into different sites of the mouse flank.", [["sites", "ANATOMY", 81, 86], ["flank", "ANATOMY", 100, 105], ["VEGF", "GENE_OR_GENE_PRODUCT", 14, 18], ["mouse", "ORGANISM", 94, 99], ["flank", "ORGANISM_SUBDIVISION", 100, 105], ["VEGF", "PROTEIN", 14, 18], ["mouse flank", "DNA", 94, 105], ["mouse", "SPECIES", 94, 99], ["mouse", "SPECIES", 94, 99], ["VEGF at different doses", "TREATMENT", 14, 37], ["mouse", "ANATOMY_MODIFIER", 94, 99], ["flank", "ANATOMY", 100, 105]]], ["The mice were sacrificed 20 min after the intradermal injections and the leaked Evans blue in each site was photographed.In vivo Tie2 activation assayIn the mustard oil induced vascular leakage model, 8 weeks old female Balb/c mice were i.v. injected with either vehicle or C4BP-ANG1 protein.", [["intradermal", "ANATOMY", 42, 53], ["site", "ANATOMY", 99, 103], ["oil", "ANATOMY", 165, 168], ["vascular", "ANATOMY", 177, 185], ["vascular leakage", "DISEASE", 177, 193], ["mice", "ORGANISM", 4, 8], ["Tie2", "GENE_OR_GENE_PRODUCT", 129, 133], ["oil", "ORGANISM_SUBSTANCE", 165, 168], ["vascular", "MULTI-TISSUE_STRUCTURE", 177, 185], ["Balb/c mice", "ORGANISM", 220, 231], ["C4BP-ANG1", "GENE_OR_GENE_PRODUCT", 274, 283], ["Tie2", "PROTEIN", 129, 133], ["C4BP", "PROTEIN", 274, 278], ["ANG1 protein", "PROTEIN", 279, 291], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 227, 231], ["the intradermal injections", "TREATMENT", 38, 64], ["the leaked Evans blue", "TREATMENT", 69, 90], ["vascular leakage model", "PROBLEM", 177, 199], ["Balb/c mice", "TREATMENT", 220, 231], ["mustard oil", "OBSERVATION", 157, 168], ["vascular", "ANATOMY", 177, 185], ["leakage model", "OBSERVATION", 186, 199]]], ["After 30 min, all the mice received i.v. injection of 100 \u03bcL Evans blue dye (1% in DPBS).", [["Evans blue", "CHEMICAL", 61, 71], ["Evans blue", "CHEMICAL", 61, 71], ["mice", "ORGANISM", 22, 26], ["Evans blue dye", "SIMPLE_CHEMICAL", 61, 75], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["100 \u03bcL Evans blue dye", "TREATMENT", 54, 75]]], ["10 uL Mustard oil (5% allyl-isoyhiocyanate diluted in mineral oil; Sigma) or mineral oil control was then applied to the dorsal and ventral surfaces of the ears.", [["oil", "ANATOMY", 85, 88], ["dorsal", "ANATOMY", 121, 127], ["ventral surfaces", "ANATOMY", 132, 148], ["ears", "ANATOMY", 156, 160], ["allyl-isoyhiocyanate", "CHEMICAL", 22, 42], ["allyl-isoyhiocyanate", "CHEMICAL", 22, 42], ["allyl-isoyhiocyanate", "SIMPLE_CHEMICAL", 22, 42], ["mineral oil", "SIMPLE_CHEMICAL", 54, 65], ["Sigma", "SIMPLE_CHEMICAL", 67, 72], ["dorsal", "TISSUE", 121, 127], ["ventral surfaces", "MULTI-TISSUE_STRUCTURE", 132, 148], ["ears", "ORGAN", 156, 160], ["uL Mustard oil", "TREATMENT", 3, 17], ["allyl-isoyhiocyanate diluted in mineral oil", "TREATMENT", 22, 65], ["Sigma)", "TREATMENT", 67, 73], ["mineral oil control", "TREATMENT", 77, 96], ["dorsal", "ANATOMY_MODIFIER", 121, 127], ["ventral", "ANATOMY_MODIFIER", 132, 139], ["surfaces", "ANATOMY_MODIFIER", 140, 148], ["ears", "ANATOMY", 156, 160]]], ["After 20 min, the ears were collected and the leaked Evans blue was quantified as described above. injection of C4BP-A1 (0.5 ug /g BW, in PBS).", [["ears", "ANATOMY", 18, 22], ["ears", "ORGAN", 18, 22], ["C4BP-A1", "GENE_OR_GENE_PRODUCT", 112, 119], ["C4BP", "PROTEIN", 112, 116], ["A1", "PROTEIN", 117, 119], ["the leaked Evans blue", "PROBLEM", 42, 63], ["C4BP", "TEST", 112, 116], ["PBS", "TEST", 138, 141], ["ears", "ANATOMY", 18, 22]]], ["Lung permeability was assessed by i.v. injecting of 100 uL Evans blue (1% in PBS).", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung permeability", "TEST", 0, 17], ["uL Evans blue", "TREATMENT", 56, 69], ["permeability", "OBSERVATION", 5, 17]]], ["One hour after Evans blue administration, the mice were euthanized and the lung tissues were collected.", [["lung tissues", "ANATOMY", 75, 87], ["Evans blue", "CHEMICAL", 15, 25], ["Evans blue", "SIMPLE_CHEMICAL", 15, 25], ["mice", "ORGANISM", 46, 50], ["lung tissues", "TISSUE", 75, 87], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["Evans blue administration", "TREATMENT", 15, 40], ["the mice", "TREATMENT", 42, 50], ["lung tissues", "ANATOMY", 75, 87]]], ["The leakage of Evans blue was quantified as described above.", [["Evans blue", "CHEMICAL", 15, 25], ["Evans blue", "SIMPLE_CHEMICAL", 15, 25], ["The leakage of Evans blue", "PROBLEM", 0, 25], ["leakage", "OBSERVATION_MODIFIER", 4, 11], ["Evans blue", "OBSERVATION", 15, 25]]]], "PMC7271824": [["IntroductionThe world is in the midst of the coronavirus disease 2019 (Covid-19) pandemic, an outbreak which was first reported in December 2019, Wuhan city, the capital of Hubei province in China [1].", [["coronavirus disease", "DISEASE", 45, 64], ["Covid-19) pandemic", "DISEASE", 71, 89], ["coronavirus", "ORGANISM", 45, 56], ["the coronavirus disease", "PROBLEM", 41, 64], ["Covid", "TEST", 71, 76], ["pandemic", "PROBLEM", 81, 89], ["coronavirus", "ANATOMY", 45, 56]]], ["By Jan 7, 2020, Chinese scientists had isolated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), initially known as a novel coronavirus 2019 (2019-nCoV), from these patients with virus-infected pneumonia [2], which was later designated coronavirus disease 2019 (Covid-19) in February 2020, by World Health Organization (WHO).IntroductionCovid-19 adds to the list of zoonotic coronavirus disease after SARS and the Middle East respiratory syndrome (MERS) [2].", [["acute respiratory syndrome coronavirus", "DISEASE", 56, 94], ["coronavirus", "DISEASE", 138, 149], ["pneumonia", "DISEASE", 208, 217], ["coronavirus disease", "DISEASE", 250, 269], ["zoonotic coronavirus disease", "DISEASE", 380, 408], ["SARS", "DISEASE", 415, 419], ["Middle East respiratory syndrome", "DISEASE", 428, 460], ["SARS-CoV-2", "ORGANISM", 98, 108], ["patients", "ORGANISM", 179, 187], ["coronavirus", "ORGANISM", 250, 261], ["coronavirus", "ORGANISM", 389, 400], ["patients", "SPECIES", 179, 187], ["severe acute respiratory syndrome coronavirus", "SPECIES", 49, 94], ["SARS-CoV-2", "SPECIES", 98, 108], ["zoonotic coronavirus", "SPECIES", 380, 400], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 49, 94], ["SARS-CoV", "TEST", 98, 106], ["a novel coronavirus", "PROBLEM", 130, 149], ["virus", "PROBLEM", 193, 198], ["infected pneumonia", "PROBLEM", 199, 217], ["coronavirus disease", "PROBLEM", 250, 269], ["Covid", "TEST", 276, 281], ["IntroductionCovid", "TREATMENT", 339, 356], ["zoonotic coronavirus disease", "PROBLEM", 380, 408], ["SARS", "PROBLEM", 415, 419], ["the Middle East respiratory syndrome", "PROBLEM", 424, 460], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82], ["infected", "OBSERVATION_MODIFIER", 199, 207], ["pneumonia", "OBSERVATION", 208, 217], ["coronavirus disease", "OBSERVATION", 250, 269], ["zoonotic coronavirus disease", "OBSERVATION", 380, 408], ["Middle", "ANATOMY_MODIFIER", 428, 434], ["respiratory syndrome", "OBSERVATION", 440, 460]]], ["SARS-CoV, MERS-CoV, and SARS-CoV-2 all belong to the \u03b2-coronavirus cluster [3], although information on the sources of SARS-CoV-2 are limited but the current data showed that the SARS-CoV-2 was a combination of virus between a bat coronavirus and a coronavirus of unknown origin [4].", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 119, 123], ["SARS", "DISEASE", 179, 183], ["bat coronavirus", "DISEASE", 227, 242], ["coronavirus", "DISEASE", 249, 260], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 10, 18], ["SARS-CoV-2", "ORGANISM", 24, 34], ["SARS-CoV-2", "ORGANISM", 119, 129], ["SARS-CoV-2", "ORGANISM", 179, 189], ["bat coronavirus", "ORGANISM", 227, 242], ["SARS-CoV-2", "DNA", 24, 34], ["bat coronavirus", "SPECIES", 227, 242], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 10, 18], ["SARS-CoV", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 119, 127], ["SARS-CoV", "SPECIES", 179, 187], ["bat coronavirus", "SPECIES", 227, 242], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 15, 18], ["SARS", "PROBLEM", 24, 28], ["SARS-CoV", "TEST", 119, 127], ["the SARS-CoV-2", "PROBLEM", 175, 189], ["virus", "PROBLEM", 211, 216], ["a bat coronavirus", "PROBLEM", 225, 242], ["a coronavirus", "PROBLEM", 247, 260], ["virus", "OBSERVATION", 211, 216], ["bat coronavirus", "ANATOMY", 227, 242], ["coronavirus", "OBSERVATION", 249, 260]]], ["After comparing with coronavirus from other animals, it was established that snakes are the most likely wildlife source for the SARS-CoV-2 [4].", [["SARS", "DISEASE", 128, 132], ["coronavirus", "ORGANISM", 21, 32], ["SARS-CoV", "SPECIES", 128, 136], ["coronavirus", "PROBLEM", 21, 32], ["the SARS", "TEST", 124, 132]]], ["Additionally, a study by Benvenuto et al. [5] revealed that the SARS-CoV-2 was closely related to the coronavirus isolated from Chinese chrysanthemum-headed bats in 2015, supporting the possibility of bats to human transmission.IntroductionA multicenter cross-sectional study in China found that 80% of patients who contracted SARS-CoV-2 exhibited mild or moderate symptoms common to other viral respiratory infections [6].", [["respiratory", "ANATOMY", 396, 407], ["SARS", "DISEASE", 64, 68], ["SARS", "DISEASE", 327, 331], ["viral respiratory infections", "DISEASE", 390, 418], ["SARS-CoV-2", "ORGANISM", 64, 74], ["coronavirus", "ORGANISM", 102, 113], ["bats", "ORGANISM", 157, 161], ["bats", "ORGANISM", 201, 205], ["human", "ORGANISM", 209, 214], ["patients", "ORGANISM", 303, 311], ["SARS-CoV-2", "ORGANISM", 327, 337], ["coronavirus", "SPECIES", 102, 113], ["human", "SPECIES", 209, 214], ["patients", "SPECIES", 303, 311], ["SARS-CoV", "SPECIES", 64, 72], ["Chinese chrysanthemum-headed bats", "SPECIES", 128, 161], ["human", "SPECIES", 209, 214], ["a study", "TEST", 14, 21], ["the SARS", "TEST", 60, 68], ["the coronavirus", "PROBLEM", 98, 113], ["IntroductionA multicenter cross-sectional study", "TEST", 228, 275], ["contracted SARS", "PROBLEM", 316, 331], ["CoV", "TEST", 332, 335], ["mild or moderate symptoms", "PROBLEM", 348, 373], ["other viral respiratory infections", "PROBLEM", 384, 418], ["coronavirus", "OBSERVATION", 102, 113], ["mild", "OBSERVATION_MODIFIER", 348, 352], ["moderate", "OBSERVATION_MODIFIER", 356, 364], ["respiratory", "ANATOMY", 396, 407], ["infections", "OBSERVATION", 408, 418]]], ["On the other hand, SARS-CoV-2 has also demonstrated an ability to cause severe disease among certain groups, including older populations and individuals with underlying health conditions such as obesity, cardiovascular disease, and diabetes [1, 7].", [["cardiovascular", "ANATOMY", 204, 218], ["obesity", "DISEASE", 195, 202], ["cardiovascular disease", "DISEASE", 204, 226], ["diabetes", "DISEASE", 232, 240], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 19, 29], ["cardiovascular", "ANATOMICAL_SYSTEM", 204, 218], ["SARS-CoV", "SPECIES", 19, 27], ["severe disease", "PROBLEM", 72, 86], ["underlying health conditions", "PROBLEM", 158, 186], ["obesity", "PROBLEM", 195, 202], ["cardiovascular disease", "PROBLEM", 204, 226], ["diabetes", "PROBLEM", 232, 240], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["disease", "OBSERVATION", 79, 86], ["cardiovascular disease", "OBSERVATION", 204, 226]]], ["While it is still too early to determine why the gender gap is emerging, this article point to several possible factors such as genetics, immunology, and behavioral as the associated factors.GeneticsThe expression and distribution of the receptor influence the route of virus infection which has a major implication for understanding the pathogenesis and dictate the therapeutic strategies [10].", [["infection", "DISEASE", 276, 285], ["virus infection", "PROBLEM", 270, 285]]], ["Angiotensin-converting enzyme-2 (ACE 2) encoded by ACE 2 gene has been proved to be the receptor for both the SARS-coronavirus (SARS-CoV) and the human respiratory coronavirus NL63 [11].", [["Angiotensin", "CHEMICAL", 0, 11], ["SARS-coronavirus", "DISEASE", 110, 126], ["Angiotensin-converting enzyme-2 (ACE 2", "GENE_OR_GENE_PRODUCT", 0, 38], ["ACE 2", "GENE_OR_GENE_PRODUCT", 51, 56], ["SARS-coronavirus", "ORGANISM", 110, 126], ["SARS-CoV", "ORGANISM", 128, 136], ["human", "ORGANISM", 146, 151], ["respiratory coronavirus", "ORGANISM", 152, 175], ["Angiotensin-converting enzyme-2", "PROTEIN", 0, 31], ["ACE 2", "PROTEIN", 33, 38], ["ACE 2 gene", "DNA", 51, 61], ["human", "SPECIES", 146, 151], ["respiratory coronavirus", "SPECIES", 152, 175], ["SARS-coronavirus", "SPECIES", 110, 126], ["SARS-CoV", "SPECIES", 128, 136], ["human respiratory coronavirus", "SPECIES", 146, 175], ["Angiotensin-converting enzyme-2 (ACE", "TREATMENT", 0, 36], ["the SARS", "TEST", 106, 114], ["coronavirus", "PROBLEM", 115, 126], ["the human respiratory coronavirus", "TEST", 142, 175], ["respiratory coronavirus", "ANATOMY", 152, 175]]], ["The current evidence on the receptors for SARS-CoV-2 suggest that ACE 2 are the responsible receptors for SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 42, 52], ["ACE 2", "GENE_OR_GENE_PRODUCT", 66, 71], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["ACE 2", "PROTEIN", 66, 71], ["SARS-CoV", "SPECIES", 106, 114], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["ACE 2", "TREATMENT", 66, 71], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114]]], ["A study by Lu and colleagues documented that there was a similarity in receptor-binding properties between SARS-CoV-2 and SARS-CoV [12].", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["SARS-CoV", "ORGANISM", 122, 130], ["SARS-CoV", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 122, 130], ["A study", "TEST", 0, 7], ["SARS", "TEST", 107, 111], ["CoV", "TEST", 112, 115], ["SARS", "PROBLEM", 122, 126]]], ["Another in vitro study demonstrated the positive correlation of ACE2 expression and the infection of SARS-CoV [13].", [["infection", "DISEASE", 88, 97], ["SARS", "DISEASE", 101, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["SARS-CoV", "ORGANISM", 101, 109], ["ACE2", "PROTEIN", 64, 68], ["SARS-CoV", "SPECIES", 101, 109], ["Another in vitro study", "TEST", 0, 22], ["ACE2 expression", "PROBLEM", 64, 79], ["the infection of SARS", "PROBLEM", 84, 105], ["infection", "OBSERVATION", 88, 97]]], ["This means that an organism whose expression of ACE 2 protein is high has a facilitated environment for pathogenesis of coronavirus.", [["coronavirus", "DISEASE", 120, 131], ["ACE 2", "GENE_OR_GENE_PRODUCT", 48, 53], ["coronavirus", "ORGANISM", 120, 131], ["ACE 2 protein", "PROTEIN", 48, 61], ["an organism", "PROBLEM", 16, 27], ["ACE 2 protein", "TEST", 48, 61], ["coronavirus", "PROBLEM", 120, 131]]], ["Now, having this positive correlation between ACE 2 and coronavirus, different studies quantified the expression of ACE 2 proteins in human cells based on gender ethnicity, for example, in studying the expression level and pattern of human ACE 2 using a single-cell RNA-sequencing (RNA-seq), analysis indicated that Asian males had higher expression of ACE 2 than female [14].", [["cells", "ANATOMY", 140, 145], ["ACE 2", "GENE_OR_GENE_PRODUCT", 46, 51], ["coronavirus", "ORGANISM", 56, 67], ["ACE 2", "GENE_OR_GENE_PRODUCT", 116, 121], ["human", "ORGANISM", 134, 139], ["cells", "CELL", 140, 145], ["human", "ORGANISM", 234, 239], ["ACE 2", "GENE_OR_GENE_PRODUCT", 240, 245], ["ACE 2", "GENE_OR_GENE_PRODUCT", 353, 358], ["ACE 2 proteins", "PROTEIN", 116, 130], ["human cells", "CELL_TYPE", 134, 145], ["human ACE 2", "PROTEIN", 234, 245], ["ACE 2", "PROTEIN", 353, 358], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 234, 239], ["ACE", "TEST", 46, 49], ["coronavirus", "PROBLEM", 56, 67], ["different studies", "TEST", 69, 86], ["ACE 2 proteins in human cells", "TREATMENT", 116, 145], ["human ACE 2", "TREATMENT", 234, 245], ["a single-cell RNA", "TREATMENT", 252, 269]]], ["Additionally, there was an evidence of differences in expression of ACE 2 between different ethnicity [11].", [["ACE 2", "GENE_OR_GENE_PRODUCT", 68, 73], ["ACE 2", "PROTEIN", 68, 73], ["ACE", "TREATMENT", 68, 71], ["evidence of", "UNCERTAINTY", 27, 38], ["differences", "OBSERVATION_MODIFIER", 39, 50]]], ["On the other hand, in establishing the expression of ACE 2 in the primary affected organ, a study conducted in Chinese population found that expression of ACE 2 in human lungs was extremely expressed in Asian male than female [10].ImmunologyTo generate an appropriately controlled response during infections, immunological checkpoints, such as the inhibitory CD200 receptor (CD200R), greatly play a great role in balancing the immune system during microbial infection by stimulating and controlling hyperimmune mediated response [15].", [["organ", "ANATOMY", 83, 88], ["lungs", "ANATOMY", 170, 175], ["immune system", "ANATOMY", 427, 440], ["infections", "DISEASE", 297, 307], ["infection", "DISEASE", 458, 467], ["ACE 2", "GENE_OR_GENE_PRODUCT", 53, 58], ["organ", "ORGAN", 83, 88], ["ACE 2", "GENE_OR_GENE_PRODUCT", 155, 160], ["human", "ORGANISM", 164, 169], ["lungs", "ORGAN", 170, 175], ["CD200 receptor", "GENE_OR_GENE_PRODUCT", 359, 373], ["CD200R", "GENE_OR_GENE_PRODUCT", 375, 381], ["immune system", "ANATOMICAL_SYSTEM", 427, 440], ["hyperimmune", "ORGANISM", 499, 510], ["ACE 2", "PROTEIN", 53, 58], ["ACE 2", "PROTEIN", 155, 160], ["inhibitory CD200 receptor", "PROTEIN", 348, 373], ["CD200R", "PROTEIN", 375, 381], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 164, 169], ["ACE 2", "PROBLEM", 53, 58], ["a study", "TEST", 90, 97], ["immunological checkpoints", "TREATMENT", 309, 334], ["the inhibitory CD200 receptor", "TREATMENT", 344, 373], ["microbial infection", "PROBLEM", 448, 467], ["lungs", "ANATOMY", 170, 175]]], ["CD200R is found in myeloid receptor [16] and expressed on macrophages, granulocytes, and dendritic cells (DCs), and it also expressed on other immune cells components such as T cells, B cells, and natural killer cells (NK cells) [17].", [["myeloid", "ANATOMY", 19, 26], ["macrophages", "ANATOMY", 58, 69], ["granulocytes", "ANATOMY", 71, 83], ["dendritic cells", "ANATOMY", 89, 104], ["DCs", "ANATOMY", 106, 109], ["immune cells", "ANATOMY", 143, 155], ["T cells", "ANATOMY", 175, 182], ["B cells", "ANATOMY", 184, 191], ["natural killer cells", "ANATOMY", 197, 217], ["NK cells", "ANATOMY", 219, 227], ["CD200R", "GENE_OR_GENE_PRODUCT", 0, 6], ["myeloid", "CELL", 19, 26], ["macrophages", "CELL", 58, 69], ["granulocytes", "CELL", 71, 83], ["dendritic cells", "CELL", 89, 104], ["DCs", "CELL", 106, 109], ["immune cells", "CELL", 143, 155], ["T cells", "CELL", 175, 182], ["B cells", "CELL", 184, 191], ["natural killer cells", "CELL", 197, 217], ["NK cells", "CELL", 219, 227], ["CD200R", "PROTEIN", 0, 6], ["macrophages", "CELL_TYPE", 58, 69], ["granulocytes", "CELL_TYPE", 71, 83], ["dendritic cells", "CELL_TYPE", 89, 104], ["DCs", "CELL_TYPE", 106, 109], ["immune cells", "CELL_TYPE", 143, 155], ["T cells", "CELL_TYPE", 175, 182], ["B cells", "CELL_TYPE", 184, 191], ["natural killer cells", "CELL_TYPE", 197, 217], ["NK cells", "CELL_TYPE", 219, 227], ["macrophages", "TEST", 58, 69], ["granulocytes", "TEST", 71, 83], ["dendritic cells", "PROBLEM", 89, 104], ["other immune cells components", "PROBLEM", 137, 166], ["T cells", "PROBLEM", 175, 182], ["B cells", "PROBLEM", 184, 191], ["natural killer cells", "TEST", 197, 217], ["myeloid", "ANATOMY", 19, 26], ["macrophages", "ANATOMY", 58, 69], ["granulocytes", "ANATOMY", 71, 83], ["dendritic cells", "OBSERVATION", 89, 104], ["immune cells", "OBSERVATION", 143, 155], ["natural killer cells", "OBSERVATION", 197, 217]]], ["A study by Karnam and colleagues [17] reveled that CD200-CD200R and sex are host factors that together determine the outcome of viral infection.", [["viral infection", "DISEASE", 128, 143], ["CD200", "GENE_OR_GENE_PRODUCT", 51, 56], ["CD200R", "GENE_OR_GENE_PRODUCT", 57, 63], ["CD200", "PROTEIN", 51, 56], ["CD200R", "PROTEIN", 57, 63], ["A study", "TEST", 0, 7], ["CD200", "TEST", 51, 56], ["viral infection", "PROBLEM", 128, 143], ["viral", "OBSERVATION_MODIFIER", 128, 133], ["infection", "OBSERVATION", 134, 143]]], ["In the study conducted in mice, lack of CD200R signaling strongly enhanced type I interferon (IFN) production and viral clearance and improved the outcome of mouse hepatitis coronavirus infection, particularly in female mice.", [["hepatitis coronavirus infection", "DISEASE", 164, 195], ["mice", "ORGANISM", 26, 30], ["CD200R", "GENE_OR_GENE_PRODUCT", 40, 46], ["type I interferon", "GENE_OR_GENE_PRODUCT", 75, 92], ["IFN", "GENE_OR_GENE_PRODUCT", 94, 97], ["mouse", "ORGANISM", 158, 163], ["hepatitis coronavirus", "ORGANISM", 164, 185], ["mice", "ORGANISM", 220, 224], ["CD200R", "PROTEIN", 40, 46], ["type I interferon", "PROTEIN", 75, 92], ["IFN", "PROTEIN", 94, 97], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 158, 163], ["hepatitis coronavirus", "SPECIES", 164, 185], ["mice", "SPECIES", 220, 224], ["mice", "SPECIES", 26, 30], ["mouse hepatitis coronavirus", "SPECIES", 158, 185], ["mice", "SPECIES", 220, 224], ["the study", "TEST", 3, 12], ["CD200R signaling strongly enhanced type I interferon (IFN) production", "PROBLEM", 40, 109], ["viral clearance", "PROBLEM", 114, 129], ["mouse hepatitis coronavirus infection", "PROBLEM", 158, 195], ["hepatitis coronavirus infection", "OBSERVATION", 164, 195]]], ["This means that organisms with high CD200R signaling have an enhance clearance of viral infection.", [["viral infection", "DISEASE", 82, 97], ["CD200R", "GENE_OR_GENE_PRODUCT", 36, 42], ["CD200R", "PROTEIN", 36, 42], ["organisms", "PROBLEM", 16, 25], ["high CD200R signaling", "PROBLEM", 31, 52], ["viral infection", "PROBLEM", 82, 97], ["viral", "OBSERVATION_MODIFIER", 82, 87], ["infection", "OBSERVATION", 88, 97]]], ["A review which looked on association between sex difference in immune responses concluded that sex-based immunological differences contribute to variations in the susceptibility to infectious diseases and responses to vaccines in males and females.", [["infectious diseases", "DISEASE", 181, 200], ["A review", "TEST", 0, 8], ["the susceptibility to infectious diseases", "PROBLEM", 159, 200], ["vaccines", "TREATMENT", 218, 226]]], ["For example, sex-based differences in human leucocytes antigen (HLA) alleles and genes that encode for interleukin (IL), IL-4, IL-10, and the IL-12 receptor, have each been associated with differential antibody responses to vaccines against measles, mumps, hepatitis A, tetanus, and diphtheria in children and adults where hormonal mechanisms are hypothesized to cause this effect [18].", [["measles, mumps, hepatitis A", "DISEASE", 241, 268], ["tetanus", "DISEASE", 270, 277], ["diphtheria", "DISEASE", 283, 293], ["human", "ORGANISM", 38, 43], ["leucocytes antigen", "GENE_OR_GENE_PRODUCT", 44, 62], ["HLA", "GENE_OR_GENE_PRODUCT", 64, 67], ["interleukin (IL)", "GENE_OR_GENE_PRODUCT", 103, 119], ["IL-4", "GENE_OR_GENE_PRODUCT", 121, 125], ["IL-10", "GENE_OR_GENE_PRODUCT", 127, 132], ["IL-12 receptor", "GENE_OR_GENE_PRODUCT", 142, 156], ["measles", "ORGANISM", 241, 248], ["mumps", "ORGANISM", 250, 255], ["hepatitis A", "ORGANISM", 257, 268], ["tetanus", "ORGANISM", 270, 277], ["children", "ORGANISM", 297, 305], ["human leucocytes antigen (HLA) alleles", "DNA", 38, 76], ["interleukin (IL), IL-4", "PROTEIN", 103, 125], ["IL", "PROTEIN", 127, 129], ["IL-12 receptor", "PROTEIN", 142, 156], ["human", "SPECIES", 38, 43], ["children", "SPECIES", 297, 305], ["human", "SPECIES", 38, 43], ["hepatitis A", "SPECIES", 257, 268], ["sex-based differences in human leucocytes antigen (HLA) alleles and genes", "PROBLEM", 13, 86], ["interleukin (IL)", "TREATMENT", 103, 119], ["IL", "TEST", 121, 123], ["the IL-12 receptor", "TREATMENT", 138, 156], ["differential antibody responses", "PROBLEM", 189, 220], ["vaccines", "TREATMENT", 224, 232], ["measles", "PROBLEM", 241, 248], ["mumps", "PROBLEM", 250, 255], ["hepatitis A", "PROBLEM", 257, 268], ["tetanus", "PROBLEM", 270, 277], ["diphtheria", "PROBLEM", 283, 293], ["hormonal mechanisms", "PROBLEM", 323, 342], ["human leucocytes", "ANATOMY", 38, 54]]], ["Another review documented that women, especially during their reproductive years, are at increased risk of developing autoimmune diseases but are more resistant to infections than men.", [["autoimmune diseases", "DISEASE", 118, 137], ["infections", "DISEASE", 164, 174], ["women", "ORGANISM", 31, 36], ["men", "ORGANISM", 180, 183], ["women", "SPECIES", 31, 36], ["men", "SPECIES", 180, 183], ["developing autoimmune diseases", "PROBLEM", 107, 137], ["infections", "PROBLEM", 164, 174], ["autoimmune diseases", "OBSERVATION", 118, 137], ["more resistant", "OBSERVATION_MODIFIER", 146, 160]]], ["This is possibly mediated by several factors including sex hormones [19].", [["possibly mediated", "UNCERTAINTY", 8, 25]]], ["The concept of sex-based immunological differences driven by sex hormone and X chromosome has been well described by Elgendy et al., [20] where blocking estrogen receptors increased the mortality due SARS-CoV infection among female mice, suggesting the role played by estrogen receptors in blocking some viral infection.BehaviorSince the first report of Covid-19 case in Wuhan, China, many clinical and epidemiological studies are coming out.", [["chromosome", "ANATOMY", 79, 89], ["estrogen", "CHEMICAL", 153, 161], ["SARS-CoV infection", "DISEASE", 200, 218], ["estrogen", "CHEMICAL", 268, 276], ["viral infection", "DISEASE", 304, 319], ["estrogen", "CHEMICAL", 153, 161], ["estrogen", "CHEMICAL", 268, 276], ["X chromosome", "CELLULAR_COMPONENT", 77, 89], ["estrogen receptors", "GENE_OR_GENE_PRODUCT", 153, 171], ["SARS-CoV", "ORGANISM", 200, 208], ["mice", "ORGANISM", 232, 236], ["estrogen receptors", "GENE_OR_GENE_PRODUCT", 268, 286], ["X chromosome", "DNA", 77, 89], ["estrogen receptors", "PROTEIN", 153, 171], ["estrogen receptors", "PROTEIN", 268, 286], ["mice", "SPECIES", 232, 236], ["SARS-CoV", "SPECIES", 200, 208], ["mice", "SPECIES", 232, 236], ["blocking estrogen receptors", "TREATMENT", 144, 171], ["SARS", "PROBLEM", 200, 204], ["CoV infection", "PROBLEM", 205, 218], ["estrogen receptors", "TREATMENT", 268, 286], ["some viral infection", "PROBLEM", 299, 319], ["epidemiological studies", "TEST", 403, 426], ["viral", "OBSERVATION_MODIFIER", 304, 309], ["infection", "OBSERVATION", 310, 319]]], ["Previously, much emphasis was initially placed on the elderly or those who have preexisting health conditions such as obesity, hypertension, and diabetes as being at risk of dying from the virus, but we are seeing with every country that provides us with sex-disaggregated data that men are more likely to die from the virus [21].BehaviorIn the two hardest hit European nations, majority of the Covid-19 deaths in Italy [8] were male, while in Spain, almost twice as many men as women have died (http://globalhealth5050.org/covid19/.", [["obesity", "DISEASE", 118, 125], ["hypertension", "DISEASE", 127, 139], ["diabetes", "DISEASE", 145, 153], ["deaths", "DISEASE", 404, 410], ["men", "ORGANISM", 283, 286], ["men", "ORGANISM", 472, 475], ["women", "ORGANISM", 479, 484], ["men", "SPECIES", 283, 286], ["men", "SPECIES", 472, 475], ["women", "SPECIES", 479, 484], ["preexisting health conditions", "PROBLEM", 80, 109], ["obesity", "PROBLEM", 118, 125], ["hypertension", "PROBLEM", 127, 139], ["diabetes", "PROBLEM", 145, 153], ["the virus", "PROBLEM", 185, 194], ["the virus", "PROBLEM", 315, 324], ["obesity", "OBSERVATION", 118, 125], ["hypertension", "OBSERVATION", 127, 139]]], ["Data from China first revealed a gender gap in deaths, where \ufeff41.9% of the admitted patients were female with majority of male sufferers dying compared to women [1].", [["deaths", "DISEASE", 47, 53], ["patients", "ORGANISM", 84, 92], ["women", "ORGANISM", 155, 160], ["patients", "SPECIES", 84, 92], ["women", "SPECIES", 155, 160], ["a gender gap in deaths", "PROBLEM", 31, 53]]], ["Accessed April 19, 2020) have confirmed the pattern.BehaviorIt is of no doubts, a part of this is biology (genetics and immunology), but a large part of this difference is also driven by gender behavior (life style), such as far higher levels of smoking and drinking among men compared to women [9].", [["smoking", "CHEMICAL", 246, 253], ["men", "ORGANISM", 273, 276], ["women", "ORGANISM", 289, 294], ["men", "SPECIES", 273, 276], ["women", "SPECIES", 289, 294], ["large", "OBSERVATION_MODIFIER", 139, 144]]], ["Further, the recent study conducted in Spain (one of the hardest hit countries in Europe) reported that women had more responsible attitude toward the Covid-19 pandemic than men [22].", [["women", "ORGANISM", 104, 109], ["men", "ORGANISM", 174, 177], ["women", "SPECIES", 104, 109], ["men", "SPECIES", 174, 177], ["the recent study", "TEST", 9, 25]]], ["This may reversibly affect their undertaking of preventive measures such as frequent hand washing, face masking, and stay at home orders.ConclusionThe biological differences in the immune systems between men and women exist which may impact our ability to fight an infection including SARS-2-CoV-2.", [["hand", "ANATOMY", 85, 89], ["infection", "DISEASE", 265, 274], ["SARS", "DISEASE", 285, 289], ["hand", "ORGANISM_SUBDIVISION", 85, 89], ["men", "ORGANISM", 204, 207], ["women", "ORGANISM", 212, 217], ["SARS-2-CoV-2", "ORGANISM", 285, 297], ["men", "SPECIES", 204, 207], ["women", "SPECIES", 212, 217], ["preventive measures", "TREATMENT", 48, 67], ["frequent hand washing", "TREATMENT", 76, 97], ["face masking", "TREATMENT", 99, 111], ["an infection", "PROBLEM", 262, 274], ["SARS", "TEST", 285, 289], ["infection", "OBSERVATION", 265, 274]]], ["Generally, females are more resistant to infections than men, and this is possibly mediated by several factors including sex hormones and high expression of coronavirus receptors (ACE 2) in men but also life style, such as higher levels of smoking and drinking among men as compared to women.", [["infections", "DISEASE", 41, 51], ["smoking", "CHEMICAL", 240, 247], ["men", "ORGANISM", 57, 60], ["coronavirus receptors (ACE 2", "GENE_OR_GENE_PRODUCT", 157, 185], ["men", "ORGANISM", 190, 193], ["men", "ORGANISM", 267, 270], ["women", "ORGANISM", 286, 291], ["coronavirus receptors", "PROTEIN", 157, 178], ["ACE 2", "PROTEIN", 180, 185], ["men", "SPECIES", 57, 60], ["men", "SPECIES", 190, 193], ["men", "SPECIES", 267, 270], ["women", "SPECIES", 286, 291], ["infections", "PROBLEM", 41, 51], ["sex hormones", "PROBLEM", 121, 133], ["coronavirus receptors (ACE", "TREATMENT", 157, 183], ["more resistant", "OBSERVATION_MODIFIER", 23, 37]]], ["Additionally, women have more responsible attitude toward the Covid-19 pandemic than men.", [["women", "ORGANISM", 14, 19], ["Covid-19", "ORGANISM", 62, 70], ["men", "ORGANISM", 85, 88], ["women", "SPECIES", 14, 19], ["men", "SPECIES", 85, 88]]], ["This may reversibly affect the undertaking of preventive measures such as frequent hand washing, wearing of face mask, and stay at home orders.", [["hand", "ANATOMY", 83, 87], ["hand", "ORGANISM_SUBDIVISION", 83, 87], ["preventive measures", "TREATMENT", 46, 65], ["frequent hand washing", "TREATMENT", 74, 95], ["face mask", "TREATMENT", 108, 117]]]], "PMC7102216": [["IntroductionSystemic lupus erythematosus (SLE) is a multisystem inflammatory disorder with a myriad of underlying immune system aberrations and patho-physiological changes, leading to heterogeneous symptoms.", [["immune system", "ANATOMY", 114, 127], ["IntroductionSystemic lupus erythematosus", "DISEASE", 0, 40], ["SLE", "DISEASE", 42, 45], ["inflammatory disorder", "DISEASE", 64, 85], ["IntroductionSystemic lupus erythematosus", "PROBLEM", 0, 40], ["a multisystem inflammatory disorder", "PROBLEM", 50, 85], ["underlying immune system aberrations", "PROBLEM", 103, 139], ["patho-physiological changes", "PROBLEM", 144, 171], ["heterogeneous symptoms", "PROBLEM", 184, 206], ["lupus erythematosus", "OBSERVATION", 21, 40], ["multisystem", "OBSERVATION_MODIFIER", 52, 63], ["inflammatory", "OBSERVATION", 64, 76], ["immune system aberrations", "OBSERVATION", 114, 139], ["heterogeneous", "OBSERVATION_MODIFIER", 184, 197], ["symptoms", "OBSERVATION", 198, 206]]], ["Immunologically, B lymphocytes generate auto-reactive antibodies to nuclear antigens, and modulate the T-cell repertoire through cytokine production and antigen presentation [1].", [["B lymphocytes", "ANATOMY", 17, 30], ["nuclear", "ANATOMY", 68, 75], ["T-cell", "ANATOMY", 103, 109], ["B lymphocytes", "CELL", 17, 30], ["T-cell", "CELL", 103, 109], ["B lymphocytes", "CELL_TYPE", 17, 30], ["auto-reactive antibodies", "PROTEIN", 40, 64], ["nuclear antigens", "PROTEIN", 68, 84], ["cytokine", "PROTEIN", 129, 137], ["B lymphocytes", "TEST", 17, 30], ["auto-reactive antibodies", "PROBLEM", 40, 64], ["nuclear antigens", "TEST", 68, 84], ["cytokine production", "TEST", 129, 148], ["lymphocytes", "ANATOMY", 19, 30]]], ["Pathologically, inflammation and immune complex deposition results in end-organ damage.", [["organ", "ANATOMY", 74, 79], ["inflammation", "DISEASE", 16, 28], ["end-organ damage", "DISEASE", 70, 86], ["immune complex", "GENE_OR_GENE_PRODUCT", 33, 47], ["organ", "ORGAN", 74, 79], ["inflammation", "PROBLEM", 16, 28], ["immune complex deposition", "PROBLEM", 33, 58], ["end-organ damage", "PROBLEM", 70, 86], ["inflammation", "OBSERVATION", 16, 28], ["complex", "OBSERVATION_MODIFIER", 40, 47], ["deposition", "OBSERVATION_MODIFIER", 48, 58], ["organ", "ANATOMY", 74, 79], ["damage", "OBSERVATION", 80, 86]]], ["Thus, targeting aberrant B cells is a promising approach in a disease where new treatments are long-awaited (none have been validated in the last 30\u201340 years); current therapeutic options can carry serious adverse effects (e.g. ovarian failure and opportunistic infections with cyclophosphamide), and significant numbers of patients fail to respond [2].IntroductionWorldwide prevalence of SLE is estimated at 5 to 50 per 100,000 (varying with methodology and ethnic group) [3]; incidence is highest in young women and 90% of those diagnosed are female.", [["B cells", "ANATOMY", 25, 32], ["ovarian", "ANATOMY", 228, 235], ["ovarian failure", "DISEASE", 228, 243], ["opportunistic infections", "DISEASE", 248, 272], ["cyclophosphamide", "CHEMICAL", 278, 294], ["SLE", "DISEASE", 389, 392], ["cyclophosphamide", "CHEMICAL", 278, 294], ["B cells", "CELL", 25, 32], ["ovarian", "ORGAN", 228, 235], ["cyclophosphamide", "SIMPLE_CHEMICAL", 278, 294], ["patients", "ORGANISM", 324, 332], ["women", "ORGANISM", 508, 513], ["aberrant B cells", "CELL_TYPE", 16, 32], ["patients", "SPECIES", 324, 332], ["women", "SPECIES", 508, 513], ["aberrant B cells", "PROBLEM", 16, 32], ["a disease", "PROBLEM", 60, 69], ["new treatments", "TREATMENT", 76, 90], ["serious adverse effects", "PROBLEM", 198, 221], ["ovarian failure", "PROBLEM", 228, 243], ["opportunistic infections", "PROBLEM", 248, 272], ["cyclophosphamide", "TREATMENT", 278, 294], ["aberrant", "OBSERVATION_MODIFIER", 16, 24], ["B cells", "OBSERVATION", 25, 32], ["disease", "OBSERVATION", 62, 69], ["new", "OBSERVATION_MODIFIER", 76, 79], ["ovarian", "ANATOMY", 228, 235], ["failure", "OBSERVATION", 236, 243], ["significant", "OBSERVATION_MODIFIER", 301, 312], ["numbers", "OBSERVATION_MODIFIER", 313, 320]]], ["Despite treatment the course of the disease is remitting-relapsing, highly variable between individuals, and 20-year survival rate remains less than 80%, largely due to cardiovascular disease [4].", [["cardiovascular", "ANATOMY", 169, 183], ["cardiovascular disease", "DISEASE", 169, 191], ["treatment", "TREATMENT", 8, 17], ["the disease", "PROBLEM", 32, 43], ["survival rate", "TEST", 117, 130], ["cardiovascular disease", "PROBLEM", 169, 191], ["disease", "OBSERVATION", 36, 43], ["cardiovascular disease", "OBSERVATION", 169, 191]]], ["Inducing and maintaining remission is often an unattainable goal, and we compromise with alleviating symptoms and limiting end-organ damage.IntroductionB cells express CD20, a surface molecule involved in regulating cell cycle initiation and differentiation; it is neither shed from the cell surface nor internalized, making it a reliable target.", [["organ", "ANATOMY", 127, 132], ["cells", "ANATOMY", 154, 159], ["surface", "ANATOMY", 176, 183], ["cell", "ANATOMY", 216, 220], ["cell surface", "ANATOMY", 287, 299], ["end-organ damage", "DISEASE", 123, 139], ["organ", "ORGAN", 127, 132], ["cells", "CELL", 154, 159], ["CD20", "GENE_OR_GENE_PRODUCT", 168, 172], ["cell", "CELL", 216, 220], ["cell surface", "CELLULAR_COMPONENT", 287, 299], ["CD20", "PROTEIN", 168, 172], ["surface molecule", "PROTEIN", 176, 192], ["alleviating symptoms", "PROBLEM", 89, 109], ["limiting end-organ damage", "PROBLEM", 114, 139], ["CD20", "PROBLEM", 168, 172], ["a surface molecule", "TREATMENT", 174, 192], ["regulating cell cycle initiation", "TREATMENT", 205, 237], ["organ", "ANATOMY", 127, 132], ["damage", "OBSERVATION", 133, 139], ["cell cycle", "OBSERVATION", 216, 226]]], ["Rituximab is a chimera of murine variable regions against CD20 and human IgG constant region.", [["Rituximab", "CHEMICAL", 0, 9], ["Rituximab", "SIMPLE_CHEMICAL", 0, 9], ["murine", "ORGANISM", 26, 32], ["CD20", "GENE_OR_GENE_PRODUCT", 58, 62], ["human", "ORGANISM", 67, 72], ["murine variable regions", "PROTEIN", 26, 49], ["CD20", "PROTEIN", 58, 62], ["human IgG constant region", "PROTEIN", 67, 92], ["murine", "SPECIES", 26, 32], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Rituximab", "TREATMENT", 0, 9], ["CD20", "PROBLEM", 58, 62], ["human IgG constant region", "PROBLEM", 67, 92]]], ["Initially introduced in the 1990s as a treatment of non-Hodgkin\u2019s lymphoma, it has more recently been licensed in the treatment of rheumatoid arthritis (RA).IntroductionBoth lymphoma and SLE have aberrant B lymphocyte activity, which rituximab targets via the CD20 ligand.", [["non-Hodgkin\u2019s lymphoma", "ANATOMY", 52, 74], ["lymphoma", "ANATOMY", 174, 182], ["B lymphocyte", "ANATOMY", 205, 217], ["non-Hodgkin\u2019s lymphoma", "DISEASE", 52, 74], ["rheumatoid arthritis", "DISEASE", 131, 151], ["RA", "DISEASE", 153, 155], ["lymphoma", "DISEASE", 174, 182], ["SLE", "DISEASE", 187, 190], ["non-Hodgkin\u2019s lymphoma", "CANCER", 52, 74], ["lymphoma", "CANCER", 174, 182], ["SLE", "CANCER", 187, 190], ["B lymphocyte", "CELL", 205, 217], ["rituximab", "SIMPLE_CHEMICAL", 234, 243], ["CD20 ligand", "GENE_OR_GENE_PRODUCT", 260, 271], ["CD20 ligand", "PROTEIN", 260, 271], ["non-Hodgkin\u2019s lymphoma", "PROBLEM", 52, 74], ["rheumatoid arthritis", "PROBLEM", 131, 151], ["IntroductionBoth lymphoma", "PROBLEM", 157, 182], ["SLE", "PROBLEM", 187, 190], ["aberrant B lymphocyte activity", "PROBLEM", 196, 226], ["rituximab", "TREATMENT", 234, 243], ["non-Hodgkin\u2019s lymphoma", "OBSERVATION", 52, 74], ["rheumatoid", "OBSERVATION_MODIFIER", 131, 141], ["arthritis", "OBSERVATION", 142, 151], ["RA", "ANATOMY", 153, 155], ["lymphoma", "OBSERVATION", 174, 182], ["aberrant", "OBSERVATION_MODIFIER", 196, 204], ["B lymphocyte activity", "OBSERVATION", 205, 226]]], ["B cells express CD20 throughout their maturation, so depletion can be highly specific and sensitive\u2014a more targeted treatment option than traditional cyclophosphamide or steroid.", [["B cells", "ANATOMY", 0, 7], ["cyclophosphamide", "CHEMICAL", 150, 166], ["steroid", "CHEMICAL", 170, 177], ["cyclophosphamide", "CHEMICAL", 150, 166], ["steroid", "CHEMICAL", 170, 177], ["B cells", "CELL", 0, 7], ["CD20", "GENE_OR_GENE_PRODUCT", 16, 20], ["cyclophosphamide", "SIMPLE_CHEMICAL", 150, 166], ["steroid", "SIMPLE_CHEMICAL", 170, 177], ["B cells", "CELL_TYPE", 0, 7], ["CD20", "PROTEIN", 16, 20], ["CD20", "PROBLEM", 16, 20], ["traditional cyclophosphamide", "TREATMENT", 138, 166], ["steroid", "TREATMENT", 170, 177], ["CD20", "OBSERVATION", 16, 20]]], ["However, autoantibody-producing plasma cells are CD20 negative, and therefore potentially resistant to rituximab.", [["plasma cells", "ANATOMY", 32, 44], ["rituximab", "CHEMICAL", 103, 112], ["plasma cells", "CELL", 32, 44], ["CD20", "GENE_OR_GENE_PRODUCT", 49, 53], ["rituximab", "SIMPLE_CHEMICAL", 103, 112], ["autoantibody-producing plasma cells", "CELL_TYPE", 9, 44], ["CD20", "PROTEIN", 49, 53], ["autoantibody", "TEST", 9, 21], ["plasma cells", "PROBLEM", 32, 44], ["CD20", "TEST", 49, 53], ["rituximab", "TREATMENT", 103, 112]]], ["In addition, long-lived plasma cells can endure antiproliferative immunosupressants and continue to produce autoantibodies [5].MethodologyThe search strategy included the terms \u201cSystemic Lupus Erythematosus\u201d and \u201cRituximab\u201d, searching Medline, Embase, Cinahl, the Cochrane library and retrospective searching of citations.", [["plasma cells", "ANATOMY", 24, 36], ["Lupus Erythematosus\u201d", "DISEASE", 187, 207], ["plasma cells", "CELL", 24, 36], ["plasma cells", "CELL_TYPE", 24, 36], ["autoantibodies", "PROTEIN", 108, 122], ["long-lived plasma cells", "TREATMENT", 13, 36], ["antiproliferative immunosupressants", "TREATMENT", 48, 83], ["autoantibodies", "PROBLEM", 108, 122], ["Systemic Lupus Erythematosus", "PROBLEM", 178, 206], ["Rituximab", "TREATMENT", 213, 222], ["Systemic", "OBSERVATION_MODIFIER", 178, 186], ["Lupus Erythematosus", "OBSERVATION", 187, 206]]], ["The manufacturer (Roche Products Ltd) was contacted regarding any trials currently awaiting publication.", [["The manufacturer (Roche Products", "TREATMENT", 0, 32]]], ["Where multiple publications under the same group of authors were found, the group was contacted to establish whether data for separate studies was derived from a common patient cohort; if this was the case only the most comprehensive and highest quality paper was included.", [["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["separate studies", "TEST", 126, 142]]], ["The selection process is summarized in Fig. 1.", [["The selection process", "TREATMENT", 0, 21]]]], "e968c943bd53c2f770231bcd954b92eea8a9d6b8": [["IntroductionIn [2] the first author proposed Non-uniform Cylindrical Algebraic Decomposition (NuCAD) as an alternative to the well-known Cylindrical Algebraic Decomposition (CAD) as a data-structure for representing sets of points in Euclidean space defined by boolean combinations of real polynomial equalities and inequalities.", [["Non-uniform Cylindrical Algebraic Decomposition (NuCAD)", "TREATMENT", 45, 100], ["known Cylindrical Algebraic Decomposition", "TREATMENT", 131, 172], ["CAD", "PROBLEM", 174, 177], ["Euclidean space", "PROBLEM", 234, 249]]], ["The process of constructing a NuCAD involves many points at which an arbitrary choice needs to be made-a choice that does not affect correctness, but can have a considerable impact on running time, memory usage, and quality of solution.", [["NuCAD", "DNA", 30, 35]]], ["In this article we only address the question of whether the semi-algebraic set is non-empty or, equivalently, whether the associated Tarski formula is satisfiable.", [["the associated Tarski formula", "PROBLEM", 118, 147]]], ["For example, to determine the satisfiability of the Tarski formula [x 2 + y 2 < 1 \u2227 y > x 2 \u2227 3x > 2y 2 + 1], we would construct a NuCAD data structure representing the decomposition of R 2 depicted in Fig. 1.", [["NuCAD", "PROTEIN", 131, 136], ["the Tarski formula", "TEST", 48, 66], ["a NuCAD data structure", "PROBLEM", 129, 151], ["Fig", "OBSERVATION", 202, 205]]], ["Depicted on the left is the semi-algebraic set defined by the Tarski formula [x 2 + y 2 < 1 \u2227 y > x 2 \u2227 3x > 2y 2 + 1] along with the curves defined by the three polynomials in the formula.", [["the Tarski formula", "TEST", 58, 76], ["y", "TEST", 94, 95], ["the curves", "TEST", 130, 140], ["left", "ANATOMY_MODIFIER", 16, 20]]], ["On the right is depicted the decomposition described by a NuCAD data structure produced from the formula.", [["NuCAD data structure", "PROTEIN", 58, 78], ["right", "ANATOMY_MODIFIER", 7, 12], ["decomposition", "OBSERVATION", 29, 42]]], ["This is not unique, as different choices during the construction lead to different NuCADs.IntroductionThe NuCAD data structure contains a sample point for each cell in the decomposition it represents.", [["cell", "ANATOMY", 160, 164], ["NuCADs", "DISEASE", 83, 89], ["NuCADs", "CANCER", 83, 89], ["cell", "CELL", 160, 164], ["NuCAD", "PROTEIN", 106, 111]]], ["In this case, two cells have sample points at which the input formula is satisfied.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23]]], ["Thus, not only do we learn that the formula is satisfiable, but we also have witness points to prove it.IntroductionNuCADs are constructed by a simple refinement process.", [["NuCADs", "GENE_OR_GENE_PRODUCT", 116, 122], ["NuCADs", "PROTEIN", 116, 122], ["a simple refinement process", "TREATMENT", 142, 169]]], ["At each step a cell is selected, and from amongst the constraints that are violated at its sample point, one is chosen to be the basis for splitting the selected cell into subcellsthus refining the decomposition.", [["cell", "ANATOMY", 15, 19], ["cell", "ANATOMY", 162, 166], ["cell", "CELL", 15, 19], ["cell", "CELL", 162, 166]]], ["The key idea is that the subcell containing the original sample point has the property that the chosen constraint is violated throughout the subcell.", [["subcell", "ANATOMY", 25, 32], ["subcell", "ANATOMY", 141, 148], ["subcell", "CANCER", 25, 32], ["subcell", "CANCER", 141, 148], ["subcell", "DNA", 25, 32]]], ["To be precise, we give the following definition of a choice function.Definition 1.A choice function maps a set of multivariate polynomials and a variable ordering to an element of the input polynomial set.", [["A choice function maps", "TEST", 82, 104], ["multivariate polynomials", "PROBLEM", 114, 138]]], ["When a cell has been selected to refine, the set of polynomials from constraints that are violated at the selected cell's sample point is given as input to a choice function, and the output of the choice function is the constraint that will be used for the next refining step.", [["cell", "ANATOMY", 7, 11], ["cell", "ANATOMY", 115, 119], ["cell", "CELL", 7, 11], ["cell", "CELL", 115, 119]]], ["Additional input consisting of state information from the selected cell and the NuCAD as a whole (e.g. the polynomials defining the selected cell's boundaries) are optionally allowed.Definition 1.It is important to point out that making good choices vs. bad choices can make orders of magnitude differences in computing time and number of cells in the resulting NuCAD.", [["cell", "ANATOMY", 67, 71], ["cell", "ANATOMY", 141, 145], ["cells", "ANATOMY", 339, 344], ["cell", "CELL", 67, 71], ["NuCAD", "GENE_OR_GENE_PRODUCT", 80, 85], ["cell", "CELL", 141, 145], ["cells", "CELL", 339, 344], ["NuCAD", "PROTEIN", 80, 85], ["NuCAD", "PROTEIN", 362, 367], ["the polynomials", "TREATMENT", 103, 118], ["the selected cell's boundaries", "TREATMENT", 128, 158]]], ["Of course for very easy problems, the difference is not that great.", [["very easy problems", "PROBLEM", 14, 32], ["very", "OBSERVATION_MODIFIER", 14, 18], ["easy", "OBSERVATION_MODIFIER", 19, 23], ["problems", "OBSERVATION", 24, 32]]], ["Likewise, there are combinations of problem and initial point for which, at every sample point, there is only one violated constraint.", [["problem", "PROBLEM", 36, 43], ["violated constraint", "OBSERVATION", 114, 133]]], ["The dimensions and component types of these vectors is fixed for a given learning problem.", [["these vectors", "TREATMENT", 38, 51], ["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["component", "OBSERVATION_MODIFIER", 19, 28], ["types", "OBSERVATION_MODIFIER", 29, 34]]], ["There is no limit on the size of the input space, since there is no bound on the number of polynomials in the input set, nor is there a bound on the number of variables, degrees, or number of terms in the individual polynomials within the set.", [["no", "UNCERTAINTY", 9, 11], ["limit", "OBSERVATION_MODIFIER", 12, 17], ["size", "OBSERVATION_MODIFIER", 25, 29], ["input space", "OBSERVATION", 37, 48], ["no", "UNCERTAINTY", 65, 67], ["bound", "OBSERVATION_MODIFIER", 68, 73], ["polynomials", "OBSERVATION", 91, 102], ["bound", "OBSERVATION_MODIFIER", 136, 141]]], ["It does not fit as a regression problem, because we don't have continuous outputs (the output being one polynomial from the set).", [["a regression problem", "PROBLEM", 19, 39], ["the output", "TEST", 83, 93]]], ["It doesn't fit as a classification problem, because each polynomial from the input set constitutes a class label, and there is not a fixed number of polynomials in the set (classification usually assuming a fixed set of labels).", [["a classification problem", "PROBLEM", 18, 42]]], ["Specifically, we could try to cast learning a choice function as a reinforcement learning problem, in which a decision made during the construction of a NuCAD for an input is rewarded or penalized by the success of the final result, appropriately discounted by its distance from that result.", [["NuCAD", "CANCER", 153, 158], ["NuCAD", "DNA", 153, 158]]], ["Unfortunately, there are two problems with this approach.", [["this approach", "TREATMENT", 43, 56], ["two", "OBSERVATION_MODIFIER", 25, 28], ["problems", "OBSERVATION", 29, 37]]], ["If we end up with a decomposition consisting of 500 cells, is that good?", [["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["a decomposition consisting of 500 cells", "TREATMENT", 18, 57]]], ["Perhaps a different sequence of choices would have yielded a decomposition into 20 cells, or perhaps 500 is in fact the minimum achievable.", [["cells", "ANATOMY", 83, 88], ["cells", "CELL", 83, 88], ["a decomposition into 20 cells", "TREATMENT", 59, 88]]], ["Second, the choices made during the construction of a NuCAD are not generally linear.", [["NuCAD", "GENE_OR_GENE_PRODUCT", 54, 59], ["linear", "OBSERVATION_MODIFIER", 78, 84]]], ["The first choice, for example, produces several sibling cells, and the further refinement of each of those sibling cells is independent of the others.", [["cells", "ANATOMY", 56, 61], ["cells", "ANATOMY", 115, 120], ["cells", "CELL", 56, 61], ["cells", "CELL", 115, 120], ["sibling cells", "CELL_TYPE", 48, 61], ["sibling cells", "CELL_TYPE", 107, 120]]], ["Moreover, it is typically observed that most symbolic algorithms for dealing with polynomial constraints behave very differently on random problems than on \"real-world\" problems.", [["polynomial constraints", "PROBLEM", 82, 104]]], ["This means that if we learn from randomly generated inputs we have to be concerned that the result might not transfer well to real-world problems or, indeed, problems that were not generated in a similar way to the training data.", [["the training data", "TEST", 211, 228]]], ["Typically all the problems within a group are very similar.", [["very", "OBSERVATION_MODIFIER", 46, 50], ["similar", "OBSERVATION_MODIFIER", 51, 58]]], ["This may result in overfitting that would only get exposed if you were to test on problems that were not from any of the groups that were used in 1 In some other contexts in which machine learning has been applied to learn heuristic choice functions in symbolic computing, for example in work about learning to choose good variable orderings, the approach has been to compute the results of all possible choices, so that one does indeed know ground truth.", [["overfitting", "PROBLEM", 19, 30]]], ["One can compute that for the three-variable formula \u2227 3 i=1 (0 < xi + 1/5 \u2227 0 < xi + 2/5 \u2227 0 > xi + 3/5 \u2227 0 > xi + 4/5), which consists solely of linear univariate constraints, there are 5,760 ways that these choices can be made, each resulting in a different NuCAD data structure in the end.", [["NuCAD", "PROTEIN", 260, 265], ["xi", "TEST", 65, 67], ["xi", "TEST", 80, 82]]], ["Finally, the current implementation of NuCAD is for \"open\" NuCAD only, and only for conjunctions.", [["NuCAD", "CHEMICAL", 39, 44], ["NuCAD", "CANCER", 39, 44], ["NuCAD", "DNA", 39, 44]]], ["This means that we are restricted to problems from the SMT-LIB that are conjunctions of strict inequalities.Using ML to Learn Choice FunctionsThe preceding examination of all the reasons why it might not appear to be promising to apply ML to the problem of learning choice functions is important to understanding why we developed the approach described below.Using ML to Learn Choice FunctionsReduce to Binary Classification: Trying to learn a choice function directly is problematic in part because the number of classes is not fixed, rather it is determined by the size of the input set of polynomials, which varies from choiceto-choice.", [["the SMT-LIB", "TREATMENT", 51, 62], ["The preceding examination", "TEST", 142, 167], ["size", "OBSERVATION_MODIFIER", 567, 571]]], ["In a crucial change of perspective, we redefine our problem to learning a choice ordering predicate, i.e. a function that takes two polynomials (and optionally extra information about the underlying cell and NuCAD context), and returns 1 if the first polynomial is a preferable choice to the second, and 0 otherwise.", [["cell", "ANATOMY", 199, 203], ["cell", "CELL", 199, 203]]], ["The choice function applied to a set of n polynomials then becomes n \u2212 1 applications of the choice ordering predicate, at each step retaining the polynomial preferred by the predicate.", [["a set of n polynomials", "TREATMENT", 31, 53]]], ["In the present experiments we accept this fact.Reduce Inputs to Fixed Size Feature Set:Having restricted the learning problem to learning a choice ordering predicate, we have reduced the dimension of the input vector to the function to be learned, but not yet fixed it to a constant.", [["the input vector", "TREATMENT", 200, 216], ["Fixed Size", "OBSERVATION_MODIFIER", 64, 74]]], ["After all, while there are now always two input polynomials, rather than an arbitrary sized set, those polynomials are still unbounded in the number of variables, degrees, number of terms and coefficient sizes.", [["unbounded", "OBSERVATION_MODIFIER", 125, 134], ["coefficient", "OBSERVATION_MODIFIER", 192, 203], ["sizes", "OBSERVATION_MODIFIER", 204, 209]]], ["The solution to this is clear cut from a machine learning perspective: extract from the two polynomials (and optionally from the cell and NuCAD context) a fixed sized set of features.", [["cell", "ANATOMY", 129, 133], ["cell", "CELL", 129, 133], ["The solution", "TREATMENT", 0, 12], ["a fixed sized set of features", "PROBLEM", 153, 182]]], ["Although part of the revolution in deep learning is that the learning algorithm is, in some sense, supposed to do this \"feature engineering\" for us, in this case our domain forces us to do it.", [["deep", "ANATOMY_MODIFIER", 35, 39]]], ["However, because of our restriction to learning choice ordering predicates, there are a number of natural comparative features, for example the difference in level 2 of the two input polynomials, or the difference in the two polynomials' total degrees, number of terms, etc.Reduce to Supervised Learning:The biggest hurdle to applying ML to this problem is that, as described above, it fits neither the supervised nor unsupervised paradigms.", [["total degrees", "OBSERVATION_MODIFIER", 238, 251]]], ["To address this, we use the fact that we have total control of the executing algorithm.", [["the executing algorithm", "TEST", 63, 86]]], ["In particular, for a given input problem, we execute NuCAD construction following the \"current\" choice ordering predicate, but we stop at a random point in the process at which we have more than one constraint violated at a sample point and thus have a choice to make.", [["NuCAD", "PROTEIN", 53, 58]]], ["This gives us the exact number of cells resulting from each polynomial we could have chosen.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39]]], ["By collecting these feature vectors and correct output values over many inputs, we produce a data set that can be used for a supervised, binary classification machine learning problem.Reduce to Supervised Learning:Of course, the \"correct\" results we gathered are only correct for what was then the \"current\" choice ordering predicate, and by learning we have derived a new choice ordering predicate.", [["correct output values", "TEST", 40, 61], ["output", "OBSERVATION_MODIFIER", 48, 54]]], ["This means we should iterate the process until the performance of NuCAD construction using the learned choice ordering predicate converges.", [["NuCAD", "DNA", 66, 71], ["NuCAD construction", "TREATMENT", 66, 84]]], ["It is not clear that this convergence will happen.", [["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15]]], ["However, our experiments indicate that we get good performance in relatively few iterations.Reduce to Supervised Learning:Learn from Randomly Generated Inputs, Evaluate With \"Real\" Input: Our approach was to learn from randomly generated formulas-formulas in five variables with many constraints, both linear and non-linear, different levels of sparsity, and different numbers of variables appearing.", [["linear", "OBSERVATION_MODIFIER", 302, 308], ["different", "OBSERVATION_MODIFIER", 359, 368], ["numbers", "OBSERVATION_MODIFIER", 369, 376]]], ["Each input formula was used to analyze only one choice-point.", [["Each input formula", "TREATMENT", 0, 18]]], ["The justification is that our initial experiments show that the learned choice ordering predicate does indeed transfer well to the \"real\" problems pulled from SMT-LIB, despite the fact that they often have very different shape and that all the problems we tested against had fewer than five variables.ExperimentsThe Tarski 3 system [9] was used in our experiments for its implementation of NuCAD.", [["NuCAD", "CHEMICAL", 390, 395], ["NuCAD", "SIMPLE_CHEMICAL", 390, 395], ["NuCAD", "PROTEIN", 390, 395]]], ["For our machine learning, we used the Keras [4] package.ExperimentsRandom formulas were generated to consist of 13 \"<\" constraints, eight quadratic and five linear, with between two and four terms.", [["the Keras [4] package", "TREATMENT", 34, 55]]], ["Below is an example of one of them.ExperimentsGiven a choice-point in a NuCAD construction and two polynomials, we construct a vector of 22 features capturing individual and comparative properties of the two polynomials and the context of the NuCAD construction.", [["NuCAD", "GENE_OR_GENE_PRODUCT", 243, 248], ["NuCAD", "DNA", 243, 248], ["a NuCAD construction", "TREATMENT", 70, 90], ["the NuCAD construction", "TREATMENT", 239, 261]]], ["Note that \"spsize\" is a function that measures the size of the internal representation of a polynomial-it is roughly proportional to the print length, but without any dependency on the length of variable names.", [["size", "OBSERVATION_MODIFIER", 51, 55], ["internal", "ANATOMY_MODIFIER", 63, 71], ["length", "OBSERVATION_MODIFIER", 143, 149], ["without", "UNCERTAINTY", 155, 162]]], ["Features 6-10 are comparative, but based on \"p * 1 \" and \"p * 2 \".", [["Features", "TEST", 0, 8]]], ["Here p * 1 is the same as p 1 , but with any term removed for which p 2 has a term with the same power product, and p * 2 is defined analogously.", [["p * 1", "DNA", 5, 10]]], ["For example, if p 1 = 2xz 2 \u2212 3zy + x + 1 and p 2 = \u2212xz 2 \u2212 2y 2 + y \u2212 5x then p * 1 = \u22123zy + 1 and p * 2 = \u22122y 2 + y.", [["example", "TEST", 4, 11], ["p", "TEST", 16, 17], ["2xz", "TEST", 22, 25], ["3zy", "TEST", 30, 33], ["\u22123zy", "TEST", 87, 91]]], ["Features 11-14 involve a process we call \"pseudo-projection\", which gives estimates of the size of the projection set arising from choosing a particular polynomial with which to refine the current cell.", [["cell", "ANATOMY", 197, 201], ["cell", "CELL", 197, 201], ["Features", "TEST", 0, 8], ["size", "OBSERVATION_MODIFIER", 91, 95]]], ["There is an existing hand-crafted heuristic used in Tarski, called \"BPC\", against which we will compare our learned heuristic.", [["hand", "ANATOMY", 21, 25]]], ["It is expressible in terms of features zero, one and three of the feature vector F for polynomials p 1 and p 2 , but we describe it more directly here as follows: if exactly one of p 1 and p 2 has total degree one, choose it; otherwise choose the polynomial with lower level, breaking ties by choosing the polynomial with smaller \"spsize\".", [["smaller", "OBSERVATION_MODIFIER", 322, 329]]], ["The first feature in our feature vector was included so that other, less capable, learning paradigms (like decision lists) would still be expressive enough to learn BPC.", [["BPC", "CANCER", 165, 168]]], ["For neural nets we could have replaced features zero and one with tdeg p 1 and tdeg p 2 , which would have been more natural, but these same feature vectors were used for experiments outside of the scope of this paper.", [["neural nets", "ANATOMY", 4, 15], ["tdeg p 1", "DNA", 66, 74], ["more natural", "OBSERVATION_MODIFIER", 112, 124]]], ["For our learning model, we use a feed forward neural network that takes a dense network with 22 inputs and dimension 22 \u00d7 22 \u00d7 5 \u00d7 5 \u00d7 1 with ReLU activation functions for internal nodes and sigmoid activation function for the output node.", [["internal nodes", "ANATOMY", 172, 186], ["output node", "ANATOMY", 227, 238], ["neural network", "MULTI-TISSUE_STRUCTURE", 46, 60], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 172, 186], ["node", "MULTI-TISSUE_STRUCTURE", 234, 238], ["a feed forward neural network", "TREATMENT", 31, 60], ["dimension", "TEST", 107, 116], ["internal nodes", "PROBLEM", 172, 186], ["the output node", "PROBLEM", 223, 238], ["nodes", "OBSERVATION", 181, 186], ["sigmoid", "ANATOMY", 191, 198], ["output node", "OBSERVATION", 227, 238]]], ["In each round the neural net is used as the choice ordering predicate for producing data, as described in the previous section.", [["neural", "ANATOMY", 18, 24], ["round", "OBSERVATION_MODIFIER", 8, 13], ["neural net", "OBSERVATION", 18, 28]]], ["From this training data, a new set of network weights was learned (starting from a different set of random weights), and this newly learned function served as the \"current\" choice ordering predicate for the subsequent round.", [["network", "MULTI-TISSUE_STRUCTURE", 38, 45], ["this training data", "TEST", 5, 23]]], ["Also shown is performance of \"BPC\" the hand-crafted heuristic that is used by default in our implementation of NuCAD.", [["hand", "ANATOMY", 39, 43], ["NuCAD", "CANCER", 111, 116], ["NuCAD", "PROTEIN", 111, 116], ["hand", "ANATOMY", 39, 43]]], ["The performance does not smoothly increase from one iteration to the next, nor show the classic \"U\" shape often seen in machine learning, which warrants further investigation.", [["further investigation", "TEST", 153, 174]]], ["The neural net resulting from the 6th iteration, \"NN06\", is the best performing network on these test problems.", [["neural", "ANATOMY", 4, 10], ["these test problems", "TEST", 91, 110], ["neural net", "OBSERVATION", 4, 14]]], ["This plot shows the performance of the trained neural networks for each round on the test data, which consists of problems generated randomly in the same way as the training data.", [["neural networks", "ANATOMY", 47, 62], ["neural networks", "MULTI-TISSUE_STRUCTURE", 47, 62], ["This plot", "TEST", 0, 9], ["the test data", "TEST", 81, 94], ["the training data", "TEST", 161, 178]]], ["Though difficult to see, \"NN06\", the network generated after the 6th round performs the best.", [["NN06", "DNA", 26, 30]]], ["Also shown is the performance of \"BPC\" the hand-crafted heuristic that is used by default in our implementation of NuCAD.ExperimentsThe crucial question is whether our learned choice ordering predicate transfers to problems that aren't of the same \"shape\" as the problems on which we trained.", [["hand", "ANATOMY", 43, 47], ["NuCAD", "CANCER", 115, 120], ["NuCAD", "PROTEIN", 115, 120], ["hand", "ANATOMY", 43, 47]]], ["These problems are conjunctions of strict inequalities derived from a subset of problems in the SMT-LIB QF NRA collection by simplifications and case splittings.", [["These problems", "PROBLEM", 0, 14]]], ["None of these problems are terribly difficult-almost all have three or fewer variables-so we also produced a more challenging set consisting of 1,000 randomly generated four variable problems, generated in a different way than our test problems: each formula consisted of x > 0 \u2227 y > 0 and nine conditions generated in Maple as randpoly([x,y,z,w],degree=2,terms=4,coeffs=rand(-9..9))>0.", [["four variable problems", "PROBLEM", 169, 191], ["Maple", "TEST", 319, 324], ["z", "TEST", 342, 343], ["degree", "TEST", 347, 353], ["terms", "TEST", 356, 361], ["coeffs", "TEST", 364, 370]]], ["These examples differ from the training data in a number of ways.", [["the training data", "TEST", 27, 44]]], ["The only linear constraints are x > 0 and y > 0, whereas the training examples had five linear constraints, each of which was a multi-term constraint, like \u22128v+7w+7x > 0, that ties variables together.", [["a multi-term constraint", "PROBLEM", 126, 149], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["constraints", "OBSERVATION", 16, 27], ["linear", "OBSERVATION_MODIFIER", 88, 94], ["constraints", "OBSERVATION", 95, 106]]], ["Figure 3 shows the performance of BPC, NN06, and NN00, a randomly weighted neural net, which serves to show the performance of a random choice function.", [["neural", "ANATOMY", 75, 81], ["NN00", "CELL_LINE", 49, 53], ["BPC", "TEST", 34, 37]]], ["Plots showing the performance of the hand-crafted heuristic BPC, the randomly weighted network NN00, and NN06, the trained network that performed best on the original set of training data.", [["hand", "ANATOMY", 37, 41], ["hand", "ORGANISM_SUBDIVISION", 37, 41], ["NN00", "CELL_LINE", 95, 99], ["NN06", "CELL_LINE", 105, 109]]], ["The left plot shows performance for the problem set stemming from the SMT-LIB, and the right plot shows performance on the four-variable randomly generated problem set.", [["LIB", "DNA", 74, 77], ["The left plot", "TEST", 0, 13], ["the right plot", "TEST", 83, 97], ["left", "ANATOMY_MODIFIER", 4, 8], ["right", "ANATOMY_MODIFIER", 87, 92]]], ["Note that NN00 failed to solve 51 problems within the 60 s timeout, BPC failed 13 problems within the 60 s timeout, and NN06 failed to solve two problems within the 60 s timeout.Future Work and AcknowledgmentsThere are several avenues for future work that should be considered.", [["BPC failed 13 problems", "PROBLEM", 68, 90]]], ["The second avenue is to apply the basic approach outlined here to different problems, for example to the problem of selecting a variable ordering in Cylindrical Algebraic Decomposition, considered in [7] , or choosing pivots in parametric Gaussian elimination.", [["the basic approach", "TREATMENT", 30, 48], ["a variable ordering in Cylindrical Algebraic Decomposition", "TREATMENT", 126, 184]]]], "PMC7149900": [["IntroductionReferring to infectious disease, respiratory tract infections engage with all surfaces in the respiratory tract.", [["respiratory tract", "ANATOMY", 45, 62], ["respiratory tract", "ANATOMY", 106, 123], ["infectious disease", "DISEASE", 25, 43], ["respiratory tract infections", "DISEASE", 45, 73], ["tract", "ORGANISM_SUBDIVISION", 57, 62], ["respiratory tract", "ORGANISM_SUBDIVISION", 106, 123], ["infectious disease", "PROBLEM", 25, 43], ["respiratory tract infections", "PROBLEM", 45, 73], ["infectious", "OBSERVATION", 25, 35], ["respiratory tract", "ANATOMY", 45, 62], ["infections", "OBSERVATION", 63, 73], ["all", "OBSERVATION_MODIFIER", 86, 89], ["surfaces", "OBSERVATION_MODIFIER", 90, 98], ["respiratory tract", "ANATOMY", 106, 123]]], ["Based on the infected zone, respiratory infections can be categorized into upper tract infection (URI or URTI) and lower tract infection (LRI or LRTI).", [["respiratory", "ANATOMY", 28, 39], ["upper tract", "ANATOMY", 75, 86], ["lower tract", "ANATOMY", 115, 126], ["respiratory infections", "DISEASE", 28, 50], ["upper tract infection", "DISEASE", 75, 96], ["URI", "DISEASE", 98, 101], ["URTI", "DISEASE", 105, 109], ["lower tract infection", "DISEASE", 115, 136], ["LRTI", "DISEASE", 145, 149], ["upper tract", "ORGANISM_SUBDIVISION", 75, 86], ["lower tract", "ORGANISM_SUBDIVISION", 115, 126], ["the infected zone", "PROBLEM", 9, 26], ["respiratory infections", "PROBLEM", 28, 50], ["upper tract infection", "PROBLEM", 75, 96], ["URI", "PROBLEM", 98, 101], ["URTI)", "PROBLEM", 105, 110], ["lower tract infection", "PROBLEM", 115, 136], ["infected", "OBSERVATION_MODIFIER", 13, 21], ["zone", "OBSERVATION_MODIFIER", 22, 26], ["respiratory", "ANATOMY", 28, 39], ["infections", "OBSERVATION", 40, 50], ["upper tract", "ANATOMY", 75, 86], ["infection", "OBSERVATION", 87, 96], ["lower tract", "ANATOMY", 115, 126], ["infection", "OBSERVATION", 127, 136]]], ["Each involves different parts of the respiratory tract infections, which vary in type and severity of microorganisms.", [["respiratory tract", "ANATOMY", 37, 54], ["respiratory tract infections", "DISEASE", 37, 65], ["respiratory tract", "ORGANISM_SUBDIVISION", 37, 54], ["the respiratory tract infections", "PROBLEM", 33, 65], ["microorganisms", "PROBLEM", 102, 116], ["respiratory tract", "ANATOMY", 37, 54], ["infections", "OBSERVATION", 55, 65]]], ["Although there are different types of respiratory tract infections, the acute form in the upper respiratory tract infection predominates and includes several complications, such as sinusitis, pharyngitis, epiglottitis, laryngitis, and tracheitis.", [["respiratory tract", "ANATOMY", 38, 55], ["upper respiratory tract", "ANATOMY", 90, 113], ["respiratory tract infections", "DISEASE", 38, 66], ["upper respiratory tract infection", "DISEASE", 90, 123], ["sinusitis", "DISEASE", 181, 190], ["pharyngitis", "DISEASE", 192, 203], ["epiglottitis", "DISEASE", 205, 217], ["laryngitis", "DISEASE", 219, 229], ["tracheitis", "DISEASE", 235, 245], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["upper respiratory", "ORGANISM_SUBDIVISION", 90, 107], ["tract", "ORGANISM_SUBDIVISION", 108, 113], ["respiratory tract infections", "PROBLEM", 38, 66], ["the upper respiratory tract infection", "PROBLEM", 86, 123], ["several complications", "PROBLEM", 150, 171], ["sinusitis", "PROBLEM", 181, 190], ["pharyngitis", "PROBLEM", 192, 203], ["epiglottitis", "PROBLEM", 205, 217], ["laryngitis", "PROBLEM", 219, 229], ["tracheitis", "PROBLEM", 235, 245], ["different", "OBSERVATION_MODIFIER", 19, 28], ["types", "OBSERVATION_MODIFIER", 29, 34], ["respiratory tract infections", "OBSERVATION", 38, 66], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["upper", "ANATOMY_MODIFIER", 90, 95], ["respiratory tract", "ANATOMY", 96, 113], ["infection", "OBSERVATION", 114, 123], ["several", "OBSERVATION_MODIFIER", 150, 157], ["complications", "OBSERVATION", 158, 171], ["sinusitis", "OBSERVATION", 181, 190], ["pharyngitis", "OBSERVATION", 192, 203], ["epiglottitis", "OBSERVATION", 205, 217], ["laryngitis", "OBSERVATION", 219, 229], ["tracheitis", "OBSERVATION", 235, 245]]], ["On the other hand, lower respiratory tract infection (LRTI) includes both acute and chorionic types, such as pneumonia and bronchitis.", [["lower respiratory tract", "ANATOMY", 19, 42], ["chorionic", "ANATOMY", 84, 93], ["respiratory tract infection", "DISEASE", 25, 52], ["LRTI", "DISEASE", 54, 58], ["pneumonia", "DISEASE", 109, 118], ["bronchitis", "DISEASE", 123, 133], ["lower", "ORGANISM_SUBDIVISION", 19, 24], ["respiratory tract", "ORGANISM_SUBDIVISION", 25, 42], ["lower respiratory tract infection (LRTI)", "PROBLEM", 19, 59], ["both acute and chorionic types", "PROBLEM", 69, 99], ["pneumonia", "PROBLEM", 109, 118], ["bronchitis", "PROBLEM", 123, 133], ["lower", "ANATOMY_MODIFIER", 19, 24], ["respiratory tract", "ANATOMY", 25, 42], ["infection", "OBSERVATION", 43, 52], ["both", "OBSERVATION_MODIFIER", 69, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["chorionic types", "OBSERVATION", 84, 99], ["pneumonia", "OBSERVATION", 109, 118], ["bronchitis", "OBSERVATION", 123, 133]]], ["Based on pathogenicity, bacterial and viral pathogens are the most common microorganisms in both types (ie, LRTI and URTI).", [["LRTI", "DISEASE", 108, 112], ["URTI", "DISEASE", 117, 121], ["pathogenicity", "PROBLEM", 9, 22], ["bacterial and viral pathogens", "PROBLEM", 24, 53], ["LRTI", "PROBLEM", 108, 112], ["pathogenicity", "OBSERVATION", 9, 22], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["viral pathogens", "OBSERVATION", 38, 53], ["most common", "OBSERVATION_MODIFIER", 62, 73], ["both types", "OBSERVATION_MODIFIER", 92, 102], ["LRTI", "OBSERVATION", 108, 112]]], ["Moreover, infection distribution leads to varieties based on the patient\u2019s age; for example, acute respiratory infections pose severe problem in childhood, which mainly occur in upper respiratory tract.", [["respiratory", "ANATOMY", 99, 110], ["upper respiratory tract", "ANATOMY", 178, 201], ["infection", "DISEASE", 10, 19], ["respiratory infections", "DISEASE", 99, 121], ["patient", "ORGANISM", 65, 72], ["upper respiratory", "ORGANISM_SUBDIVISION", 178, 195], ["tract", "ORGANISM_SUBDIVISION", 196, 201], ["patient", "SPECIES", 65, 72], ["acute respiratory infections", "PROBLEM", 93, 121], ["severe problem", "PROBLEM", 127, 141], ["infection", "OBSERVATION", 10, 19], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory", "ANATOMY", 99, 110], ["infections", "OBSERVATION", 111, 121], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["problem", "OBSERVATION", 134, 141], ["upper", "ANATOMY_MODIFIER", 178, 183], ["respiratory tract", "ANATOMY", 184, 201]]], ["Although the bacterial pathogens play a significant role in intensifying LRTIs, the major acute respiratory infections occur in upper respiratory tract, in these cases viral pathogens are the primary common pathogens, including influenza A and B, parainfluenza (type 1 and 3), adenovirus, and respiratory syncytial virus.", [["respiratory", "ANATOMY", 96, 107], ["upper respiratory tract", "ANATOMY", 128, 151], ["LRTIs", "DISEASE", 73, 78], ["respiratory infections", "DISEASE", 96, 118], ["upper respiratory tract", "DISEASE", 128, 151], ["influenza A and B", "DISEASE", 228, 245], ["parainfluenza", "DISEASE", 247, 260], ["respiratory syncytial virus", "DISEASE", 293, 320], ["upper respiratory", "ORGANISM_SUBDIVISION", 128, 145], ["tract", "ORGANISM_SUBDIVISION", 146, 151], ["influenza A", "ORGANISM", 228, 239], ["B", "GENE_OR_GENE_PRODUCT", 244, 245], ["parainfluenza (type 1", "ORGANISM", 247, 268], ["adenovirus", "ORGANISM", 277, 287], ["respiratory syncytial virus", "ORGANISM", 293, 320], ["parainfluenza", "SPECIES", 247, 260], ["respiratory syncytial virus", "SPECIES", 293, 320], ["adenovirus", "SPECIES", 277, 287], ["respiratory syncytial virus", "SPECIES", 293, 320], ["the bacterial pathogens", "PROBLEM", 9, 32], ["intensifying LRTIs", "PROBLEM", 60, 78], ["the major acute respiratory infections", "PROBLEM", 80, 118], ["upper respiratory tract", "PROBLEM", 128, 151], ["viral pathogens", "PROBLEM", 168, 183], ["the primary common pathogens", "PROBLEM", 188, 216], ["influenza A", "PROBLEM", 228, 239], ["parainfluenza", "PROBLEM", 247, 260], ["adenovirus", "PROBLEM", 277, 287], ["respiratory syncytial virus", "PROBLEM", 293, 320], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["pathogens", "OBSERVATION", 23, 32], ["significant", "OBSERVATION_MODIFIER", 40, 51], ["intensifying", "OBSERVATION_MODIFIER", 60, 72], ["LRTIs", "OBSERVATION", 73, 78], ["major", "OBSERVATION_MODIFIER", 84, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory infections", "OBSERVATION", 96, 118], ["upper", "ANATOMY_MODIFIER", 128, 133], ["respiratory tract", "ANATOMY", 134, 151], ["respiratory", "ANATOMY", 293, 304], ["syncytial virus", "OBSERVATION", 305, 320]]], ["Some of the common pathogens of the respiratory tract are listed in Table 16.1.", [["respiratory tract", "ANATOMY", 36, 53], ["pathogens of the respiratory tract", "DISEASE", 19, 53], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["common", "OBSERVATION_MODIFIER", 12, 18], ["pathogens", "OBSERVATION", 19, 28], ["respiratory tract", "ANATOMY", 36, 53]]], ["Pathogen biodiversity, complexity, and mixed infections in many cases of respiratory tract infection have generated several problems for the treatment of respiratory infections.", [["respiratory tract", "ANATOMY", 73, 90], ["respiratory", "ANATOMY", 154, 165], ["infections", "DISEASE", 45, 55], ["respiratory tract infection", "DISEASE", 73, 100], ["respiratory infections", "DISEASE", 154, 176], ["respiratory tract", "ORGANISM_SUBDIVISION", 73, 90], ["Pathogen biodiversity", "PROBLEM", 0, 21], ["mixed infections", "PROBLEM", 39, 55], ["respiratory tract infection", "PROBLEM", 73, 100], ["respiratory infections", "PROBLEM", 154, 176], ["biodiversity", "OBSERVATION", 9, 21], ["complexity", "OBSERVATION_MODIFIER", 23, 33], ["mixed", "OBSERVATION_MODIFIER", 39, 44], ["infections", "OBSERVATION", 45, 55], ["respiratory tract", "ANATOMY", 73, 90], ["respiratory", "ANATOMY", 154, 165], ["infections", "OBSERVATION", 166, 176]]], ["For example, various bacterial pathogens are encountered in several cases of viral infections.", [["viral infections", "DISEASE", 77, 93], ["various bacterial pathogens", "PROBLEM", 13, 40], ["viral infections", "PROBLEM", 77, 93], ["various", "OBSERVATION_MODIFIER", 13, 20], ["bacterial", "OBSERVATION_MODIFIER", 21, 30], ["pathogens", "OBSERVATION", 31, 40], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infections", "OBSERVATION", 83, 93]]], ["Therefore, the treatment of respiratory infections is a complex therapy which consists of several chemotherapy strategies.1., 2., 3.", [["respiratory", "ANATOMY", 28, 39], ["respiratory infections", "DISEASE", 28, 50], ["respiratory infections", "PROBLEM", 28, 50], ["a complex therapy", "TREATMENT", 54, 71], ["several chemotherapy strategies", "TREATMENT", 90, 121], ["respiratory", "ANATOMY", 28, 39], ["infections", "OBSERVATION", 40, 50]]], ["Antiviral (the same as antibacterial medication) is used to control the treatment and prevention of respiratory infections.IntroductionThere are several restrictive factors, such as medication resistance, recurrency, and inflammation, which will guide researchers to find new effective compounds.", [["respiratory", "ANATOMY", 100, 111], ["respiratory infections", "DISEASE", 100, 122], ["inflammation", "DISEASE", 221, 233], ["Antiviral (the same as antibacterial medication", "TREATMENT", 0, 47], ["the treatment", "TREATMENT", 68, 81], ["respiratory infections", "PROBLEM", 100, 122], ["several restrictive factors", "PROBLEM", 145, 172], ["medication resistance", "PROBLEM", 182, 203], ["recurrency", "PROBLEM", 205, 215], ["inflammation", "PROBLEM", 221, 233], ["new effective compounds", "PROBLEM", 272, 295], ["respiratory", "ANATOMY", 100, 111], ["infections", "OBSERVATION", 112, 122], ["several", "OBSERVATION_MODIFIER", 145, 152], ["restrictive factors", "OBSERVATION", 153, 172], ["inflammation", "OBSERVATION", 221, 233]]], ["This will be an important field in drug development for respiratory infections.", [["respiratory", "ANATOMY", 56, 67], ["respiratory infections", "DISEASE", 56, 78], ["respiratory infections", "PROBLEM", 56, 78], ["respiratory", "ANATOMY", 56, 67], ["infections", "OBSERVATION", 68, 78]]], ["Natural compounds are considered to be one of the main sources in new drug development.", [["Natural compounds", "TREATMENT", 0, 17], ["new", "OBSERVATION_MODIFIER", 66, 69]]], ["Historically, numerous plants have been utilized as traditional medicinesby people in many nations.4 Many of these plants have been investigated for their antimicrobial and antiviral properties.5., 6., 7., 8., 9.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["their antimicrobial and antiviral properties", "TREATMENT", 149, 193], ["plants", "OBSERVATION", 115, 121]]], ["With regard to massive variation among natural products, chemical structure diversity causes different antimicrobial potential in natural compounds.10", [["massive variation", "PROBLEM", 15, 32], ["natural products", "TREATMENT", 39, 55], ["massive", "OBSERVATION_MODIFIER", 15, 22], ["variation", "OBSERVATION_MODIFIER", 23, 32], ["natural products", "OBSERVATION", 39, 55], ["chemical structure", "OBSERVATION", 57, 75], ["different", "OBSERVATION_MODIFIER", 93, 102], ["antimicrobial", "OBSERVATION_MODIFIER", 103, 116], ["natural compounds", "OBSERVATION", 130, 147]]]], "PMC7079756": [["IntroductionNuclear factor-\u03baB (NF-\u03baB) was first identified as a B-cell transcription factor protein that binds to the immunoglobulin heavy chain and the kappa light chain enhancers (Sen and Baltimore 1986, 1987).", [["IntroductionNuclear factor-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 29], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 31, 36], ["B-cell", "CELL", 64, 70], ["immunoglobulin heavy chain", "GENE_OR_GENE_PRODUCT", 118, 144], ["kappa light chain", "GENE_OR_GENE_PRODUCT", 153, 170], ["IntroductionNuclear factor-\u03baB", "PROTEIN", 0, 29], ["NF", "PROTEIN", 31, 33], ["\u03baB", "PROTEIN", 34, 36], ["B-cell transcription factor protein", "PROTEIN", 64, 99], ["immunoglobulin heavy chain", "PROTEIN", 118, 144], ["kappa light chain enhancers", "DNA", 153, 180], ["IntroductionNuclear factor-\u03baB", "TEST", 0, 29]]], ["It is now known to comprise a family of ubiquitous proteins conserved from the fruit fly Drosophila melanogaster to humans.", [["fruit fly", "ORGANISM", 79, 88], ["Drosophila melanogaster", "ORGANISM", 89, 112], ["humans", "ORGANISM", 116, 122], ["ubiquitous proteins", "PROTEIN", 40, 59], ["Drosophila melanogaster", "SPECIES", 89, 112], ["humans", "SPECIES", 116, 122], ["fruit fly", "SPECIES", 79, 88], ["Drosophila melanogaster", "SPECIES", 89, 112], ["humans", "SPECIES", 116, 122], ["ubiquitous proteins", "PROBLEM", 40, 59]]], ["NF-\u03baB controls the expression of more than 400 genes involved in a plethora of functions, such as immunoreceptor expression and expression of chemokines, cytokines, cell adhesion molecules, proliferation, transformation, apoptosis, angiogenesis, oxidative stress, invasion, and metastasis (Baeuerle and Henkel 1994; Giuliani et al. 2001; Kim et al. 2006; Lee and Burckart 1998).", [["cell", "ANATOMY", 165, 169], ["metastasis", "DISEASE", 278, 288], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 165, 169], ["NF-\u03baB", "PROTEIN", 0, 5], ["chemokines", "PROTEIN", 142, 152], ["cytokines", "PROTEIN", 154, 163], ["cell adhesion molecules", "PROTEIN", 165, 188], ["chemokines", "PROBLEM", 142, 152], ["cytokines", "TREATMENT", 154, 163], ["cell adhesion molecules", "PROBLEM", 165, 188], ["proliferation", "PROBLEM", 190, 203], ["transformation", "PROBLEM", 205, 219], ["apoptosis", "PROBLEM", 221, 230], ["angiogenesis", "PROBLEM", 232, 244], ["oxidative stress", "PROBLEM", 246, 262], ["invasion", "PROBLEM", 264, 272], ["metastasis", "PROBLEM", 278, 288], ["oxidative stress", "OBSERVATION", 246, 262], ["invasion", "OBSERVATION_MODIFIER", 264, 272], ["metastasis", "OBSERVATION", 278, 288]]], ["Extensive research has been carried out in the last few years to understand the role of NF-\u03baB in inflammation and cancer in order to design strategies for blocking excessive NF-\u03baB activity.", [["cancer", "ANATOMY", 114, 120], ["inflammation", "DISEASE", 97, 109], ["cancer", "DISEASE", 114, 120], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 88, 93], ["cancer", "CANCER", 114, 120], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 174, 179], ["NF-\u03baB", "PROTEIN", 88, 93], ["NF-\u03baB", "PROTEIN", 174, 179], ["inflammation", "PROBLEM", 97, 109], ["cancer", "PROBLEM", 114, 120], ["blocking excessive NF", "PROBLEM", 155, 176], ["inflammation", "OBSERVATION", 97, 109], ["cancer", "OBSERVATION", 114, 120]]], ["This article focuses on NF-\u03baB signaling pathways, emphasizing their role during pulmonary inflammation and cancer and their modulation with therapeutic agents.IntroductionFive mammalian NF-\u03baB family members have been characterized and cloned.", [["pulmonary", "ANATOMY", 80, 89], ["cancer", "ANATOMY", 107, 113], ["pulmonary inflammation", "DISEASE", 80, 102], ["cancer", "DISEASE", 107, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 24, 29], ["pulmonary", "ORGAN", 80, 89], ["cancer", "CANCER", 107, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 186, 191], ["NF-\u03baB", "PROTEIN", 24, 29], ["mammalian NF-\u03baB family members", "PROTEIN", 176, 206], ["pulmonary inflammation", "PROBLEM", 80, 102], ["cancer", "PROBLEM", 107, 113], ["therapeutic agents", "TREATMENT", 140, 158], ["pulmonary", "ANATOMY", 80, 89], ["inflammation", "OBSERVATION", 90, 102], ["cancer", "OBSERVATION", 107, 113]]], ["These are RelA (p65), RelB, c-Rel, NF-\u03baB 1 (p50/p105), and NF-\u03baB 2 (p52/p100) (Barkett and Gilmore 1999; Dutta et al. 2006; Ghosh et al. 1998; Hayden and Ghosh 2004; Jeong et al. 2004; Mercurio and Manning 1999; Nabel and Verma 1993; Pahl 1999; Shishodia and Aggarwal 2004).", [["RelA", "GENE_OR_GENE_PRODUCT", 10, 14], ["RelB", "GENE_OR_GENE_PRODUCT", 22, 26], ["c-Rel", "GENE_OR_GENE_PRODUCT", 28, 33], ["NF-\u03baB 1", "GENE_OR_GENE_PRODUCT", 35, 42], ["p50", "GENE_OR_GENE_PRODUCT", 44, 47], ["NF-\u03baB 2", "GENE_OR_GENE_PRODUCT", 59, 66], ["p52", "GENE_OR_GENE_PRODUCT", 68, 71], ["RelA", "PROTEIN", 10, 14], ["p65", "PROTEIN", 16, 19], ["RelB", "PROTEIN", 22, 26], ["c", "PROTEIN", 28, 29], ["Rel", "PROTEIN", 30, 33], ["NF", "PROTEIN", 35, 37], ["\u03baB 1", "PROTEIN", 38, 42], ["p50", "PROTEIN", 44, 47], ["p105", "PROTEIN", 48, 52], ["NF-\u03baB 2", "PROTEIN", 59, 66], ["p52", "PROTEIN", 68, 71], ["RelA", "TEST", 10, 14], ["RelB", "TEST", 22, 26], ["c", "TEST", 28, 29], ["NF", "TEST", 35, 37], ["NF", "TEST", 59, 61], ["p52", "TEST", 68, 71], ["Barkett", "TEST", 79, 86], ["Gilmore", "TEST", 91, 98], ["Pahl", "TEST", 234, 238], ["Shishodia", "TEST", 245, 254]]], ["NF-\u03baB family members share a highly conserved 300 amino acid Rel homology domain (RHD), responsible for their dimerization, binding to DNA and I\u03baB (inhibitor of NF-\u03baB) (Blank et al. 1992; Chen and Ghosh 1999; Gilmore 1990, 2006; Hayden and Ghosh 2004; Perkins and Gilmore 2006).", [["amino acid", "CHEMICAL", 50, 60], ["amino acid", "CHEMICAL", 50, 60], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["amino acid", "AMINO_ACID", 50, 60], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 143, 146], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 161, 166], ["NF-\u03baB family members", "PROTEIN", 0, 20], ["300 amino acid Rel homology domain", "PROTEIN", 46, 80], ["RHD", "PROTEIN", 82, 85], ["I\u03baB", "PROTEIN", 143, 146], ["inhibitor of NF-\u03baB", "PROTEIN", 148, 166], ["amino acid Rel homology domain", "TREATMENT", 50, 80], ["their dimerization", "PROBLEM", 104, 122], ["I\u03baB (inhibitor of NF", "TREATMENT", 143, 163]]], ["The N-terminal part of the RHD contains the DNA-binding domain, whereas close to the C-terminal end of the RHD lies the nuclear localization sequence (NLS) which is essential for the transport of active NF-\u03baB complexes into the nucleus.", [["nuclear", "ANATOMY", 120, 127], ["nucleus", "ANATOMY", 228, 235], ["N", "CHEMICAL", 4, 5], ["C", "CHEMICAL", 85, 86], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["NLS", "GENE_OR_GENE_PRODUCT", 151, 154], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 203, 208], ["nucleus", "CELLULAR_COMPONENT", 228, 235], ["N-terminal part", "PROTEIN", 4, 19], ["RHD", "PROTEIN", 27, 30], ["DNA-binding domain", "PROTEIN", 44, 62], ["C-terminal end", "PROTEIN", 85, 99], ["RHD", "PROTEIN", 107, 110], ["nuclear localization sequence", "PROTEIN", 120, 149], ["NLS", "PROTEIN", 151, 154], ["NF-\u03baB complexes", "PROTEIN", 203, 218], ["the DNA-binding domain", "PROBLEM", 40, 62], ["-terminal", "OBSERVATION_MODIFIER", 5, 14], ["RHD", "OBSERVATION", 27, 30], ["binding domain", "OBSERVATION", 48, 62], ["RHD", "OBSERVATION", 107, 110], ["active", "OBSERVATION_MODIFIER", 196, 202], ["nucleus", "ANATOMY", 228, 235]]], ["NF-\u03baB proteins can be further subdivided into two groups: RelA, RelB and c-Rel which contain potent transactivation domains (TDs) within sequences C-terminal to the RHD are included in first group whereas, p50 and p52 which do not possess TDs and, therefore, cannot act as sole transcriptional activators comprise the second group.", [["C", "CHEMICAL", 147, 148], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["RelA", "GENE_OR_GENE_PRODUCT", 58, 62], ["RelB", "GENE_OR_GENE_PRODUCT", 64, 68], ["c-Rel", "GENE_OR_GENE_PRODUCT", 73, 78], ["RHD", "GENE_OR_GENE_PRODUCT", 165, 168], ["p50", "GENE_OR_GENE_PRODUCT", 206, 209], ["p52", "GENE_OR_GENE_PRODUCT", 214, 217], ["TDs", "GENE_OR_GENE_PRODUCT", 239, 242], ["NF-\u03baB proteins", "PROTEIN", 0, 14], ["RelA", "PROTEIN", 58, 62], ["RelB", "PROTEIN", 64, 68], ["c", "PROTEIN", 73, 74], ["Rel", "PROTEIN", 75, 78], ["transactivation domains", "PROTEIN", 100, 123], ["TDs", "PROTEIN", 125, 128], ["RHD", "DNA", 165, 168], ["p50", "PROTEIN", 206, 209], ["p52", "PROTEIN", 214, 217], ["TDs", "PROTEIN", 239, 242], ["potent transactivation domains", "PROBLEM", 93, 123], ["the RHD", "TEST", 161, 168], ["RHD", "OBSERVATION", 165, 168]]], ["The TDs consist of abundant serine, acidic and hydrophobic amino acids which are essential for transactivation activity (Mercurio and Manning 1999; Perkins 2007; Wang and Baldwin 1998; Zhong et al. 1997).IntroductionThe RHD of all Rel proteins (except Rel B) contains a phosphorylation site for PKA (25 aa N-terminal to the NLS).", [["amino acids", "CHEMICAL", 59, 70], ["serine", "CHEMICAL", 28, 34], ["amino acids", "CHEMICAL", 59, 70], ["N", "CHEMICAL", 306, 307], ["serine", "AMINO_ACID", 28, 34], ["acidic", "AMINO_ACID", 36, 42], ["hydrophobic", "AMINO_ACID", 47, 58], ["amino acids", "AMINO_ACID", 59, 70], ["Rel", "GENE_OR_GENE_PRODUCT", 231, 234], ["Rel B", "GENE_OR_GENE_PRODUCT", 252, 257], ["PKA", "GENE_OR_GENE_PRODUCT", 295, 298], ["TDs", "PROTEIN", 4, 7], ["Rel proteins", "PROTEIN", 231, 243], ["Rel B", "PROTEIN", 252, 257], ["phosphorylation site", "PROTEIN", 270, 290], ["PKA", "PROTEIN", 295, 298], ["25 aa N-terminal", "PROTEIN", 300, 316], ["NLS", "PROTEIN", 324, 327], ["hydrophobic amino acids", "TEST", 47, 70], ["transactivation activity", "PROBLEM", 95, 119], ["all Rel proteins", "TEST", 227, 243], ["a phosphorylation site", "TREATMENT", 268, 290], ["PKA", "TEST", 295, 298]]], ["Phosphorylation of this site may be required for nuclear localization of the Rel proteins and/or may be involved in the transcriptional activity and DNA-binding (Scheinman et al. 1995; Wissink et al. 1997; Zhong et al. 1997).", [["nuclear", "ANATOMY", 49, 56], ["nuclear", "CELLULAR_COMPONENT", 49, 56], ["Rel", "GENE_OR_GENE_PRODUCT", 77, 80], ["DNA", "CELLULAR_COMPONENT", 149, 152], ["Rel proteins", "PROTEIN", 77, 89], ["Phosphorylation of this site", "PROBLEM", 0, 28]]], ["NF-\u03baB is localized in cytoplasm associated with I\u03baB inhibitory proteins in inactive form.", [["cytoplasm", "ANATOMY", 22, 31], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 22, 31], ["I\u03baB inhibitory proteins", "GENE_OR_GENE_PRODUCT", 48, 71], ["NF-\u03baB", "PROTEIN", 0, 5], ["I\u03baB inhibitory proteins", "PROTEIN", 48, 71], ["I\u03baB inhibitory proteins", "TREATMENT", 48, 71], ["inactive", "OBSERVATION", 75, 83]]], ["Family members of I\u03baB family include-I\u03baB\u03b1, I\u03baB\u03b2, I\u03baB\u03b3 (derived from the C-terminal of p100), I\u03baB\u03b5, BCl-3, pp40 (a chicken homolog), cactus (a Drosophila homolog), and avian swine fever virus protein p28.2 (Baldwin 1996; Barkett and Gilmore 1999; Hatada et al. 1992; Hayden and Ghosh 2004).", [["swine fever", "DISEASE", 173, 184], ["C", "CHEMICAL", 72, 73], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 18, 21], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 37, 41], ["I\u03baB\u03b2", "GENE_OR_GENE_PRODUCT", 43, 47], ["I\u03baB\u03b3", "GENE_OR_GENE_PRODUCT", 49, 53], ["I\u03baB\u03b5", "GENE_OR_GENE_PRODUCT", 93, 97], ["BCl-3", "GENE_OR_GENE_PRODUCT", 99, 104], ["pp40", "GENE_OR_GENE_PRODUCT", 106, 110], ["chicken homolog", "GENE_OR_GENE_PRODUCT", 114, 129], ["Drosophila homolog", "ORGANISM", 142, 160], ["avian swine fever virus", "ORGANISM", 167, 190], ["I\u03baB family", "PROTEIN", 18, 28], ["I\u03baB\u03b1", "PROTEIN", 37, 41], ["I\u03baB\u03b2", "PROTEIN", 43, 47], ["I\u03baB\u03b3", "PROTEIN", 49, 53], ["C-terminal of p100", "PROTEIN", 72, 90], ["I\u03baB\u03b5", "PROTEIN", 93, 97], ["BCl", "PROTEIN", 99, 102], ["pp40", "PROTEIN", 106, 110], ["chicken homolog", "DNA", 114, 129], ["Drosophila homolog", "DNA", 142, 160], ["chicken", "SPECIES", 114, 121], ["Drosophila", "SPECIES", 142, 152], ["avian swine fever virus", "SPECIES", 167, 190], ["chicken", "SPECIES", 114, 121], ["Drosophila", "SPECIES", 142, 152], ["avian swine fever virus", "SPECIES", 167, 190], ["I\u03baB\u03b5", "TEST", 93, 97], ["BCl", "TEST", 99, 102], ["a chicken homolog", "TREATMENT", 112, 129], ["a Drosophila homolog", "TREATMENT", 140, 160]]], ["The balance of localization of NF-\u03baB is dependent on I\u03baB\u03b1 degradation which leads to the exposure of masked NLS of p65 and also reduces the contribution of nuclear export sequence of I\u03baB\u03b1 (Arenzana-Seisdedos et al. 1997; Johnson et al. 1999).", [["nuclear", "ANATOMY", 156, 163], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 31, 36], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 53, 57], ["p65", "GENE_OR_GENE_PRODUCT", 115, 118], ["nuclear", "CELLULAR_COMPONENT", 156, 163], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 183, 187], ["NF-\u03baB", "PROTEIN", 31, 36], ["I\u03baB\u03b1", "PROTEIN", 53, 57], ["NLS", "PROTEIN", 108, 111], ["p65", "PROTEIN", 115, 118], ["nuclear export sequence", "PROTEIN", 156, 179], ["I\u03baB\u03b1", "PROTEIN", 183, 187], ["I\u03baB\u03b1 degradation", "PROBLEM", 53, 69], ["masked NLS of p65", "PROBLEM", 101, 118]]], ["NF-\u03baB functions only as a dimer, the most abundant activated dimeric form consists of a p50 or p52 subunit and a p65 subunit.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["p50", "GENE_OR_GENE_PRODUCT", 88, 91], ["p52", "GENE_OR_GENE_PRODUCT", 95, 98], ["p65", "GENE_OR_GENE_PRODUCT", 113, 116], ["NF-\u03baB", "PROTEIN", 0, 5], ["dimer", "PROTEIN", 26, 31], ["p50", "PROTEIN", 88, 91], ["p52 subunit", "PROTEIN", 95, 106], ["p65 subunit", "PROTEIN", 113, 124], ["a p50 or p52 subunit", "TREATMENT", 86, 106]]], ["However, NF-\u03baB dimer composition depends on cell type, nature of stimulus or lag time after initial exposure to stimuli (Barkett and Gilmore 1999; Hayden and Ghosh 2004; Perkins 1997; Saccani et al. 2003).", [["cell", "ANATOMY", 44, 48], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 9, 14], ["cell type", "CELL", 44, 53], ["NF-\u03baB dimer", "PROTEIN", 9, 20], ["NF", "TEST", 9, 11]]], ["Homo- or heterodimers of p50 and p52 have been reported to repress \u03baB site-dependent transcription in vivo (Lernbecher et al. 1993), possibly by competing with other transcriptionally active dimers (e.g., p50/RelA) for DNA binding.", [["p50", "GENE_OR_GENE_PRODUCT", 25, 28], ["p52", "GENE_OR_GENE_PRODUCT", 33, 36], ["\u03baB", "GENE_OR_GENE_PRODUCT", 67, 69], ["p50", "GENE_OR_GENE_PRODUCT", 205, 208], ["RelA", "GENE_OR_GENE_PRODUCT", 209, 213], ["DNA", "CELLULAR_COMPONENT", 219, 222], ["heterodimers", "PROTEIN", 9, 21], ["p50", "PROTEIN", 25, 28], ["p52", "PROTEIN", 33, 36], ["\u03baB site", "DNA", 67, 74], ["transcriptionally active dimers", "PROTEIN", 166, 197], ["p50", "PROTEIN", 205, 208], ["RelA", "PROTEIN", 209, 213], ["heterodimers of p50", "TREATMENT", 9, 28], ["p50/RelA", "TREATMENT", 205, 213], ["DNA binding", "PROBLEM", 219, 230]]], ["Interestingly, \u03baB-site-dependent transcriptional activation by p50/p50 has been demonstrated in vitro (Lin et al. 1995).Classical Pathway ::: NF-\u03baB Signaling PathwaysNF-\u03baB signaling occurs through classical and non-classical pathways.", [["\u03baB", "GENE_OR_GENE_PRODUCT", 15, 17], ["p50", "GENE_OR_GENE_PRODUCT", 63, 66], ["p50", "GENE_OR_GENE_PRODUCT", 67, 70], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 142, 147], ["PathwaysNF-\u03baB", "GENE_OR_GENE_PRODUCT", 158, 171], ["\u03baB-site", "DNA", 15, 22], ["p50", "PROTEIN", 63, 66], ["p50", "PROTEIN", 67, 70], ["NF-\u03baB", "PROTEIN", 142, 147], ["PathwaysNF", "PROTEIN", 158, 168], ["-\u03baB", "PROTEIN", 168, 171], ["\u03baB", "TEST", 15, 17], ["p50/p50", "TEST", 63, 70], ["dependent", "OBSERVATION_MODIFIER", 23, 32], ["transcriptional activation", "OBSERVATION", 33, 59]]], ["In the classical pathway, tumor necrosis factor \u03b1 (TNF-\u03b1) stimulation leads to activation/phosphorylation of I\u03baB kinase (IKK) complex which then phosphorylates two N-terminal serine residues of I\u03baB proteins.", [["tumor", "DISEASE", 26, 31], ["necrosis", "DISEASE", 32, 40], ["N", "CHEMICAL", 164, 165], ["serine", "CHEMICAL", 175, 181], ["tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 26, 49], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["I\u03baB kinase", "GENE_OR_GENE_PRODUCT", 109, 119], ["IKK", "GENE_OR_GENE_PRODUCT", 121, 124], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 194, 197], ["tumor necrosis factor \u03b1", "PROTEIN", 26, 49], ["TNF", "PROTEIN", 51, 54], ["I\u03baB kinase (IKK) complex", "PROTEIN", 109, 133], ["N-terminal serine residues", "PROTEIN", 164, 190], ["I\u03baB proteins", "PROTEIN", 194, 206], ["tumor necrosis factor", "PROBLEM", 26, 47], ["TNF", "TEST", 51, 54], ["activation/phosphorylation of I\u03baB kinase", "TEST", 79, 119], ["phosphorylates", "TEST", 145, 159], ["terminal serine residues", "TREATMENT", 166, 190], ["I\u03baB proteins", "PROBLEM", 194, 206], ["tumor", "OBSERVATION_MODIFIER", 26, 31], ["necrosis", "OBSERVATION", 32, 40]]], ["The IKK complex comprised IKK\u03b1, IKK\u03b2 and a regulatory subunit of IKK\u03b3 which is an NF-\u03baB essential modulator (NEMO) (Mercurio et al. 1999; Rothwarf et al. 1998; Yamaoka et al. 1998).", [["IKK", "GENE_OR_GENE_PRODUCT", 4, 7], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 26, 30], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 32, 36], ["IKK\u03b3", "GENE_OR_GENE_PRODUCT", 65, 69], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["NEMO", "GENE_OR_GENE_PRODUCT", 109, 113], ["IKK complex", "PROTEIN", 4, 15], ["IKK\u03b1", "PROTEIN", 26, 30], ["IKK\u03b2", "PROTEIN", 32, 36], ["regulatory subunit", "PROTEIN", 43, 61], ["IKK\u03b3", "PROTEIN", 65, 69], ["NF-\u03baB", "PROTEIN", 82, 87], ["NEMO", "PROTEIN", 109, 113], ["The IKK complex", "TEST", 0, 15], ["IKK\u03b1", "TEST", 26, 30], ["IKK\u03b2", "TEST", 32, 36], ["an NF", "TEST", 79, 84]]], ["IKK\u03b1 and IKK\u03b2 form homo or hetero dimers.", [["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 9, 13], ["hetero dimers", "SIMPLE_CHEMICAL", 27, 40], ["IKK\u03b1", "PROTEIN", 0, 4], ["IKK\u03b2", "PROTEIN", 9, 13], ["homo or hetero dimers", "PROTEIN", 19, 40], ["IKK", "TEST", 0, 3], ["IKK", "TEST", 9, 12], ["hetero dimers", "PROBLEM", 27, 40]]], ["Although IKK\u03b1 and IKK\u03b2 cooperate for I\u03baB phosphorylation, these kinases differ in the signal they mediate.", [["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 9, 13], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 18, 22], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 37, 40], ["IKK\u03b1", "PROTEIN", 9, 13], ["IKK\u03b2", "PROTEIN", 18, 22], ["I\u03baB", "PROTEIN", 37, 40], ["kinases", "PROTEIN", 64, 71], ["IKK", "TEST", 9, 12], ["IKK", "TEST", 18, 21], ["I\u03baB phosphorylation", "PROBLEM", 37, 56], ["these kinases", "TEST", 58, 71]]], ["IKK\u03b1 and IKK\u03b2 have 52% amino acid homology with similar structural organization including kinase domain, leucine zipper and helix-loop-helix domains (Delhase et al. 1999; DiDonato et al. 1997; Li et al. 1999; Mercurio et al. 1997; Regnier et al. 1997; Woronicz et al. 1997; Zandi et al. 1997).", [["amino acid", "CHEMICAL", 23, 33], ["amino acid", "CHEMICAL", 23, 33], ["leucine", "CHEMICAL", 105, 112], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 9, 13], ["amino acid", "AMINO_ACID", 23, 33], ["leucine", "AMINO_ACID", 105, 112], ["IKK\u03b1", "PROTEIN", 0, 4], ["IKK\u03b2", "PROTEIN", 9, 13], ["kinase domain", "PROTEIN", 90, 103], ["leucine zipper and helix-loop-helix domains", "PROTEIN", 105, 148], ["IKK", "TEST", 0, 3], ["IKK\u03b2", "TEST", 9, 13], ["amino acid homology", "TEST", 23, 42], ["kinase domain", "TEST", 90, 103], ["leucine zipper", "TREATMENT", 105, 119]]], ["MAP kinase domain of these proteins consists of closely spaced serine residues at positions 176 and 180 in IKK\u03b1 and positions 177 and 181 in IKK\u03b2.", [["serine", "CHEMICAL", 63, 69], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 0, 10], ["serine", "AMINO_ACID", 63, 69], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 107, 111], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 141, 145], ["MAP kinase domain", "PROTEIN", 0, 17], ["IKK\u03b1", "PROTEIN", 107, 111], ["IKK\u03b2", "PROTEIN", 141, 145], ["MAP kinase domain", "TEST", 0, 17], ["these proteins", "TEST", 21, 35], ["closely spaced serine residues", "PROBLEM", 48, 78], ["IKK", "TEST", 107, 110], ["closely spaced", "OBSERVATION_MODIFIER", 48, 62], ["serine residues", "OBSERVATION", 63, 78]]], ["Phosphorylation of these serine residues by upstream kinases activates IKK kinase (DiDonato et al. 1997; Vanden Berghe et al. 1998; Zandi et al. 1997).", [["serine", "CHEMICAL", 25, 31], ["serine", "AMINO_ACID", 25, 31], ["IKK kinase", "GENE_OR_GENE_PRODUCT", 71, 81], ["upstream kinases", "PROTEIN", 44, 60], ["IKK kinase", "PROTEIN", 71, 81], ["DiDonato", "PROTEIN", 83, 91], ["Phosphorylation", "TREATMENT", 0, 15], ["these serine residues", "PROBLEM", 19, 40], ["upstream kinases", "TEST", 44, 60], ["IKK kinase", "TEST", 71, 81]]], ["Signals which induce NF-\u03baB activity cause phosphorylation of I\u03baB\u2019s, subsequently leading to their dissociation and degradation thereby allowing NF-\u03baB proteins to enter the nucleus and induce gene expression (Fig. 1).", [["nucleus", "ANATOMY", 172, 179], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 21, 26], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 61, 64], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 144, 149], ["nucleus", "CELLULAR_COMPONENT", 172, 179], ["NF-\u03baB", "PROTEIN", 21, 26], ["I\u03baB", "PROTEIN", 61, 64], ["NF-\u03baB proteins", "PROTEIN", 144, 158], ["NF", "TEST", 21, 23], ["phosphorylation of I\u03baB\u2019s", "PROBLEM", 42, 66], ["their dissociation", "PROBLEM", 92, 110], ["NF", "TEST", 144, 146], ["nucleus", "ANATOMY", 172, 179]]], ["The ubiquitination and subsequent degradation of I\u03baB\u2019s are mediated by the multicatalytic ATP-dependent 26S proteasome complex, the evidence for which was provided by the experiments with peptide aldehyde inhibitors of the proteasome, e.g., calpain inhibitor I (ALLN) (Karin and Ben-Neriah 2000).", [["ATP", "CHEMICAL", 90, 93], ["aldehyde", "CHEMICAL", 196, 204], ["ATP", "CHEMICAL", 90, 93], ["aldehyde", "CHEMICAL", 196, 204], ["ALLN", "CHEMICAL", 262, 266], ["I\u03baB", "GENE_OR_GENE_PRODUCT", 49, 52], ["ATP", "SIMPLE_CHEMICAL", 90, 93], ["26S", "GENE_OR_GENE_PRODUCT", 104, 107], ["calpain inhibitor I", "GENE_OR_GENE_PRODUCT", 241, 260], ["ALLN", "SIMPLE_CHEMICAL", 262, 266], ["I\u03baB", "PROTEIN", 49, 52], ["26S proteasome complex", "PROTEIN", 104, 126], ["proteasome", "PROTEIN", 223, 233], ["calpain", "PROTEIN", 241, 248], ["The ubiquitination", "PROBLEM", 0, 18], ["I\u03baB\u2019s", "TREATMENT", 49, 54], ["the multicatalytic ATP", "TEST", 71, 93], ["peptide aldehyde inhibitors", "TREATMENT", 188, 215], ["the proteasome", "TREATMENT", 219, 233], ["calpain inhibitor", "TREATMENT", 241, 258], ["proteasome complex", "OBSERVATION", 108, 126]]]], "PMC5989030": [["Four Japanese Black calves, 30 to 45-days-old, were presented to the University of Missouri (MU) Veterinary Health Center (VHC) with a history of decreased milk intake and hypoproteinemia.", [["milk", "ANATOMY", 156, 160], ["hypoproteinemia", "DISEASE", 172, 187], ["calves", "ORGANISM", 20, 26], ["milk", "ORGANISM_SUBSTANCE", 156, 160], ["calves", "SPECIES", 20, 26], ["decreased milk intake", "PROBLEM", 146, 167], ["hypoproteinemia", "PROBLEM", 172, 187], ["Black calves", "OBSERVATION", 14, 26], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["milk intake", "OBSERVATION", 156, 167], ["hypoproteinemia", "OBSERVATION", 172, 187]]], ["Anadditional calf was presented directly to the MU Veterinary Medical Diagnostic Laboratory (VMDL) for post-mortem examination.", [["calf", "ORGANISM", 13, 17], ["calf", "SPECIES", 13, 17], ["post-mortem examination", "TEST", 103, 126], ["calf", "ANATOMY", 13, 17]]], ["The calves belonged to a group of 14 embryo transfer calves, allfrom the same embryo flush.", [["embryo", "ANATOMY", 37, 43], ["embryo", "ANATOMY", 78, 84], ["calves", "ORGANISM", 4, 10], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 43], ["calves", "ORGANISM", 53, 59], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 78, 84], ["calves", "SPECIES", 4, 10], ["calves", "SPECIES", 53, 59], ["a group of 14 embryo transfer calves", "TREATMENT", 23, 59], ["the same embryo flush", "TREATMENT", 69, 90], ["calves", "ANATOMY", 4, 10], ["embryo flush", "OBSERVATION", 78, 90]]], ["The embryos had been transferred into 14 Holstein recipients housed on a farm in southwest Missouri.", [["embryos", "ANATOMY", 4, 11], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 4, 11], ["recipients", "ORGANISM", 50, 60]]], ["The recipient dams were vaccinated 5 to 6 months before calvingwith a multivalent killed vaccine against infectious bovine rhinotracheitis virus (IBR), bovine virus diarrhea virus (BVDV) Type 1 and 2, parainfluenza virus Type 3 (PI-3), and bovinerespiratory syncytial virus and Campylobacter fetus, Leptospira canicola, L. grippotyphosa, L. hardjo, L.icterohaemorrhagiae, and L. Pomona (Vira Shield 6+VL5; Novartis Animal Health US, Larchwood, IA, U.S.A.), a Salmonella Typhimurium core antigenvaccine (Endovac-Dairy; Immvac, Columbia, MO, U.S.A.), and a Staphylococcus aureus bacterin (Lysigin; Boehringer Ingelheim Vetmedica, St. Joseph, MO, U.S.A.).", [["infectious bovine rhinotracheitis virus", "DISEASE", 105, 144], ["bovine virus diarrhea", "DISEASE", 152, 173], ["bovinerespiratory syncytial virus", "DISEASE", 240, 273], ["Campylobacter fetus", "DISEASE", 278, 297], ["Leptospira canicola", "DISEASE", 299, 318], ["Staphylococcus aureus", "DISEASE", 555, 576], ["dams", "ORGANISM", 14, 18], ["infectious", "ORGANISM", 105, 115], ["bovine", "ORGANISM", 116, 122], ["rhinotracheitis virus", "ORGANISM", 123, 144], ["IBR", "ORGANISM", 146, 149], ["bovine virus diarrhea virus", "ORGANISM", 152, 179], ["BVDV) Type 1", "ORGANISM", 181, 193], ["parainfluenza virus Type 3", "ORGANISM", 201, 227], ["PI-3", "ORGANISM", 229, 233], ["bovinerespiratory syncytial virus", "ORGANISM", 240, 273], ["Campylobacter fetus", "ORGANISM", 278, 297], ["Leptospira canicola", "ORGANISM", 299, 318], ["L. grippotyphosa", "ORGANISM", 320, 336], ["L. hardjo", "ORGANISM", 338, 347], ["L.icterohaemorrhagiae", "ORGANISM", 349, 370], ["L. Pomona", "ORGANISM", 376, 385], ["Salmonella Typhimurium", "ORGANISM", 459, 481], ["Staphylococcus aureus bacterin", "ORGANISM", 555, 585], ["Boehringer Ingelheim Vetmedica", "ORGANISM", 596, 626], ["St. Joseph", "ORGANISM", 628, 638], ["bovine", "SPECIES", 116, 122], ["rhinotracheitis virus", "SPECIES", 123, 144], ["bovine", "SPECIES", 152, 158], ["virus diarrhea virus", "SPECIES", 159, 179], ["BVDV", "SPECIES", 181, 185], ["parainfluenza virus", "SPECIES", 201, 220], ["bovinerespiratory syncytial virus", "SPECIES", 240, 273], ["Campylobacter fetus", "SPECIES", 278, 297], ["Leptospira canicola", "SPECIES", 299, 318], ["L. grippotyphosa", "SPECIES", 320, 336], ["L. hardjo", "SPECIES", 338, 347], ["L. Pomona", "SPECIES", 376, 385], ["Salmonella Typhimurium", "SPECIES", 459, 481], ["Staphylococcus aureus", "SPECIES", 555, 576], ["bovine rhinotracheitis virus", "SPECIES", 116, 144], ["IBR", "SPECIES", 146, 149], ["bovine virus diarrhea virus", "SPECIES", 152, 179], ["BVDV", "SPECIES", 181, 185], ["Type 1", "SPECIES", 187, 193], ["parainfluenza virus Type 3 (PI-3", "SPECIES", 201, 233], ["bovinerespiratory syncytial virus", "SPECIES", 240, 273], ["Campylobacter fetus", "SPECIES", 278, 297], ["Leptospira canicola", "SPECIES", 299, 318], ["L. grippotyphosa", "SPECIES", 320, 336], ["L. hardjo", "SPECIES", 338, 347], ["L. Pomona (Vira Shield 6+VL5", "SPECIES", 376, 404], ["Salmonella Typhimurium", "SPECIES", 459, 481], ["Staphylococcus aureus bacterin", "SPECIES", 555, 585], ["The recipient dams", "TREATMENT", 0, 18], ["a multivalent killed vaccine", "TREATMENT", 68, 96], ["infectious bovine rhinotracheitis virus", "PROBLEM", 105, 144], ["bovine virus diarrhea virus", "PROBLEM", 152, 179], ["parainfluenza virus Type", "TEST", 201, 225], ["PI", "TEST", 229, 231], ["bovinerespiratory syncytial virus", "PROBLEM", 240, 273], ["Campylobacter fetus", "PROBLEM", 278, 297], ["Leptospira canicola", "TEST", 299, 318], ["L. grippotyphosa", "TEST", 320, 336], ["L. hardjo", "TEST", 338, 347], ["L.icterohaemorrhagiae", "PROBLEM", 349, 370], ["a Salmonella Typhimurium core antigenvaccine", "TREATMENT", 457, 501], ["a Staphylococcus aureus bacterin", "PROBLEM", 553, 585], ["syncytial virus", "OBSERVATION", 258, 273], ["Campylobacter fetus", "ANATOMY", 278, 297], ["Staphylococcus aureus", "OBSERVATION", 555, 576]]]], "PMC7386203": [["BackgroundGenome-wide association studies (GWAS) seek to robustly link genetic loci with diseases and other heritable traits [1\u20134].", [["BackgroundGenome-wide association studies", "PROBLEM", 0, 41], ["diseases", "PROBLEM", 89, 97], ["other heritable traits", "PROBLEM", 102, 124]]], ["Nowadays, thanks to the rapid development of large-scale biobanks with well-genotyped and well-phenotyped cohorts, conducting case-control studies has become easier than ever.", [["large-scale biobanks", "TREATMENT", 45, 65], ["large", "OBSERVATION_MODIFIER", 45, 50]]], ["The UK Biobank (UKBB) is a flagship project of these efforts, having recruited a cohort of over 500,000 individuals, each with a full genotype and thousands of curated phenotypes (including medical history, lab tests, a variety of physical measures and comprehensive lifestyle questionnaires) [8, 9].BackgroundDespite the enormous impact of GWAS, inherent difficulties still limit its success [2, 10].", [["lab tests", "TEST", 207, 216], ["physical measures", "TREATMENT", 231, 248], ["GWAS", "PROBLEM", 341, 345], ["inherent difficulties", "PROBLEM", 347, 368], ["enormous", "OBSERVATION_MODIFIER", 322, 330], ["impact", "OBSERVATION_MODIFIER", 331, 337]]], ["Among the key factors is its limited statistical power, partly caused by the large number of tested variants across the genome.", [["genome", "CELLULAR_COMPONENT", 120, 126], ["large", "OBSERVATION_MODIFIER", 77, 82], ["genome", "ANATOMY", 120, 126]]], ["This limiting factor is especially crucial when dealing with rare variants of small effect sizes [10].", [["small effect sizes", "PROBLEM", 78, 96], ["small effect", "OBSERVATION_MODIFIER", 78, 90], ["sizes", "OBSERVATION_MODIFIER", 91, 96]]], ["Due to linkage disequilibrium (LD) and population stratification, even when a genomic locus is robustly implicated with a phenotype, pinning the exact causal variants is a convoluted task [6].BackgroundThree major strategies are commonly used for prioritizing the most likely entities (e.g., variants or genes) causally affecting the phenotype.", [["genomic locus", "DNA", 78, 91], ["linkage disequilibrium (LD) and population stratification", "PROBLEM", 7, 64], ["a genomic locus", "PROBLEM", 76, 91], ["a phenotype", "PROBLEM", 120, 131], ["the phenotype", "PROBLEM", 330, 343], ["most likely", "UNCERTAINTY", 264, 275]]], ["There are numerous methods that aggregate GWAS summary statistics at the level of genes, often by combining them with data from expression quantitative trait locus (eQTL) studies or functional annotations of genes and pathways [14\u201317].BackgroundThe third strategy seeks to implicate genes directly, by carrying the association tests at the level of annotated functional elements in the first place.", [["annotated functional elements", "DNA", 349, 378], ["expression quantitative trait locus (eQTL) studies", "PROBLEM", 128, 178], ["the association tests", "TEST", 311, 332], ["numerous", "OBSERVATION_MODIFIER", 10, 18], ["functional elements", "OBSERVATION", 359, 378]]], ["The most commonly used gene-level method is SKAT, which aggregates the signal across an entire genomic region, be it a gene or any other functional entity (or just a collection of SNPs) [18, 19].", [["SKAT", "GENE_OR_GENE_PRODUCT", 44, 48], ["SKAT", "PROTEIN", 44, 48]]], ["Another approach, recently explored by methods such as PrediXcan [20] and TWAS [21], tests whether the studied phenotypes correlate with gene expression levels predicted from genetic variants.", [["the studied phenotypes", "TEST", 99, 121], ["gene expression levels", "PROBLEM", 137, 159]]], ["Under this paradigm, the association test comprised two stages.", [["the association test", "TEST", 21, 41]]], ["First, an independent reference panel is used to train a prediction model of gene expression (in a particular tissue) as a function of the genetic makeup of a sample.", [["tissue", "ANATOMY", 110, 116], ["tissue", "TISSUE", 110, 116]]], ["The learned model is then applied on the phenotyped dataset, and the predicted gene expression levels are tested against phenotypes of interest.", [["the predicted gene expression levels", "TEST", 65, 101]]], ["The advantages of this approach include a reduced burden of multiple testing and more concrete and interpretable discoveries.BackgroundA natural enhancement to these approaches would be a protein-centric method that considers the effects of genetic variants on the functionality of genes, rather than affecting their abundance (be it at the transcript or protein level).BackgroundWe present Proteome Wide Association Study (PWAS) (Fig. 1).", [["this approach", "TREATMENT", 18, 31], ["multiple testing", "TEST", 60, 76], ["BackgroundA natural enhancement", "PROBLEM", 125, 156], ["a protein-centric method", "PROBLEM", 186, 210], ["genetic variants", "PROBLEM", 241, 257], ["natural enhancement", "OBSERVATION", 137, 156]]], ["PWAS is based on the premise that causal variants in coding regions affect phenotypes by altering the biochemical functions of the genes\u2019 protein products (Fig. 1a).", [["PWAS", "DNA", 0, 4], ["coding regions", "DNA", 53, 67], ["protein products", "PROTEIN", 138, 154], ["Fig. 1a", "PROTEIN", 156, 163], ["causal variants in coding regions affect phenotypes", "PROBLEM", 34, 85]]], ["Such functional alterations could be, for example, changes to a protein\u2019s enzymatic activity or binding capacity (e.g., of a ligand, DNA/RNA molecule, or another protein).", [["DNA", "CELLULAR_COMPONENT", 133, 136], ["DNA/RNA molecule", "PROTEIN", 133, 149], ["a protein", "TEST", 62, 71], ["binding capacity", "TEST", 96, 112], ["a ligand, DNA/RNA molecule", "TEST", 123, 149]]], ["To capture these effects, PWAS quantifies the extent to which proteins are damaged given an individual\u2019s genotype.", [["PWAS", "PROTEIN", 26, 30], ["an individual\u2019s genotype", "PROBLEM", 89, 113]]], ["Specifically, PWAS considers any variant that affects the coding regions of genes (e.g., missense, nonsense, frameshift).", [["PWAS", "DNA", 14, 18], ["coding regions", "DNA", 58, 72]]], ["It quantifies the impact of these variants on the function of the affected proteins using FIRM, a machine learning model that considers the rich proteomic context each affecting variant [22].", [["FIRM", "PROTEIN", 90, 94], ["a machine learning model", "TREATMENT", 96, 120], ["FIRM", "OBSERVATION", 90, 94]]], ["For each gene (in the context of a specific individual), PWAS assigns two scores, to cover the two elementary modes of heritability: dominant and recessive inheritance (other modes of heritability, including additive effects, can be represented as a composition of the two).", [["recessive inheritance", "DISEASE", 146, 167], ["PWAS", "DNA", 57, 61], ["dominant and recessive inheritance", "PROBLEM", 133, 167], ["dominant", "OBSERVATION_MODIFIER", 133, 141]]], ["Intuitively, the dominant effect score is intended to express the probability of at least one hit damaging the protein function, while the recessive score attempts to express the probability of at least two damaging hits.", [["the dominant effect score", "PROBLEM", 13, 38], ["the recessive score", "PROBLEM", 135, 154], ["dominant", "OBSERVATION_MODIFIER", 17, 25], ["effect", "OBSERVATION_MODIFIER", 26, 32], ["protein function", "OBSERVATION", 111, 127], ["damaging hits", "OBSERVATION", 207, 220]]], ["PWAS then tests, using routine statistical analysis, if a gene\u2019s effect scores are associated with the phenotype.", [["PWAS", "DNA", 0, 4], ["tests", "TEST", 10, 15], ["routine statistical analysis", "TEST", 23, 51], ["a gene\u2019s effect scores", "PROBLEM", 56, 78], ["the phenotype", "PROBLEM", 99, 112]]], ["In the case of a binary phenotype, a significant correlation would mean that the effect scores of cases are different than those of controls, namely that the protein is more (or less) damaged in affected individuals.", [["a binary phenotype", "PROBLEM", 15, 33], ["the effect scores of cases", "PROBLEM", 77, 103]]]], "2d1e4c5b70ba81e76c746d52b62cfca439eda753": [["Then, 16 FangCangs were built and 15 used to manage about a quarter of all Covid patients in the provincial capital city.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["These enabled admissions of most mildly or moderately infected patients.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["most mildly or moderately infected patients", "PROBLEM", 28, 71], ["most mildly", "OBSERVATION_MODIFIER", 28, 39], ["moderately", "OBSERVATION_MODIFIER", 43, 53], ["infected", "OBSERVATION", 54, 62]]], ["There, vital signs were regularly checked and, based on the Chinese National Guideline for Covid, 3 nasal O 2 was supplied to those whose SpO 2 became \u226493% [but not severe enough for ICU admission].", [["O 2", "CHEMICAL", 106, 109], ["vital signs", "TEST", 7, 18], ["Covid, 3 nasal O 2", "TREATMENT", 91, 109]]], ["FangCangs' peak bed usage was over 95%.", [["FangCangs", "SIMPLE_CHEMICAL", 0, 9]]]], "61c63c5c959c12b0b4c9a85bc8f1fe7f41cecf86": [["Melanocortin-4 receptor (MC4R) deficiency is the commonest monogenic cause of obesity.", [["obesity", "DISEASE", 78, 85], ["Melanocortin-4 receptor", "GENE_OR_GENE_PRODUCT", 0, 23], ["MC4R", "GENE_OR_GENE_PRODUCT", 25, 29], ["Melanocortin-4 receptor", "PROTEIN", 0, 23], ["MC4R", "PROTEIN", 25, 29], ["Melanocortin-4 receptor (MC4R) deficiency", "TREATMENT", 0, 41], ["obesity", "PROBLEM", 78, 85], ["obesity", "OBSERVATION", 78, 85]]], ["However, studies have reported prevalence varying from 1 to 12; penetrance remains elusive with non-obese carriers reported recently and clinical expression variation along the life is also uncertain.", [["studies", "TEST", 9, 16], ["non-obese carriers", "PROBLEM", 96, 114], ["clinical expression variation", "PROBLEM", 137, 166]]], ["We provide a comprehensive molecular and phenotypic characterization of MC4R-induced obesity in a large European population.", [["obesity", "DISEASE", 85, 92], ["MC4R", "GENE_OR_GENE_PRODUCT", 72, 76], ["MC4R", "DNA", 72, 76], ["MC4R", "PROBLEM", 72, 76], ["induced obesity", "PROBLEM", 77, 92], ["obesity", "OBSERVATION", 85, 92], ["large", "OBSERVATION_MODIFIER", 98, 103]]], ["Newly identified missense mutations were functionally characterized.", [["Newly identified missense mutations", "PROBLEM", 0, 35], ["missense mutations", "OBSERVATION", 17, 35]]], ["We also provided obesity-related phenotypes, including questionnaire-based appetitive behaviour.", [["obesity", "DISEASE", 17, 24], ["obesity", "PROBLEM", 17, 24], ["related phenotypes", "PROBLEM", 25, 43], ["obesity", "OBSERVATION", 17, 24]]], ["Forty-three obese probands (1.46%) and four non-obese controls (0.15%) carried MC4R pathogenic mutations; familial penetrance was 60% for heterozygotes.", [["familial penetrance", "DISEASE", 106, 125], ["MC4R", "GENE_OR_GENE_PRODUCT", 79, 83], ["four non-obese controls", "TREATMENT", 39, 62], ["MC4R pathogenic mutations", "PROBLEM", 79, 104], ["familial penetrance", "PROBLEM", 106, 125], ["heterozygotes", "PROBLEM", 138, 151]]], ["The longitudinal study of relatives with available data evidenced an age-dependent penetrance (21% at 20years vs. 60% at >40yrs) suggesting MC4R-deficiency as a late-onset obesity disorder.", [["MC4R-deficiency", "DISEASE", 140, 155], ["obesity disorder", "DISEASE", 172, 188], ["MC4R", "GENE_OR_GENE_PRODUCT", 140, 144], ["The longitudinal study", "TEST", 0, 22], ["available data", "TEST", 41, 55], ["dependent penetrance", "PROBLEM", 73, 93], ["MC4R-deficiency", "PROBLEM", 140, 155], ["a late-onset obesity disorder", "PROBLEM", 159, 188], ["late-onset", "OBSERVATION_MODIFIER", 161, 171], ["obesity", "OBSERVATION", 172, 179]]], ["Comparing the 97 carriers with their 81 WT relatives, we observed that the risk of obesity decreased across generations: it is multiplied by 3.4 for children carriers and by 1.7 for adults >52yrs (p=9.6 10 -4 ) but the risk to become obese after 52 when carrying a pathogenic mutation remains significant (p=10 -11 ).", [["obesity", "DISEASE", 83, 90], ["children", "ORGANISM", 149, 157], ["children", "SPECIES", 149, 157], ["obesity", "PROBLEM", 83, 90], ["obese", "PROBLEM", 234, 239], ["a pathogenic mutation", "PROBLEM", 263, 284], ["obesity", "OBSERVATION", 83, 90], ["obese", "OBSERVATION", 234, 239]]]]}